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C H A P T E R 1 
General introduction: the leukocyte integrin LFA-1 and its 
ligands ICAM-1, -2 and -3 

Introduction 
Leukocyte integrins 
C ells express a variety of specialized proteins that allow them to adhere to extracellular matrix proteins or to each other These pioteins are termed adhesion molecules Cell-cell and cell-
matrix interactions mediated by adhesion molecules are crucial for many processes in the body, in­
cluding embryonic development, the maintenance of tissue integrity and the initiation and propa­
gation of immune responses within the immune system A family of proteins specialized in medi­
ating cell adhesion and communication is the integrin family ot adhesion receptors Integrins are 
type I tiansmembrane glycopioteins consisting of an α and a β chain that are non-covalently asso­
ciated and have relatively short cytoplasmic tails At present 14 different α chains and 8 β chains 
have been defined Although many β chains associate with distinct α chains and certain α subunits 
associate with more than one β chain, only twenty different heterodimers have been described 
Based on shared β subunits, eight subfamilies of integrins can be distinguished within the integrin 
family While some subfamilies, including the β, family, are broadly expressed, other subfamilies 
have a restricted tissue expression, such as the β2 family that is leukocyte specific (1,2) Integrins 
mediate cell adhesion by binding to a wide array of ligands, including extracellular matrix proteins 
like collagen, plasma proteins such as fibrinogen and transmembrane glycoproteins that belong to 
the immunoglobulin superlamily, like ICAM 1 Many integrins bind to more than one ligand, and 
some ligands bind to more than one integrin This suggests that there is a redundancy in the reper­
toire of integrin ligand interactions a cell can use for adhesive interactions in vivo A common fea­
ture of integrins is that they require a physiological temperature, the presence of extracellular Ca2+ 
and/or Mg2+ and an intact cytoskeleton, to bind ligand (3) 
The functional significance of integrins has clearly been demonstrated by natural or induced ge­
netic defects in integrin subunits, that abolish integrin mediated adhesive functions in vivo (4) In­
tegrins of the β, family link cells to the extracellular matnx and thereby play an impoitant role in 
tissue organization Germhne disruption of α4β, (5) and α5β, (6) expression in mice is lethal, dem­
onstrating the role of β, integrins in embryonic development Integrins ot the β2 family are critical 
lor adhesion of leukocytes to endothelial cells at sites of inflammation and subsequent migration of 
leukocytes into the underlying tissue Their importance is best illustrated in patients suffering from 
the leukocyte adhesion deficiency (LAD) syndrome, which is caused by a critical point mutation or 
deletion in the β2 subunit LAD patients often die at a very young age of recurrent bacterial infec­
tions, because of impaired leukocyte adhesive functions (7-9) These examples underscore the im­
portance of integrins in many physiological processes m vivo 
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Integrili 
LFA-1 
(aLß2, CDl la/CD 18) 
Mac-1 
(α
Μ
β 2 CD lib/CD 18) 
pl50,95 
(ctxß2, CDl le/CD 18) 
« D ß i 
(CDl Id/CD 18) 
expression 
lymphocytes 
myeloid, monocytic 
cells, NK cells 
myeloid, monocytic 
cells lymphocytes 
myeloid, monocytic 
cells, lymphocytes 
ligands 
ICAM-l 
ICAM-2 
ICAM-3 
ICAM 4 (LW blood 
group antigen) (33 34) 
Tclcnc.ephahn (31,32) 
СЗЫ 
ICAM-1 
ICAM-2 
ICAM-4 (LW blood 
group antigen) (33,34) 
Fg Factor X, Heparin 
denatured proteins, 
CD23, HK( 15-
20 261,262) 
> 
СЗЫ (264) 
LPS (265) 
Fg, CD23, denatured 
proteins, 
(16,18,266 267) 
ICAM-3 (13) 
function 
Τ cell/B cell interaction (60 61) and 
CTL/targel interaction (56-59,258) leu 
kocyte adhesion to endothelium and 
transendolhelul migration (65-70) 
NK cell/target interaction (85) leuko 
cyte adhesion to resting endothelium 
(39) plalelel/lcukocyle interaction (40) 
APC/lymphocyte interaction (86-90) 
neutrophil aggregation (259) 
9 
; 
phagocytosis ot opsonized particles 
Chemotaxis (20,260) 
transendothelul migration (63-67) 
adhesion to resting endothelium (28) ' 
> 
1 
neutrophil dfíKreííation (263) 
Chemotaxis migration 
cytokine production ' 
antigen presentation'' 
Table 1. Expression and function of $2 integrins Abbreviation1; used C3bi complement factor 
3bi, Fg, fibrinogen, HK, high molecular weigtht kinmogen, LPS, lipopolysaccharide, CTL, cyto 
toxic Τ lymphocyte, NK cell, natural killer cell, APC antigen presenting cell 
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Leukocytes express various integrins belonging to the β, subfamily and the leukocyte specific β2 
and β7 ïntegrin subfamilies The β2 subfamily of integrins comprises LFA-1 (aLß2, CD11 a/CD 18) 
mainly expressed on lymphocytes, Mac-1 (сс^2, CDllb/CDI8) and pl50,95 (αΜβ2, CDllc/CD18) 
expressed on monocytes, macrophages and granulocytes and the recently identified aDß2 
(COI Id/CD 18), which is expressed on monocytes, macrophages granulocytes and to a lower extent 
on lymphocytes (Table 1) (10-13) Both pl50,95 and Mac-1 can be stored in peroxidase-negative 
granules, that dcgranulate upon stimulation with inflammatory mediators, resulting in a rapid in-
crease in surface expression of these molecules (14) Mac-1 and ρ 150,95 bind to a variety of pro­
teins including serum components like fibrinogen and tactor X, and the complement factor C3bi 
(15-20) In addition, LFA-1, Mac-1 and aDß2 mediate cell-cell interactions by binding to trans-
membrane ligands that belong to the Ig-superfamily ICAM-1, -2, -3 (21-27), ICAM-1 and ICAM-
2 (28-30), and ICAM-3 (13), respectively (see below) Recently, two othei members of the Ig-
superfamily were found to bind to ß, integrins Telencephahn, expressed in the brain, binds to 
LFA-1 (31,32), whereas 1CAM 4, or the LW blood group antigen, binds to both LFA-1 and Mac-1 
(33,34) Expression and function of the β2 integrins and their ligands are summarized in Table 1 
Expression and function of intercellular adhesion molecules 1, 2 and 3 
ICAM-1, -2 and -3 are type I transmembrane glycoproteins that belong to the Ig-superfamily 
and have 5, 2 and 3 Ig-like domains, respectively (Fig 1) ICAM-1, 2 and -3 have relatively short 
cytoplasmic tails that share little sequence homology ICAM-1 is expressed on a variety of cell 
types including endothelial cells, epithelial cells and leukocytes, and expression can be strongly 
enhanced by ini laminatoi у cytokines (35) In contrast, expression of ICAM-2 (36) and ICAM-3 
(37,38) is not enhanced by cytokines ICAM-2 is found on leukocytes, endothelial cells and plate­
lets (39,40), while ICAM-3 shows the most restricted expression, since it is only found on leuko­
cytes, with the exception of endothelial cells in certain tumors, including carcinoma's and lym­
phoma's (37,38,41-47) In addition to their membrane-bound form, soluble forms of ICAM-1 and 
ICAM-3 can be detected in serum (48,49) Elevated levels are found in patients suffering from in­
flammatory or auto-immune diseases, although elevation of sICAM-1 and sICAM-3 levels are not 
necessarily linked (49 52) Although LFA-1 and Mac-1 both bind to ICAM-1, they interact with 
distinct domains in ICAM-1 molecules LFA-1 binds to the first Ig-like domain of ICAM-1, Mac-1 
to the third domain Furthermore, adhesion of Mac-1 to ICAM-1 is enhanced by deglycosylation of 
the third Ig-like domain of ICAM-1, whereas adhesion of LFA-1 to 1С AM-1 is not affected by de­
glycosylation (30,53) Although ICAM-1, -2 and -3 all bind to LFA-1, there are clear indications 
13 
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that LFA-1 may bind to these ligands with different affinities. ICAM-1 binds most strongly, 
ICAM-3 is least effective and ICAM-2 intermediate in its capacity to bind LFA-1 (54). 
s-s s-s s-s s-s s-s UODÖD 
s-s s-s 
34% { 31% ( 35% 
s-s s-s s-s s-s s-s 
<20%( 36%)( 50% ( 52%1( 77%ll 33% 
ICAM-1 
ICAM-2 
ICAM-3 
Figure 1. Structure of ICAM-1, -2 and -3. ICAM-1, -2 and -3 are type I transmembrane glyco-
proteins belonging to the Ig-superfamily, that have 5, 2 and 5 ¡g-like domains, respectively. For 
each Ig-like domain of ICAM-2 and -3 and their cytoplasmic tails, homology with the correspond-
ing domains of ICAM-1 is indicated. 
The distinct tissue distribution of ICAM-1, -2 and -3 already suggests that binding of leukocyte 
integrins to each of these ligands may be involved in different immunological processes. Experi-
ments using blocking antibodies directed against ICAM molecules or genetic disruption of 1CAM 
expression in mice (55), clearly show that ICAM-1, -2 and -3 are involved in distinct LFA-1 de-
pendent adhesive interactions in the immune system. It has been well established that LFA-
1/ICAM-l interactions are critical for interaction of CTL with their target cells (56-59) and partici-
pate in Τ/ В cell interactions (60,61). Binding of Mac-1 and LFA-1 to ICAM-1 is pivotal for adhe­
sion and diapedesis of granulocytes and lymphocytes through endothelium at sites of inflammation 
(62-70). Mice lacking ICAM-1 expression exhibit reduced sensitivity to ischemic injury, collagen 
induced arthritis, graft versus host disease and septic shock (71-76). On the other hand, they show 
reduced clearance of viral, fungal and bacterial infections (75,77-79), indicating that ß2 integrin 
mediated adhesion to ICAM-1 is involved in both detrimental and beneficial immune-responses. 
Finally, ICAM-1 is implicated in rhinovirus infection and malaria, since both rhinoviruses and 
malaria parasites use ICAM-1 to bind and enter host cells (80-84). 
Although the role of ICAM-2 is poorly defined, LFA-l/ICAM-2 interactions have been shown 
to enhance the interaction of NK cells with their target cells (85) and arc implicated in homing of 
14 
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lymphocytes to resting endothelium (39). Expression of ICAM-2 on platelets furthermore suggests 
involvement of ICAM-2 in binding of leukocytes to platelets (40). 
Although all leukocytes express high levels of ICAM-3, its expression is most pronounced on 
resting Τ cells, since these lack high levels of ICAM-1 and -2. Therefore, ICAM-3 has been pro­
posed to be important in the initiation of an immune response (26). Although ICAM-3 is not very 
effective in supporting LFA-1 mediated adhesion (54), several reports suggest that ICAM-3/LFA-1 
adhesion may be involved in the interaction of lymphocytes with antigen presenting cells, includ­
ing Langerhans cells in the skin (86-90). Recently, the leukocyte integrin aDß2 was cloned and 
shown to preferentially bind ICAM-3 (13). Since aDß2 is expressed on cells of the monocytic line-
age including macrophages, it will be interesting to determine whether engagement of ICAM-3 by 
aDß2 is also involved in the initiation of an immune response. 
Domains in the extracellular part of integrin α and β subunits impli­
cated in ligand binding 
Integrin α subunits have large extracellular domains consisting of 950-1100 aminoacids (Fig. 2). 
Within the N-terminal part of the extracellular domain, three or four conserved EF-hand like motifs 
are found, that share homology with motifs in classical Ca2+ binding proteins such as calmodulin 
and have been implicated in cation binding by integrins (91). 
O L^ coon 
I domain EF-hands 
Ш 
MIDAS cysteine-rich 
GFFKR 
Nl-b 
TM 
β I domain 
LITIHDR ^KEYRRFEKE y t NPXY -f. TTT ^ N P K Y 
Figure 2. Structure of the a and ßsubunit of LFA-1. MIDAS: metal ion dependent adhesion site. 
EF-hands:EF-hand like motifs. ß-I domain: conserved region resembling the I domain. Cystein-
rich: disulfide-bonded region. TM: transmembrane region. GFFKRJLITIHDR/NPXY: conserved 
sequences involved in integrin activation. EYRRFEKE/NPXY/TTT/NPKY: conserved sequences in-
volved in localization of integrins to focal adhesions and association with the cytoskeleton. 
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Classical EF hand motifs consist of 13 residues, of which the oxygenated amino acids at posi­
tions 1, 3, 5, 7, 9 and 12 form a divalent cation binding pocket (92) (Fig 2) Although integnn EF-
hand like domains lack the critical residue at position twelve, they appeal to be involved in binding 
of both cation and hgand to integrins (93-96) 
A subgroup of ct-subunits consisting of a,, Oj, a,, a,,, a ,^, aD and ccL has a 200 amino-acids long 
inserted or I domain (also termed the Α-domain), that is homologous to domains found in several 
proteins like von Willebrand factor and complement factor-B (13,97-99) The I domains of inte­
grins play an essential role in hgand recognition Many antibodies that block hgand binding of the 
ccLß2, α
Μ
β 2, α,β, and α2β, integrins map to this domain (100-112) Moreover, recombinant I do­
mains o fa ,ß 2 , α
Μ
β 2, α,β, and c^ β ι bind to their respective ligands m vitro (28,100,101,108,113-
121) Resolution of the crystal structure of the I domains of LFA-1 and Mac-1, has revealed the 
presence of a divalent cation binding motif or so called MIDAS (metal ion dependent adhesion 
site) within integnn I domains, that binds Mn2+ or Mg2+ (122-125) Mutational analysis has clearly 
demonstrated that residues involved in cation coordination are critical for hgand binding of all I 
domain containing integrins (102,105,113,123,126-129) Recently, additional residues in proximity 
of the MIDAS motif have been implicated in ligand binding of LFA-1 (106) In addition, different 
ligands appear to bind to partly overlapping, but distinct sequences within integnn I domains 
(111,130,131), indicating that ligand binding to integnn I domains is likely to be complex in na­
ture, involving multiple contact sites between integnn and ligand 
Integnn β subunits have a large extracellular domain (675-700 aminoacids), that contains a cys-
teine-nch domain with internal disulfide bonds (Fig 2) Within the amino tei minai part of integnn 
β subunits a conserved sequence is found that resembles the MIDAS motif in integnn 1 domains 
and is crucial for both ligand and cation binding to integrins (Π2-139) Together, these findings 
suggest that binding of cations to cation binding sequences in integnn α and β subunits may di­
rectly influence the binding of integrins to their ligands, either by dnectly contributing to a ligand 
binding pocket, or by creating a ligand binding tertiary structure of the integnn molecule In addi­
tion to regulation of integnn conformation and ligand binding, piobably resulting in the enhanced 
affinity of integrins for their ligands, divalent cations have also been shown to affect the avidity ot 
integrin-ligand interactions On Τ cells, organization of LFA-1 into clusters, coi relates with high 
affinity binding of Ca2+ to LFA-1 (140,141) 
16 
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Integrins are conformationally sensitive molecules 
On many cell types integrins can exist in both active and inactive states that bind to ligand with 
different affinities (1). Evidence has accumulated that these different affinity states represent dif­
ferent conformers of the integrin, and that conformational changes in integrins can be induced by 
binding of integrins to divalent cations, ligand or particular antibodies (132). Several unique mono­
clonal antibodies have been described that either induce or detect these conformational changes 
(Fig. 3). 
Figure 3. Alterations in integrin conformation. During integrin activation and ligand binding in­
tegrins undergo multiple conformational changes induced or detected by several classes of unique 
antibodies. A) activating antibodies that induce or stabilize a high affinity state of integrin mole­
cules. B) antibodies that detect integrin molecules in a high affinity state. C) antibodies recogniz­
ing ligand induced binding sites on integrins (LIBS). D) antibodies recognizing epitopes induced 
by integrin clustering. 
Integrin activating antibodies increase adhesion of integrins to their ligands upon binding to in­
tegrin α or β chains, probably by stabilizing an active conformer of the integrin molecule (Fig. ЗА). 
Integrin activating antibodies include KIM185, KIM127 (142,143) and CBR LFA-1/2 (144) di-
17 
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rected against ß2, MEM-83 and NKI-L16 directed against the at subunit (110,145), D33C directed 
against the aIIb subunit (146) and TS2/16 directed against β, (147,148) Integnn molecules that 
have acquired an active conformation, are detected by another class of specific antibodies (Fig 
3B) For example, the PAC 1 antibody directed against a[Ib, recognizes α,,,,β, molecules on acti 
vated platelets that have a high affinity for their ligand fibrinogen, whereas it does not recognize 
antß^ integrins on resting platelets (149,150) Similarly, the antibodies CBRM1/5 directed against 
aM and HUTS-4, -7, and 21 directed against β,, detect activated conformers of α
Μ
β2 and α,β, inte 
grins, respectively (151,152) Several integrins express neo-epitopes upon ligand binding (LIBS), 
that can be detected by neo-epitope specific antibodies (Fig 3C) These include the M24 antibody 
that recognizes a Mg2+ dependent epitope on a, expressed upon binding of α, β, to ICAM 1 (153) 
and LIBS2 (154), AP5 (155) and 9EG7 (156) that recognize epitopes induced upon ligand binding 
of β, and β, integrins, respectively Finally, antibodies have been descnbed that detect conforma 
tional changes in integnn molecules induced by redistribution of integrins on the cell surface (3D) 
These include the Ca2+ dependent antibody NKJ-L16 directed against o ,^ that recognizes an epitope 
induced by reorganization of LFA-1 into clusters on the cell surlace (140,145) The finding that 
several of these unique antibodies recognize cation dependent epitopes (KIM127, NKI-L16, M24, 
AP5, 12G10, D33C and 9EG7), strongly suggests that cations are directly involved in altenng the 
conformation of integnn molecules (132) This notion is supported by the observation that the di 
valent cation Mn2+ directly enhances the affinity of multiple integrins lor their ligands (157,158) 
Taken together, these findings demonstrate that during integnn activation and ligand binding, inte 
grin molecules undergo multiple conformational changes Such molecular alterations can be in 
duced by intracellular signals (see below), but also from the outside ot the cell by activating anti 
bodies or cations (Mn2+), that directly bind to integnn molecules 
Integrins: two-way signaling molecules 
Inside-out signaling 
On many cells integrins can be activated through intracellular signals, usually induced by trig­
gering of cell surface receptors This phenomenon is otien referred to as inside-out signaling and 
thought to involve conformational alterations in integnn molecules that increase the affinity of in 
tegnns for their ligands, as discussed above (Fig 4,1) For example LFA 1 expressed on Τ cells 
shows poor binding to its ligand ICAM-1 However, upon cross linking ol sui face receptors like 
the TCR/CD3 receptor complex or addition of phorbolesters that activate PKC, LFA 1 binding to 
ICAM-1 is strongly increased (159 162) Engagement of multiple surface receptors has been 
18 
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Figure 4. Two-way signaling by integrins. A) Signals generated by triggering of surface receptors 
induce a conformational change in integrins that increases their affinity for ligand (inside-out sig­
naling). Upon ligand binding integrins in turn transmit signals into the cell (outside-in signaling). 
B) Role of Focal Adhesion Kinase (FAK) in integrin mediated signaling. FAK is a docking protein 
for a variety of signaling and cytoskeletal proteins. Src and Csk: S re family kinases; paxillin, talin 
vinculin and F-actin: cytoskeletal proteins; Grb2 and Crk: adapter proteins implicated in activa­
tion of the Ras pathway through binding to the guanine nucleotide exchange factors SOS and C3G; 
pl30Cas: Crk substrate. FAT domain: focal adhesion targeting domain. Integrin binding domain: 
domain implicated in binding to cytoplasmic tails of β subunits. SH2 and SH3 domains: protein 
modules involved in protein-protein interactions through binding to phospho-tyrosine- (Y) and 
proline-rich peptide motifs (PPP), respectively. 
19 
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shown to induce integnn-ligand interactions of β,, β3, β7 and β2 ïntegrins, indicating that inside out 
signaling is a common pathway for integrin activation (summarized in (1,163)) Inside out signal-
ing involves activation of protein kinase С and elevation of intracellular Ca1+ levels as a result of 
phospholipase-C mediated phospho-mositide lipid breakdown In addition, protein phosphorylation 
appears to be a key event in modulating integrin adhesiveness (159,160,163) Although these find 
ings indicate that integrin activation involves multiple intracellular signaling pathways, how these 
pathways ultimately alter the affinity of integrins for their hgands, is only starting to emerge 
Several investigations indicate that conserved domains in the cytoplasmic tails of integrin α 
subunits are involved in the regulation of integrin affinity (Fig 2) Upon deletion or mutation of a 
conserved GFFKR sequence in the cytoplasmic tails of integrin α subunits, integrins acquire a con 
stitutively active state, independent of cell type (164 167) This suggests that in the intact integrin, 
this region is involved in keeping the integrin in an inactive conformer Recent studies suggest that 
the nuclear protein calreticuhn directly binds the GFFKR sequence and thus regulates integrin acti 
vation Calreticuhn associates with the α subunit of ο^β, upon activation of the integiin Moreovei, 
ES cells or fibroblasts from calreticuhn deficient mice show impaired integrin mediated adhesion 
that is restored by overexpression of calreticuhn (168 170) How calreticuhn regulates integrin ad 
hesion remains speculative Integrin activation may involve binding ol cytoplasmic proteins to se­
quences within the cytoplasmic tails of integrin subunits that facilitate subsequent binding of cal­
reticuhn to the GFFKR sequence, resulting in a change in the atfinity ol the integrin Alternatively, 
integrin activation may involve release of a calreticuhn inhibitory protein Irom integrin cytoplas­
mic tails In monocytes and lymphocytes activation ol α
Μ
β 2 is associated with dissociation of the F 
actin cytoskeleton, suggesting that cytoskeletal proteins may be such inhibitory proteins (141,171 
173) 
Conserved domains in the cytoplasmic tails of integriti β subunits aie also involved in integrin 
activation (Fig 2) Mutation of a conserved NPXY motif prevents acquisition of a high athnity 
state of β, integrine, as detected by the PAC-1 antibody (see above) (174) On the other hand, dele 
tion or mutation of a LITIHDR motif in the β3 cytoplasmic tail induces a high affinity state of β-, 
integrins (175-177) It has been proposed that in vivo a salt bridge between charged residues in the 
conserved LITIHDR motif in integrin β subunits and the GFFKR motif in integrin α subunits, 
serves to keep the integrin in a low affinity state (175) Recently, a novel protein was identified that 
associates with the cytoplasmic tail ol β,, termed cytohesin Overexpiession of cytohesin or its 
SEC7 homology domain, enhances LFA-1 mediated adhesion (178) implicating this protein in ac 
tivation of LFA-1 Interestingly, the pleckstnn homology (PH) domain ol cytohesin binds 
PI(3,4,5)P3, a product of РІЗ-kinase, suggesting that PI3 kinase may be upstream of cytohesin in 
20 
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LFA-1 activation (179) Similarly, overexpression of endonexin, a protein that specifically binds to 
the β, cytoplasmic tail, induces a high affinity state of the al[bß3 ïntegrin, as detected by the PAC-1 
antibody (180-182) These findings imply that integnn activation involves association of specific 
proteins with the cytoplasmic tails of both integnn α and β subunits 
In addition to regulation by intracellular proteins, integnn activation can also be modulated 
through interaction of integrins with extracellular proteins Association of β, integrins or Mac-1 
with the urokinase receptor (uPAR), a GPI linked cell surface protein, results in inhibition of adhe­
sion of these integrins, that is reveised upon binding of uPAR to vitronectin Since binding of 
uPAR to vitronectin is dependent on its interaction with integnn, it appears that uPAR and integnn 
function are tightly interconnected (183,184) 
Outside-in signaling mediated by integrins 
It has become clear that upon hgand binding, integrins transmit signals from the extracellular 
environment into the cytosol, often referred to as outside in signaling Ligation of integnn mole­
cules by antibodies or hgand has been shown to induce changes in intracellular pH (185) and intra­
cellular calcium levels (186-188) increased tyrosine phosphorylation of intiacellular proteins 
(163,189) and ultimately affects cytoskcletal reorganization, gene expiession and proliferation 
(163,190,191) Since the cytoplasmic tails of integrins lack enzymatic activity, these cellular re­
sponses must be mediated by signaling molecules that directly or indirectly associate with inte­
grins 
Role of focal adhesion assembly in outside-in signaling 
Studies with β, and ß^ integrins have shown that inside out signaling in fibroblasts and platelets 
requires the hgand dependent reorganization of integrins into focal adhesions, transmembrane 
junctions between the extracellular matnx and the cytoskeleton (192) Focal adhesions strengthen 
integnn dependent adhesion through linkage of integrins with the cytoskeleton and contain a vari-
ety of molecules implicated in integrins mediated signaling, like kinases, phosphatases and adapter 
proteins (191,193) It has been shown that localization ot integrins to focal adhesions is dependent 
on the cytoplasmic tails ot integnn β subunits Specific residues in the cytoplasmic tail of integnn β 
subunits critical for localization of integrins to focal adhesions (Fig 2) include three conserved 
threonine residues (TTT), essential for spreading and stable hgand binding oí ß2 integrins (165) 
and three clusters of conserved amino acids (NPXY, NPKY and EYRRFEKE), involved in linkage 
of integrins to the cytoskeleton (194,195) In addition, localization ot integrins to focal adhesions 
may involve binding of cytoplasmic tails of integnn β subunits to the cytoskeletal pioteins α 
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actinin, talin and filamin (196-200) that in turn associate with other cytoskeletal proteins like actin, 
vinculin, tensin and paxilhn (191) 
One of the key proteins involved in β, and β, ïntegrin dependent focal adhesion assembly, is the 
125 kDa protein Focal Adhesion Kinase (FAK) FAK localizes to focal adhesions through a focal 
adhesion targeting (FAT) sequence (201) and is rapidly phosphorylated on tyrosine upon β, inte 
grin mediated spreading of fibroblasts or epithelial cells, or upon α,,,,β, mediated platelet aggrega­
tion (202) Although no direct interaction between FAK and integrins has been demonstrated in 
vivo, FAK can bind to peptides mimicking the β,, β, or β, cytoplasmic tails in vitro (203) In addi­
tion to its function as a tyrosine kinase, FAK functions as a docking protein for a variety of signal­
ing molecules (Fig 4) These include tyrosine kinases of the Src family (204), cytoskeletal proteins 
such as paxilhn and talin (205,206) and the adapter protein Gib2 (207) and the Crk substrate 
pl30Cas (208,209), that may link FAK to activation of the Ras pathway Together, these data im 
ply that FAK phosphorylation and localization to focal adhesions is a first step in the accumulation 
of integrin dependent signaling complexes (191,193,210,211) 
Recent studies indicate that full assembly of integrin dependent signaling complexes requires 
interaction of integrin with multivalent ligands that induce both occupancy and aggregation of inte­
grins (190,212,213) Integrin mediated signal transduction in fibroblasts and platelets is further­
more dependent on an intact cytoskeleton, since cytochalasin D prevents integrin mediated signal­
ing in these cells (163,214) Dimenzation of the integrin may induce actin polymerization and sub 
sequent association of kinases to the cytoskeleton Alternatively, kinases already linked to the inte­
grin by cytoskeletal proteins, may become activated by dimenzation of integrins The observation 
that dominant negative Rho mutants prevent the accumulation of focal adhesion complexes in­
duced upon interaction of ß, integrins with extracellular matrix (215), indicates that activity of Rho 
family GTPases is required for integrin dependent focal adhesion assembly Rho activity has been 
proposed to be critical for clustering of integrins (215), suggesting that Rho activity and occupancy 
of integrins by multivalent ligands are both required for assembly ol integrin dependent adhesion 
complexes 
A novel family of proteins involved in outside-in signaling by β, and ß, integrins is the trans-
membrane^ superfamily (tetraspan or TM4SF proteins), that includes CD9, CD81 and CD63 
Members of this family can be co-purified with α,,,,β-, and α,β,, α4β,, α,β, and α6β, integrins and are 
involved in transmitting intracellulai signals, such as elevation of intracellular Ca1+ levels, protein 
tyrosine phosphorylation and proliferation In addition, α3β, CD63-CD81 complexes contain a PI4 
kinase, suggesting that tetraspan proteins link integrins to PI4-kinase mediated phospho-inositide 
signaling These results show that integrin mediated outside-in signaling is not restricted to signal 
ing through FAK (216,217) 
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Signaling mediated by ß2 integrins 
Although it has been clearly demonstrated that ß2 integnns can transmit intracellular signals re-
sulting in elevation of intracellular pH (185) and Ca2+ (186-188,218), tyrosine phosphorylation 
(219,220), activation of specific kinases (219) and proliferation (221-225), it is still unclear 
whether ß2 integrin mediated outside-in signaling requires the formation of integrin dependent sig-
naling complexes, as has been described for β, and β, integnns. CHO cells expressing chimeric 
cxMbp1 integrins that contain the cytoplasmic tails of aL and β2, reorganize into focal adhesions on 
fibrinogen, suggesting that the cytoplasmic tails of a, and β2 contain the information required for 
localization of LFA-1 to focal adhesions (165) In addition, it has been shown that LFA-1 can or­
ganize into clusters on activated Τ cells, that enhance LFA-1 dependent adhesion (140,141). It is 
atti active to hypothesize that these clusters may represent ß2 integrin dependent focal adhesions in 
lymphocytes. 
The role of FAK in ß2 integrin dependent signal transduction remains unclear. Although pep-
tides derived from the β2 cytoplasmic tail bind to FAK in vitro (203) to date no activation of FAK 
upon engagement of ß2 integrins has been reported. However, two FAK homologues have been 
identified in lymphocytes that may participate in β2 mediated signal transduction. FakB is phos-
phorylated upon TCR engagement or ligation of β2 and associates with SH3 domain of phospholi-
pase-Cyl (226). RAFTK (CAKß, PYK2) is also expressed in lymphocytes and phosphorylated 
upon TCR engagement. Phosphorylated RAFTK associates with the Src family kinase Fyn, the 
adapter protein Grb2 and the cytoskeletal protein paxilhn (227), suggesting that RAFTK, like FAK 
participates in the assembly of complexes containing multiple signal transduction molecules. In В 
cells or Τ cells, engagement of ß, integrins results in activation of FAK or RAFTK, and their asso-
ciation with pl30Cas or the Cas homologues pl05HEFl or pl05Cas-L (lymphocyte type Cas) 
(228-231). Interestingly, LFA-l/ICAM-1 mediated intercellular adhesion induces tyrosine phos-
phorylation of pl30Cas and its association with Crk (232) Combining these results, it is attractive 
to hypothesize that ligand binding of ß2 integrins on lymphocytes induces formation of signaling 
complexes that include FAK or FAK homologues. 
Another kinase implicated in β2 mediated signal transduction, is the Src family kinase Fgr (219). 
Fgr is activated upon β2 integrili dependent adhesion of neutrophils to Fg and appears to be essen­
tial for neutrophil function, since neutrophils from Fgr deficient mice fail to generate an oxidative 
burst upon binding to Fg, Fn or collagen (233) In addition, spreading of neutrophils over fibrino­
gen is accompanied by the activation of the protein tyrosine kinase Syk and the formation of pro­
tein complexes that contain the β2 subunit, Syk and the Src family kinases Fgr and Lyn (234). Re­
cently, several novel proteins have been identified that specifically associate with the cytoplasmic 
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tails of β,, β3 or a l lb integrin subunits, and have been implicated in outside-in signaling mediated by 
β, and β, integnns (180,235-237) It will be interesting to determine whether binding of the re 
cently cloned cytohesin (178) to the cytoplasmic tail of β,, is similarly involved in β2 integrin me 
didted outside-in signaling in lymphocytes 
Role of 1С AM-1 and ICAM-3 in signal transduction 
ICAM-1,-2 and -3 appear to bind to partly overlapping, but distinct binding sites within the I 
domain of LFA-1, and differ in their capacity to support LFA-1 mediated adhesion (*54,11 1) 
Therefore, it is conceivable that binding of different ligands to LFA-1 may elicit different LFA 1 
dependent signals in lymphocytes This notion is supported by the finding that immobilized puri­
fied ICAM-3 proteins are less effective in inducing LFA-1 dependent costimulation ol Τ cells than 
immobilized purified ICAM-1 proteins (54) Moreover activation induced cell death in Τ cells in 
duced by SEB rechallenge, appears to involve LFA-l/ICAM-2 interactions, but no interaction of 
LFA-1 with ICAM-1 (238) Finally, upon binding of LFA-1 to purified ICAM I, resting Τ cells aie 
primed for costimulation by purified B7, whereas binding ot LFA 1 to ICAM 2 does not result in 
priming (221) 
Several reports indicate that also ICAM 1 and ICAM-3 can function as signal transduction 
molecules, whereas the role of ICAM-2 as a signaling molecule has been poorly characterized 
Cross-linking of ICAM-1 by antibodies attenuates IgM induced elevation ot intracellular calcium 
levels in В cells, enhances IL-2 receptor expression on В cells upon ligation of MHC class II, and 
costimulates the oxidative burst in monocytes (239-241) ICAM-1 cioss linking furthermore in­
duces tyrosine phosphorylation and inactivation of the cdc2 kinase in Τ cells, and tyrosine phos­
phorylation of cortactin, an actin binding protein and a substrate of Sic, in brain microvessel endo 
thelial cells (242,243) Finally, cross linking of ICAM-1 on a synovial cell line, induces activation 
of the transcription factor AP 1 and transcription of the IL-1 β gene (244) 
ICAM-3 has been extensively characterized as a signal transducing molecule Cellular responses 
induced by antibody engagement of ICAM-3, include Τ cell costimulation (245,246), activation of 
β, and β2 integnns (247-250) and the induction of morphological changes in activated Τ cells (247) 
ICAM-3 cross-linking furthermore induces elevation of intracellular calcium levels (251,252) and 
induction of tyrosine phosphorylation (251,253), probably through activation ot Src family kinases 
like Lek and Fyn, that associate with the cytoplasmic tail of ICAM 3 (251,254) Mutagenesis 
analysis of the ICAM-3 cytoplasmic tail has revealed that serine residues at positions 489 and 515 
are important for ICAM-3 mediated signal transduction, including Τ cell costimulation, and the in 
duction of homotypic aggregation and cell spreading Since Ser489 is phosphorylated m vivo and can 
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be phosphorylated by PKC in vitro, these results point to an important role oí serine phosphoryla-
tion of the ICAM-3 cytoplasmic tail, in ICAM-3 mediated signal transduction (90,255) Finally, 
ICAM-1 and -2 can associate with the cytoskeleton, by binding of their cytoplasmic tails to cy-
toskeletal proteins The cytoplasmic tails of ICAM-1 and ICAM-2 contain binding sites for the cy-
toskeletal protein a-actinin (256,257), whereas the cytoplasmic tail of ICAM-2 binds to the mem-
brane-cytoskeleton linker protein eznn (85) 
In summary, these data clearly indicate that at least ICAM 1 and -3 can function as signal 
transduction molecules, but also show that signals transduced by ICAM-1 or ICAM-3, are not 
identical Since ß2 integrins also transduce signals into the cytosol, these data may implicate that 
cell-cell adhesion mediated by ß2 integrins and ICAM's results in two-way signaling, involving 
both the integrin and ICAM molecules Evidence that both types of adhesion molecules involved in 
an adhesive interaction contribute to signal transduction, is provided by the finding that tyrosine 
phosphorylation of pl30Cas and its association with Crk is dependent on LFA-l/ICAM-1 mediated 
homotypic В cell adhesion (232) Since no phosphorylation of pl30Cas is observed upon interac­
tion of В cells with purified LFA-1 or ICAM 1 proteins, these data suggest that pl30Cas phos­
phorylation is dependent on signals transmitted by both ICAM-1 and LFA-1 
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Scope of this thesis 
LFA-l mediates adhesion by binding to one of its ligands ICAM-1, 2 or -3 The aim of this the­
sis is to investigate whether the interaction of LFA-l with ICAM 1 or ICAM-3 is structurally dis­
tinct and to determine whether engagement of LFA-l by ICAM-1 or ICAM-3 differentially affects 
adhesion and signal transduction in the immune system Chapter 2 describes an antibody directed 
against the CD1 la I domain that selectively inhibits LFA-l mediated adhesion to ICAM-2 and -3, 
but does not interfere with binding to ICAM-1, suggesting that binding sites for ICAM-1, -2 and -3 
within LFA-l are not identical In chapter 3, residues in the CD1 la I domain are identified that are 
critical for binding of LFA-l to ICAM-3, but not for ICAM-1 binding, suggesting that ICAM-1 and 
-3 indeed bind to distinct sites within LFA-l In chapter 4, the epitope in the CD1 la I domain is 
identified that is recognized by antibodies that selectively interfere with binding of LFA-l to 
ICAM 3 Alignment of this epitope and residues identified in chapter 3 with the crystal structure of 
the CD1 la I domain, reveals a novel region within the I domain that is critical for binding of LFA 
1 to ICAM-3 In chapter 5, evidence is presented that although ICAM-3 is not a very high affinity 
adhesion ligand for LFA-l on resting Τ cells, low affinity interactions of LFA-l with ICAM-3 
regulate LFA 1 binding to ICAM-1 and affect signal transduction Finally, in chapter 6, measure 
ment of LFA-l/ICAM-1 interactions using surface plasmon resonance, suggests that although 
ICAM-1 is the primary adhesion ligand for LFA-l, LFA 1 binds to ICAM-1 with very low athnity, 
and indicates that dimenc ICAM-1 molecules are more potent than monomenc ICAM-1 in binding 
to LFA-l 
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LF'A-1-mediated Τ lymphocyte adhesion to ICAM-1, -2 and 3 
Summary 
LFA-l (CD1 la/CD18) mediates leukocyte adhesion by binding to one of its ligands, 
ICAM-1, ICAM-2 or 1CAM 3 Here, we investigated whether stimuli known to in­
duce adhesion to ICAM-1 were also capable of inducing LFA-l-mediated adhesion 
of Τ lymphocytes to ICAM 2 and -3 transfectants We observed that phorbol 12-
mynstate 13-acetate, Mn2\ cross-linking of CD3 or activating antibodies against 
LFA-l enhanced LFA-l-mediated Τ cell adhesion to ICAM-2 and -3, although to a 
lesser extent than to ICAM 1 These results indicate that similar to what has been 
reported for adhesion to ICAM-1, activation of LFA-l is also required for adhesion 
to ICAM-2 and -3 Furthermore, the results suggest that ICAM-1 is the major ligand 
for LFA-l on activated Τ lymphocytes Interestingly, we observed that in contrast to 
activating antibodies against CD18, activating antibodies against CD1 la were inca­
pable of inducing adhesion of LFA-l to all three ligands The antibody MEM-83 
stimulated binding to ICAM-1, while at the same time inhibiting the interaction of 
LFA-l with ICAM-2 and -3 The antibody NKI-L16 selectively induced adhesion to 
ICAM-1 and -2, but not to ICAM-3 Our results suggest that different conformations 
of LFA-l are required to support adhesion to ICAM-1, -2 or -3, and that ligands may 
bind on different sites of the LFA-l molecule 
L FA-l (CD 11 a/CD 18) is a cell adhesion molecule that is involved in a broad range of immu­nological processes (1,2) LFA-l belongs to the ß2- (CD 18) family of integrins, which consist 
of an α-chain and a ß-chain which are non covalently linked (3) Thus far three ligands for LFA-l 
have been described ICAM-1 (4), ICAM-2 (5) or ICAM-3 (6-9), which are all members of the Ig-
superfamily and have 5, 2 and 5 Ig-hke domains respectively (5-8,10-12) ICAM-1 is expressed on 
many cell types including lymphocytes and certain epithelial cells ICAM-1 is strongly up-
regulated on endothelial cells by various inflammatory cytokines (13), and is therefore important 
for the migration of leukocytes through endothelial cell layers into inflamed tissue (14) ICAM-2 is 
mainly expressed on vascular endothelium and some lymphoid cells In contrast to ICAM-1, 
ICAM-2 is not induced by cytokines (5,15,16) ICAM-2 is the predominant ligand for LFA-l on 
resting endothelial cells, and has therefore been suggested to be important for recirculation of rest-
ing lymphocytes (15) In contrast to ICAM 1 and -2, ICAM-3 is only expressed on leukocytes with 
the exception of some endothelial cells in tumors (17,18) Since ICAM-3 is the most abundantly 
expressed ICAM on resting lymphocytes it has been proposed to be the major ligand for LFA-l 
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during the initiation of immune responses This hypothesis is supported by the finding that resting 
lymphocytes adhere to purified LFA-1 predominantly through ICAM-3 (9) Recent reports suggest 
that ICAM-3 does not only serve as an adhesion receptor, but is also involved in signal transduc­
tion (19,20) ICAM-3 is a co-stimulatory molecule for both resting and activated T-cells (19) Fur­
thermore, it was shown that crosshnking of ICAM-3 by anti-ICAM-3 mAb increases the avidity of 
LFA-1 for 1С AM-1 (20) 
Considerable information has been gathered about the regulation of LFA-1-mediated adhesion 
to ICAM-1 LFA-1 does not mediate stable adhesion to ICAM 1 unless activated (21-23) This ac­
tivation can be induced by different stimuli and requires a physiological temperatuie, an intact cy-
toskeleton and the presence of divalent cations (24) Cross-linking of certain surface receptors on Τ 
lymphocytes, such as CD2 and CD3 (22,23) or addition of the phorbol ester PMA (25,26) generate 
intracellular signals that increase the avidity of LFA-1 for ICAM-1 In addition, divalent cations 
such as Mn2+ have been shown to stimulate LFA-1-mediated adhesion (27) Enhanced LFA-1 -
mediated binding to ICAM-1 is furthermore observed upon binding ol certain unique activating 
antibodies directed against the LFA-1 α- orß-chain Since Fab iragments of most ol these antibod-
ies induce adhesion, activation is not caused by crosshnking but is most likely due to the induction 
of a conformational change within the molecule (28 32) Thus far, five LFA-1 activating antibodies 
have been described, which all bind to distinct epitopes (van Kooyk et al , submitted) NKI-L16 
(28,29) and MEM-83 (30) recognize epitopes on the LFA-1 α-chain (CD1 la), while KIM 127 (31), 
KIM185 (32) and MEM-48 (van Kooyk et al, submitted) are directed against the common ß2-chain 
(CD18) Since little is known about requirements for adhesion oí LFA-1 to ICAM-2 and -3, we 
here investigated whether stimuli known to induce LFA-1-mediated adhesion to ICAM-1 were also 
capable of stimulating binding of Τ lymphocytes to ICAM-2 and -3 
2. Materials and methods 
2.1 m Abs and Chemicals 
The following mAbs were used NKI-L15 (IgG2A) (33), NKI-LI6 (lgG2A) (28,29) and MEM-
83 (IgGl) (30) directed against the α-chain of LFA-1 (CD1 la), MEM-48 (IgGl) (van Kooyk et al, 
submitted), KIM127 (IgGl) (31) and KIM185 (IgGl) (32) leactive with the LFA-1 ß-chain 
(CD18), mAb CBR-IC2/2 (IgG2A) reactive with ICAM-2 (CD102)(15), mAb CBR-IC3/1 (IgGl) 
(9) and mAb CBR-IC3/2 (IgG2A) (8) reactive with ICAM-3 (CD50), mAb CLB-T3/4E (IgE) (34) 
reactive with CD3, RR 1/1 (IgGl) (25) and REK-1 (IgGl) reactive with ICAM-1 MAbREK-1 was 
obtained by immunizing BALB/c mice with a CTL clone Subsequently hybridoma supernatants 
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were screened for reactivity with ICAM 1 transfectants (CD54) All mAbs were used at a concen­
tration of 5-10 μ§/ιη1 Reagents used were PMA (50 ng/ml, Sigma Chemical Co , St Louis, MO) 
and MnCl2 (10 mM, diluted in Hepes/NaCl buffer, Sigma) 
2.2 Cells 
The Τ cell clone JS136 (35) was cultured as described previously (29) Mouse L cells expressing 
ICAM-1 under control of the CMV AD 169 immediate early promoter, were obtained as described 
(36) L cells and L cell transfectants were cultured in Iscoves medium with L-glutamin (Gibco) 
supplemented with 5% FCS 
2.3 Immunofluorescence 
Cells were incubated (30 min, 4°C) in PBS containing 1% wt/vol BS A (Sigma Chemical Co ) 
and 0 02% wt/vol azide with appropriate dilutions of the different mAb, followed by incubation 
with FITC-labeled goat F(ab) 2 anti mouse IgG antibody (GAM-FITC, Nordic, Tilburg, the Neth 
erlands) for 30 mm at 4°C The relative fluorescence intensity was measuied on a FACScan 
(Becton Dickinson, Mountain View, CA) 
2.3 Generation of mouse L cell transfectants expressing human ICAM-2 or ICAM-3 cDNA 
Human ICAM-2 and ICAM 3 cDNA in the pCDM8 vectoi were used as described previously 
(12) The plasmid PGK-hyg containing a fragment coniemng hygromycin resistance under control 
of a PGK promoter, was obtained fiom Di Η te Riele (37) Mouse L cells were cotransfected with 
PGK-hyg plasmid and pCDM8-ICAM 2 or pCDM8-ICAM-3 constructs, using calcium phosphate 
coprecipitation according manufacturers procedures (Calcium phosphate transfection system, BRL 
Life Technologies, Ine , Gaithersbuig, MD) L cells expressing high amounts of human ICAM-2 or 
ICAM-3 were obtained following selection in medium containing 500 μg/ml hygromycin В 
(Calbiochem, San Diego, CA) and subsequent positive sorting on a FACStar (Becton Dickinson) 
2.4 Adhesion assay 
Monolayers of L cells transfected with ICAM-1, -2 or -3 or non-transfected L cells were grown 
in 96-wells tissue culture plates In these wells Na^'CrOj labelled Τ lymphocytes were incubated 
with PMA (50 ng/ml), Mn2+ (ImM) or with blocking or activating antibodies (5-10 μg/ml) during 
10 minutes at room temperature, cells were centnfuged at 400 rpm for 1 mm and were subse­
quently incubated at 37°C during 30 min Non-adherent cells were washed away with warm me 
dium, adherent cells were lysed with 1% Triton X-100 and radioactivity was quantified Results are 
expressed as the mean per cent of cells binding from triplicate wells 
49 
Chapter 2 
3. Results 
3.1 Distinct binding of Τ lymphocytes to ICAM-1, -2 or -3 transfectants upon activation of 
LFA-1 
To investigate the regulation of Τ lymphocyte adhesion to ICAM-1, -2 and -3, we generated sta­
ble mouse L cell transfectants expressing high levels of ICAM-1, -2 or ICAM-3 (Fig. 1). 
control ICAM-1 ICAM-2 ICAM-3 
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L cells 
L-ICAM-1 
L-ICAM-2 
L-ICAM-3 
relative fluorescence intensity 
Figure 1. Expression of ICAM-1, -2 and -3 on L cell transfectants. Mouse L cells were trans-
fected with human ICAM-1, -2 or -3 cDNA as described in section 2.3. L cell transfectants and 
non-transfected L cells were stained with antibodies against ICAM-1 (REK-1), ICAM-2 (CBR-IC 
2/2) or ICAM-3 (CBR-IC 3/2) and GAM-FITC second antibody. 
ICAM-1, -2 and -3 expressed on these cells is functional, since the LFA-1 activating antibody 
KIM185 (CD18) induced adhesion of the Τ cell clone JS136 to either one of these transfectants. 
The Τ cell clone JS136 was selected for experiments, because of its high expression of LFA-1 on 
the cell surface (29). Adhesion was specific since it could be blocked by antibodies directed against 
LFA-1 or by antibodies directed against ICAM-1, -2 and -3 respectively (Fig. 2). 
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Next we determined whether various stimuli known to activate the LFA-l/ICAM-1 interaction 
were also capable of inducing LFA-1 -mediated binding of the Τ cell clone JS136 to ICAM-2 or -3 
transfectants (Fig. 3). 
L-ICAM-] L -ICAM-2 L-ICAM-3 
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Figure 2. Adhesion ofJS136 Τ cells to monolayers of L-ICAM-I, -2 or -3 transfectants is LFA-
1/ICAM specific. Adhesion of Τ cells on monolayers of L-ICAM-1. -2 or -3 transfectants was de­
termined after 30' incubation at 37°C, in the presence of medium alone ( D ) or in the presence of 
the LFA-1 activating antibody KIM185 (Ш ) at 10 pg/ml, with or without blocking antibodies 
against LFA-1 (NKI-L15), ICAM-1 (RR1/1). ICAM-2 (CBR-IC2/2) or ICAM-3 (CBR-ÍC3/1 + CBR-
IC3/2) (10 pg/ml). Results are expressed as the mean percent of adherent cells from triplicate 
wells. Non-specific adhesion to non-transfected L cells, which was less than 5%, was subtracted 
from adhesion to L-ICAM-1, -2 and -3 transfectants. Data are representative of 3 experiments. 
We observed that Mn2+, PMA and crosslinking of CD3 increased adhesion of JS136 Τ cells to 
ICAM-2 and -3, however to a lesser extent than adhesion to ICAM-1. LFA-1-mediated adhesion of 
JS136 could also be induced by LFA-1 activating antibodies. Interestingly, we observed differ­
ences in the capacity of the various antibodies to induce adhesion to ICAM-1. -2 or -3. Activating 
antibodies directed against the LFA-1 ß-chain induced adhesion to all three ligands. KIM 185 was 
most effective and strongly increased adhesion to ICAM-1 -2 and -3, while KIM127 increased ad-
hesion to ICAM-1 to a higher extent than adhesion to ICAM-2 and -3. MEM-48 strongly increased 
adhesion to ICAM-1 and to a lesser extent to ICAM-2, while only weak binding to ICAM-3 was 
observed. In contrast to the activating antibodies against the LFA-1 ß-chain, activating antibodies 
directed against the α-chain were not capable of stimulating adhesion to all three ligands. NKI-L16 
induced adhesion to ICAM-1 and -2 but not to ICAM-3, while MEM-83 stimulated binding to only 
ICAM-1. 
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Figure 3. Adhesion ofJS136 Τ cells to 
L-ICAM-1, -2 and -3 transfectants in­
duced by various LFA-1 activating 
stimuli. JSI36 Τ cells were incubated 
on monolayers of L-ICAM-1, -2 or -3 
transfectants as described in Figure 2, 
in the presence of medium alone ( D ) 
or in the presence of PMA (50 ng/ml) 
or antibodies against CD3 (10 ßg/ml) 
(Ш ), activating antibodies against the 
LFA-1 a- or ß-chain (10 ßg/ml) (ЕЭ ), 
or Mn2+ (Ш ) (ІтМ). Data are repre­
sentative of 6 experiments. 
Ъ.1 MEM-83 induces LFA-1-mediated Τ cell adhesion to ICAM-1, but inhibits binding to 
ICAM-2 and ICAM-3 
In an attempt to explain the observation that MEM-83 only induced LFA-1-mediated Τ cell ad­
hesion to ICAM-1, we investigated whether MEM-83 interfered with binding of LFA-1 to ICAM-2 
and -3 (Fig. 4). To this end we combined stimuli that induced adhesion of JS136 Τ cells to all three 
Iigands with the MEM-83 antibody. We observed that LFA-1-mediated Τ cell adhesion to ICAM-2 
induced by KIM185 was blocked to background levels by MEM-83, whereas adhesion 
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Figure 4. Inhibition of LFA-
1-mediated adhesion of 
JS136 Τ cells to L-ICAM-2 
and -3 transfectants by the 
activating antibody MEM-83 
(CDHa). The number of ad­
herent JS136 Τ cells on 
monolayers of L-ICAM-1, -2 
or -3 transfectants was deter­
mined as described in Figure 
2, in the presence of medium 
alone ( D ), the activating an­
tibodies KIM185 or KIM127 
(CD 18; 10 ßg/ml), PMA (50 
ng/ml) or in the presence of a 
combination of these stimuli 
with MEM-83 (10 ßg/ml: • ). 
Data are representative of 
three experiments. 
Stimuli 
Control 
MEM-83 
PMA 
PMA + MEM-83 
KIM 185 
KIM185 + MEM-83 
KIM127 
KIM127 + MEM-83 
Stimuli 
Control 
MEM-83 
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PMA + MEM-83 
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KIM185 + MEM-83 
KIM127 
KIM127 + MEM-83 
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MEM-83 
PMA 
PMA + MEM-83 
KIM185 
KIM185 + MEM-83 
KIM127 
KIM127+ MEM-83 
L-ICAM-1 
20 30 
Adhesion (%) 
L-ICAM-2 
L-ICAM-3 
induced by KIM127 or PMA was only partially inhibited. In contrast, MEM-83 inhibited adhesion 
to ICAM-3, irrespective of the stimulus used to induce adhesion. In contrast, induced adhesion to 
ICAM-l transfectants was unaffected by the MEM-83 antibody, indicating that binding of MEM-
83 does not interfere with binding of KIM127 or KIM185 to LFA-1, since these mAb recognize 
distinct epitopes on LFA-1 (van Kooyk et al., submitted). 
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3.3 NKI-L16 stimulates LFA-1-mediated Τ cell adhesion to ICAM-1 and -2, but not to 
ICAM-3 
Since NKI-L16, like MEM-83, did not induce LFA-1-mediated Τ cell adhesion to ICAM-3, we 
investigated whether NKI-L16 inhibited binding of LFA-1 to ICAM-3 (Fig. 5). We observed that 
in contrast to MEM-83, adhesion induced by KIM185, KIM127 or PMA was unaffected by the 
NKI-L16 antibody. These results indicate that the inability of NKI-L16 to induce adhesion to 
ICAM-3 is not due to inhibition of the interaction of LFA-1 with ICAM-3. 
Stimuli 
Control 
NKI-L16 
PMA 
PMA + NKI-L16 
KIM 185 
KIM185 +NKI-L16 
KIM127 
KIM127 +NKI-L16 
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KIM185 
KIM185 +NKI-L16 
KIM 127 
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L-ICAM-1 
20 30 
Adhesion (%) 
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Figure 5. LFA-1-mediated ad­
hesion of JS136 Τ cells to L-
ICAM-3 transfectants is not 
inhibited by NKI-L16. The 
number of adherent JS136 Τ 
cells on monolayers of L-1С AM-
1, -2 or -3 transfectants was 
determined as described in Fig. 
2, in the presence of medium 
alone ( D ), the activating anti­
bodies KIM 185 or KIM 127 
(CD 18; 10 ßg/ml), PMA (50 
ng/ml) or in the presence of a 
combination of these stimuli 
with NK1-L16 (10 μ^Ι) ( • ). 
Data are representative of three 
experiments. 
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Discussion 
Using stable transfectdnts expressing ICAM-l, -2 or 3 cDNA we investigated the capacity of 
LFA-1 to bind to each of these hgands The results show that (1) similar to what has been reported 
for ICAM-1, activation of LFA-1 is also required for adhesion to ICAM 2 and -3 (2) Activation of 
LFA-1 yields high Τ cell adhesion to ICAM-l, intermediate adhesion to ICAM-2, and low adhe­
sion to ICAM-3, suggesting that ICAM-l is the major hgand for LFA-1 on activated Τ lympho­
cytes (3) Adhesion to ICAM-l and ICAM-2 can be induced by activating antibodies directed 
against the LFA-la- or ß-chain, while binding to ICAM-3 is only induced by activating antibodies 
against the LFA-1 ß-chain (4) MEM-83 induces adhesion to only ICAM-l, since it blocks the in-
teraction of LFA-1 with ICAM-2 and -3 (5) NKI-L16 induces adhesion to only ICAM-l and -2 
and not to ICAM-3, however it does not inhibit binding of LFA 1 to ICAM-3 
The results obtained with MEM-83 suggest that this antibody is able to enforce a conformational 
change on LFA-1 that enhances adhesion to ICAM-l, but renders LFA-1 inaccessible to ICAM-2 
and ICAM-3 This may imply that ICAM 1 binds to a site in the LFA-1 molecule which is distinct 
from the binding sites for ICAM-2 and -3 MEM-83 maps to the I domain, supporting the hypothe-
sis that the I domain is involved in binding of LFA-1 to its ligands (38-41) However, the observa-
tion that MEM-83 is unable to induce adhesion to ICAM-2 and-3, does not exclude that the I do-
main is involved in binding of LFA-1 to ICAM-2 or -3, since it is still possible that binding sites 
for ICAM-2 and -3, when located in the I domain, are stencally hindered by MEM-83 Studies us-
ing purified I domain fragments will be required to elucidate whether the I domain is involved in 
binding of LFA-1 to ICAM-2 and -3 In contrast to MEM 83, the incapacity of NKI-L16 to induce 
adhesion to ICAM-3 was not due to inhibition of the interaction of LFA-1 with ICAM-3 These 
results therefore suggest that LFA-1 can acquire a conformation that selectively binds to ICAM-l 
and -2, but not to ICAM-3 From these data it is tempting to speculate that binding of LFA-1 to its 
different ligands may involve exposition of ligand-specific binding sites or induction of ligand-
specific conformational changes in LFA-1 This notion is supported by the observation that adhe-
sion of β, integrins to their different ligands may also involve distinct conformational changes in 
integrin molecules The β, integrin activating antibody TS2/16 (CD29) induced stronger adhesion 
of VLA-4 to fibronectin than to VCAM-1, under sub optimal conditions (42) In addition the acti­
vating antibody TASC (CD29) inhibited adhesion of ß, integrins to vitronectin, while it promoted 
adhesion to laminin and collagen (43) However, our results do not exclude the possibility that the 
incapacity of NKI-L16 and MEM-83 to induce adhesion to ICAM 3 and ICAM-2 and -3 respec-
tively, may be due to differences in the glycosylation of ICAM-l, -2 and -3 molecules Interest-
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ingly, both ICAM-2 and ICAM-3 have three possible N-hnked glycosylation sites in the first Ig-
like domain, whereas ICAM-1 lacks glycosylation in its first domain (5,6,8,11,12) N-linked glyco-
sylation in the first Ig-like domain may interfere with binding of ICAM-2 and -3 to the conforma-
tions of LFA-1 induced by MEM-83 orNKI-L16. 
In contrast to the activating antibodies directed against the LFA-1 ß-chain, PMA or cross-linking 
of CD3 only slightly increased adhesion to ICAM-3, suggesting that activation of LFA-1 through 
intracellular signals does not result in strong binding of activated Τ cells to ICAM-3 However, it 
should be noted that an ever increasing number of cell surface receptors expressed by Τ cells has 
been implicated in activation of LFA-1 (44-49). It is therefore possible that adhesion of LFA-1 to 
ICAM-3 requires intracellular signals generated upon triggering of surface receptors distinct from 
CD3. In contrast to our results, Campanero et al. (20) observed high adhesion ot Τ cells to ICAM-3 
purified from neutrophils, upon stimulation with PMA, NKI-L16 or CD3 cioss-hnking. A possible 
explanation for these different results might be that ICAM-3 transfected into murine fibioblasts is 
differently glycosylated than ICAM-3 on neutrophils, and therefore less effective in supporting ad­
hesion of LFA-1. However, the observation that strong adhesion to ICAM-3 transfectants was in­
duced by activating antibodies against CD 18, argues against this possibility Furthermore, ìmmu-
noprecipitation of ICAM-3 from L-ICAM-3 transfectants revealed a 128 kD protein (not shown), 
which is comparable to the size of ICAM-3 on lymphocytes (124 kD). Since ICAM-3 on neutro-
phils is 135 kD in size (17), this indicates that ICAM-3 molecules on L-ICAM-3 tiansfectants do 
not differ largely in overall glycosylation from ICAM-3 molecules on neutrophils. Finally, LFA-1 -
mediated adhesion to purified ICAM-3 molecules may differ from adhesion to ICAM-3 tiansfec-
tants. It has been shown that LFA-1 expressed on leukocytes requires activation to bind to ICAM-
1, while purified LFA-1 molecules are constitutively active (9,10,21-23), suggesting that coating of 
the purified receptors induces a conformational change in LFA-1. Similarly, coated purified 
ICAM-3 molecules may be more capable of supporting adhesion than ICAM-3 molecules imbed-
ded in the cell membrane. Therefore, direct comparison of the different models is required to de-
termine which model most closely represents physiological conditions. 
Conformational changes in LFA-1 may determine the ligand specificity of LFA-1, however dif-
ferential expression of ligands on different cell types is another mechanism to regulate LFA-1-
mediated adhesion. ICAM-3 is the most abundantly expressed ligand on resting lymphocytes and 
has therefore been proposed to be an important ligand for LFA-1 during the initiation of immune 
responses. This hypothesis is supported by the finding that resting lymphocytes bind to purified 
LFA-1 predominantly through ICAM-3 (9). Purified LFA-1 molecules are constitutively active, 
supporting our finding that activation of LFA-1 is required for adhesion to ICAM-3. Wc showed 
that LFA-1 on resting lymphocytes can hardly be activated to bind to ICAM-1 (50), ICAM-2 or -3 
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(unpublished observations) Therefore, these results imply that during the initiation of immune re-
sponses ICAM-3 on resting lymphocytes has to bind to LFA-1 on more activated cells These cells 
might be antigen presenting cells, but possibly also other cell types are involved To get more in 
sight into the role ot LFA-1 /ICAM-3 in the initiation of immune responses, identification of these 
cells is therefore of major importance 
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Summary 
We have identified amino acid residues, within the evolutionary conserved I do-
main of the α-chain (CD1 la) of the leukocyte integnn leukocyte function-associated 
antigen (LFA) 1 that are critical for intercellular adhesion molecule (ICAM) 3 
(CD50) binding ICAM-3, a ligand of LFA-1, is thought to mediate intercellular ad­
hesion essential for the initiation of immune responses Using a panel ol hu­
man/murine I domain chimeras and point mutants, we observed that the Ile-Lys-Gly-
Asn motif, located in the N-terminal part of the CD1 la I domain, is required for 
ICAM-3 but not ICAM-1 binding These findings demonstrate that the I domain of 
C D l l a contains distinct functional subdomains for ligand specific binding An 
aspartic acid located at position 137, that is essential to ICAM 1/LFA-1 interactions 
(Edwards, С Ρ , M Champe, Τ Gonzalez, Μ E Wessinger, S A Spencer, L G 
Presta, Ρ W Berman, and S С Bodary, 1995 J Biol Chem 270 12635-12640), was 
also critical for ICAM-3 binding, whereas serine at position 139 did not effect 
ICAM-1 or ICAM-3 binding A synthetic peptide containing the Ile-Lys-Gly-Asn 
motif inhibited ICAM-3 dependent adhesion and prohleration of Τ cells at micro-
molar concentiations, suggesting that this peptide interferes with immune recogni­
tion These observations underscore the importance of ICAM-3 in leukocyte func­
tion, and may lead to development of a new category of immunosuppressive agents 
T he integnn leukocyte function-associated antigen (LFA) 1 (CD1 la/CD 18) is a leukocyte spe­cific adhesion receptor that modulates adhesive interactions and signaling functions in the 
immune system (1-3) LFA-1 mediates cell-cell adhesion upon binding to its hgands intercellular 
adhesion molecule (ICAM) 1 (CD54), ICAM-2 (CD 102) or ICAM-3 (CD50) (4-8) Several studies 
(9-13) have demonstrated that activation of LFA-1 is required for adhesion, and that this can be in­
duced in vitro by engagement ol the Τ cell receptor/CD3 complex Alternatively, LFA-1 can be 
activated by exposure to divalent cations (Mn2*), or treatment with activating monoclonal antibod­
ies (mAbs) to CD 11 a or CD 18 
Although LFA 1 binding sites have been located in the amino-terminal Ig-domains of ICAM-1 
and -3 (14-16), precise determination of the ligand binding sites in LFA-1 is still lacking It has 
been postulated that the 200-amino acid inserted or "I" domains, which are found in the α-chains of 
integrins LFA-1 (CDlla, aL), Мае-I (CDllb, aM), pl50,95 (CDllc, a x ) , VLA-1 (a,), VLA-2 (a 2) 
and α
Ε
β7, and are homologous to the type A domains of von Willebrand factor, cartilage matrix-
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binding protein and complement factor В (17,18), are essential to ligand binding (19-23) The ob 
servations that most blocking mAbs to CD1 la map to the I domain (22-24) and that recombinant I 
domains both inhibit integrin mediated adhesion and possess ligand binding activity (19-21), un 
derscore the role ot the I domain in ligand binding 
In this study a panel ol human/murine CDlla I domain mutants were used to identify amino 
acids that were essential for the binding of LFA-1 to ICAM 3 We observed that residues located in 
the N-terminal portion of the I domain of CD1 la aie critical for ICAM 3 binding, but not foi 
ICAM-1 binding 
Materials and Methods 
Antibodies 
Function blocking mAbs directed against human CD1 la NKI-L15 (11), human CD18 (MHM23) 
(25) and murine CD1 la (M17) (26) were used mAbs Rek-1 (anti-ICAM 1, CD54) (6) and AZN-
IC3 1 (anti-ICAM-3, CD50) (Binnerts et al, manuscript in preparation) were used to inhibit LFA-
1/ICAM-l or LFA-1/ICAM 3 interactions, respectively For cell adhesion studies the activating 
antibody KIM185, directed against CD18 (12) was used The mAb T3b, directed against CD3 (27) 
was used for Τ cell costimulation assays 
Generation of CDlla I domain mutants 
The generation of human/mouse (H/M) chimeras, the I domain point mutants and mu3, has been 
described previously (24,28) Mul and mu2 were generated by overlap extension PCR Briefly, 
using full-length human CD1 la cDNA (pRK LFAam) and mu3 cDNA as templates, the N- and С 
terminal halves of the mul and mu2 I domains were generated by PCR (mul tor residues 125 234 
mu3 was used and for residues 235-308 pRK LFAam was used, mu2 for residues 125-234 pRK 
LFAa
m
 was used and for residues 235 308 mu3 was used) The Bglll at residue 297 was removed 
from the mul I domain The two halves of mul and mu2 were joined by overlapping extension 
PCR and cloned into the CD1 la at the appiopnate I domain restriction sites (Nari, Bgl II mul, 
Nari, PAM 1 mu2) 
Expression of CDlla I domain mutants in 293 cells 
Mutated CD1 la and wild type CD 18 cDNAs were cloned into the RK 5 and RK 7 expression 
plasmids and transfected into the 293 human kidney adenocarcinoma cell line, using a standard 
calcium phosphate coprecipitation method (29) Transfection efficiencies ranged from 20-70% 
After three days, transfectants were harvested by EDTA (5 mM) treatment and were assayed for 
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adhesion to ICAM-1 and ICAM-3 Staining of the transfectants with various anti-LFA-1 mAbs re­
vealed that the mutations did not affect the overall conformation of the LFA-1 heterodimer (28) 
(data not shown). 
Adhesion to ICAM-1 and ICAM-3 
ICAM-1 and ICAM-3 fusion proteins consisting of the five domains of ICAM-1 or ICAM-3 
fused to a human IgGl Fc fragment (ICAM-lFc, ICAM-3Fc, respectively) were isolated from su-
pernatants of L cell cultuies stably transfected with pICAM-lFc and pICAM-3Fc, respectively 
(7,16). Culture supernatant was punlied by protein A column affinity chromatography and eluted 
by 3.5M MgCl2 and 10% glycerol 96-well plates (Maxisorb, Nunc, Roskilde, Denmark) were pre-
coated with 4 μg/ml Goat anti-human Fc (Jackson immunoresearch laboratories, Inc., Westgrove, 
PA) for 2 h at 37°C, and blocked with 1% BSA (Boehnngei, Mannheim) (1 h at RT) ICAM-lFc or 
ICAM-3FC proteins were coated O/N at 4°C or at 37°C for 2 h, at a concentration of 200 ng/well 
Tiansfected 293 cells (200,000 cells per well) were added in adhesion buffer (0 14 M NaCl, 0.02 M 
Hepes, 0.2% Glucose, 1 mM MgCl2 and I mM СаСІ2), with the anti-CD18 activating m Ab 
KIM185(12), and allowed to adhere for 1 5 h at 37°C Non-adherent cells were removed by 
washing 3 times with PBS, and cell attachment was measuied using the PNAG method of Landc-
gren (30) The mean OD405 of triplicate wells was determined and corrected lor the expression 
levels of CD1 la/CD 18 on the distinct transfectants. For comparison 50,000 cells gave an average 
OD of 1. For adhesion of the human Τ cell line HSB (obtained from ATCC), cells (40 000/well) 
were labelled with 5lCr for 45 min at 37°C Cells were incubated with different concentrations of 
synthetic peptides followed by activation with KIM 185. Subsequently, cells were incubated on 
ICAM-1 Fc or ICAM-3FC coated plates for 30 min at 37°C in the presence of peptides and 
KIM 185 Non-adherent cells weie removed by three washes with adhesion buffer, adhering cells 
were lysed with 1% Tnton-XlOO, and radioactivity was quantified Results are expressed as the 
mean percentage of adhesion of triplicate wells 
Proliferation assay 
96-well plates (Maxisorb, Nunc) were coated with suboptimal concentrations of anti-CD3 anti­
bodies (T3b, 10 ng/well, 1 h 37°C), followed by Goat anti-human Fc (400 ng/well, 1 h 37°C), 1% 
BSA (100 μΐ/well, 30 minutes, 37°C) and ICAM-lFc or lCAM-3Fc proteins (100 ng/well, 1 h at 
37°C). Resting PBL obtained by centrifugal elutnation from normal donors as described previously 
(31) were added (100,000 cells/well) and cultured for three days On day 3 cells were pulsed for 16 
h with [^thymidine (1 52 TBq/mmol, 0 5 μα/well; Buckinghamshire, UK) and 
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C D l l a I domain mutants 
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Figure 1. Amino acid sequences of the murine and human CDlla I domains and the HIM I do­
main chimeras and point mutants. Schematic representation of CDlla with the location of the 1 
domain and the metal binding (EF hand) domains. Chimeras were generated in which the complete 
human I domain was replaced with the corresponding murine residues (amino acids 125-311; 
mu3), or in which the N-terminal portion of the human 1 domain {amino acids 125-222; mul), or 
the C-terminal portion of the human I domain (amino acids 223-311; mu2) were exchanged for the 
murine I domain residues. Human/murine chimeras (H/M48-54, I126M, K127A, G12HA, N129K) 
contained f rom one to five murine residues substituted for the human I domain sequences (24). The 
Ala substitutions for conserved residues are shown for the constructs D137A and S139A. The hu­
man residues are represented by a dash and where the sequence differs from the human sequence 
the residue is shown. All chimeric proteins and H/M mutants were expressed in the human kidney 
cell line 293 as LFA-1 (CDlla/CD18) heterodimers. 
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uptake was quantified to measure ICAM-1 or ICAM-3 dependent proliferation. To determine 
whether induced proliferation was LFA-1 and ICAM-1 specific, cells were cultured in the presence 
of function blocking antibodies at a concentration of 10 μg/ml. 
Results and Discussion 
Despite the high sequence homology between human and mouse LFA-1, murine LFA-1 does 
not bind human ICAM-1 (32). Exploiting this species specificity we determined that substitution of 
murine I domain sequences into human C D l l a abolished the ability of LFA-1 to bind ICAM-1 
(28). In this study we adopted a similar strategy to determine the role of I domain sequences in 
LFA-l/ICAM-3 interactions. A panel of human/murine CD1 la I domain mutants were used, some 
of which correspond to epitopes recognized by CD1 la blocking mAbs (24), to identify amino acids 
that were essential for the binding of LFA-1 to ICAM-3 (Fig. 1). 
(HMOS OD4Ü5 OD405 OD40S 
С D 
II 0.5 I l.S 2 2J II 0.5 I U 2 ZJ 0 0.5 I ІЛ 2 2.5 3 3.5 4 l) 0.2 0.4 0.6 0.H 1 1.2 1.4 
ІІШ05 OD405 " » « 5 ОШСИ 
Figure 2. LFA-1 mediated adhesion ofH/M CDlla I domain chimeras and point mutants to pu­
rified human ICAM-1 and ICAM-3. 293 cells, transfected with pAdv RNA (mock) or together with 
wildtype human CD18 and the indicated CDlla constructs, were tested for their capacity to bind 
ICAM-1 (white) and ICAM-3 (black) in the presence of 5-20 pg/ml activating anti-CD18 mAb 
(KIM185) [12]. A) Adhesion of the mul, mu2 and mu3 chimeric proteins to human ICAM-1 and 
ICAM-3. B) Adhesion of the H/M I domain chimeras to human ICAM-1 and ICAM-3. С and D) Ad­
hesion of the I domain point mutants to human ICAM-1 and ICAM-3. One representative experi­
ment out of three is shown. 
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The capacity of 293 cells transfected with cDNAs encoding chimeric CD1 la and human CD 18, 
to bind purified human ICAM-lFc and ICAM-3Fc is shown in Fig. 2A. Wild type human 
CDlla/CD18 transfectants bound both ICAM-1 and ICAM-3. As had been previously shown with 
ICAM-1 (28), the mu3 chimera (which contains the complete murine I domain) did not bind hu­
man ICAM-3. FACS analysis, using the M17, NKI-L16 and MHM23 m Abs (11,25,26), showed 
that the mu3 chimera contains the expected murine I domain epitopes as well as human CD1 la and 
CD 18 epitopes, suggesting that this heterodimer was correctly folded (28). Thus it appeared that 
the I domain of murine LFA-1 lacked the binding site(s) for ICAM-3 as well as ICAM-1. We also 
observed that mul (which contains the N-terminal portion of the murine I domain) bound ICAM-1 
but not ICAM-3, whereas mu2 (which contains the C-terminal portion of the murine I domain) 
bound to both ICAM-1 and ICAM-3. We conclude that the N-terminal portion of the human I do­
main contains residues critical to ICAM-3 binding, and that ICAM-1 and ICAM-3 bind to distinct 
sites within the I domain of LFA-1. Precise mapping of residues involved in ICAM-1 binding is in 
progress. 
To precisely locate the ICAM-3 binding site in the N-terminal portion of the I domain, we tested 
the ability of seven H/M chimeras to bind ICAM-3. (Fig. 2) The overall conformation of these H/M 
LFA-1 chimeras was intact , and did not affect ICAM-1 binding (24,28) Of all H/M chimeras 
tested only H/M53, in which the human He-126 and Asn-129 were replaced with murine residues 
Met and Lys respectively, completely abrogated adhesion to ICAM-3 (Fig. 2B) In contiast, the ad­
hesion of this mutant to a wide range of concentrations of ICAM-1 showed identical binding as that 
of wild-type CD1 la (data not shown). This indicates that the loss of binding of H/M53 to ICAM-3 
was not due to the low affinity of ICAM-3, compared to ICAM-1, for LFA-1 Point mutations of 
Ile-126 and Asn-129 revealed that only the replacement of Asn with Lys at position 129 dramati­
cally reduced the adhesion to ICAM-3. When the Lys-127 and Gly-128, which are conserved be­
tween the human and mouse, were mutated to Ala only the Lys-127 mutation led to reduced bind­
ing to ICAM-3. These data demonstrate that residues critical for ICAM-3 binding are located in the 
N-terminal portion of the I domain of CD1 la within the Ile-Lys-Gly-Asn motif at positions 126-
129, and that Lys-127 and Asn-129 are critical to ICAM-3 binding (Fig 2C). 
It is interesting to note that the Ile-Lys-Gly-Asn sequence was previously found to be critical for 
the binding of several mAbs to murine and human CD1 la that block binding to ICAM-1 (24). Al­
though subsequent studies (28) demonstrated that these residues were not dnectly involved in 
ICAM-1 binding, the fact that an immediately adjacent sequence (residues 130-143) was highly 
conserved among the CDU integnn I domains, as well as homologous domains of other proteins 
(e.g. cartilage matrix protein, von Willebrand factor and factor В (33)), suggested that this was a 
functionally significant domain. Studies by Michishita et al (19) showed that mutation of Asp-140-
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Gly-Ser to Ala-Gly-Ala of the closely related integrili CD1 lb abolished binding to C3bi. Recent X-
ray diffraction studies of the I domain of Mac-1 have shown Asp-140 and Ser-142 to be part of a 
novel cation binding site in which the acidic side chain coordinates directly to a Mg2+ ion (34). 
Studies of CD 11a (28) have shown that the homologous Asp-137 in CD 11 a was critical to ICAM-1 
binding. We found that mutation of Asp-137 to Ala abrogated binding to ICAM-3 (Fig. 2D). In 
contrast, mutation of Ser-139 to Ala did not profoundly effect LFA-1 binding to ICAM-1 or 
ICAM-3, suggesting that Ser-139 of CD1 la may not be involved in cation coordination. Since the 
residues corresponding to the Ile-Lys-Gly-Asn motif were absent from the Mac-1 I domain frag­
ment used for the X-ray diffraction study (34), and since Mac-1 lacks a homologous sequence it 
will be of interest to determine the structure and proximity of this motif to the CD1 la cation bind­
ing site. 
0 25 50 75 100 125 0 25 50 75 100 125 
concentration (\iglm\) concentration ^g/ml) 
— α — peptide 1 CIKGNVDLVFLFDG 
—V— peptide 2 GRPGFQECIKGNVDLVFLFDG 
— o — peptide 3 MLQGRPGFQECIKGNVD 
Figure 3. Inhibition of LFA-1/ICAM-3 mediated adhesion by low concentrations of synthetic I 
domain peptides. The LFA-1 expressing HSB Τ cell clone was pre-incubated with different con­
centrations of the indicated synthetic peptides (6.25 μg/ml-200 ßg/ml) followed by activation with 
the anti-CDl8 mAb KIMI85 (10 ßg/ml). The capacity of the peptides to block binding to ICAM-1 
or ICAM-3 was measured. Results are expressed as the mean percent of inhibition of cell binding 
from triplicate wells. Standard deviation was less than 8%. One representative experiment out of 
three is shown. 
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To obtain further insight into the role of the Ile-Lys-Gly-Asn (126-129) and the Asp-137 se­
quences in binding of ICAM-3 to LFA-1, a series of peptides that spanned this region of CD1 la 
were synthesized (Fig. 3). Interestingly, we observed that low concentrations of one peptide effi­
ciently inhibited the ability of the LFA-1 expressing T-cell clone HSB to bind to ICAM-3, but not 
to ICAM-1 (peptide 2; IC50 = 25 μg/ml; 10.8 μΜ). In contrast the two other peptides, (peptides 1 
and 3) which also contain the Ile-Lys-Gly-Asn motif did not inhibit LFA-1 mediated adhesion at 
concentrations up to 100 μg/ml. These data indicate that the sequences surrounding the this motif 
are important for the inhibitory effect of peptide 2. 
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Figure 4. Inhibition of ICAM-3 costimulation of peripheral blood lymphocytes (PBL) with I do­
main peptides. Resting PBLs (100,000 cells per well) were cultured in the presence of the synthetic 
peptides (100 μβ/ml; depicted in figure 3), on plates coated with ICAM-1 Fc (white) and ICAM-3Fc 
(black) (100 ng/well) along with suboptimal concentrations of anti-CD3 mAb ( 1 ng/well) for 3 days 
at 37°C. One experiment out of three, in which triplicate determinations were carried out, is 
shown. 
Since ICAM-3 is thought to play a role in the initiation of the immune response, we investigated 
whether the Ile-Lys-Gly-Asn containing peptides also affected immune function. We assayed 
whether the peptides would inhibit either the ICAM-1, or ICAM-3/CD3-induced co-stimulation of 
resting PBL proliferation (35). As illustrated in Fig. 4, peptide 2 inhibited ICAM-3 induced prolif­
eration, but not ICAM-1 induced proliferation. Peptides 1 and 3 were inactive. The inhibitory ac­
tivity of the peptides is likely to result from binding of the peptide to residues of ICAM-3 that are 
involved in LFA-1 binding. This is currently under investigation. 
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Comparison of the sequence homology of the I domains of the other CD 18 integrins indicated 
that the Ile-Lys-Gly-Asn motif is unique to CD1 la, suggesting that LFA-1 contains a unique bind­
ing site for ICAM-3. Indeed no studies have reported Mac-1- or pl50/95-mediated binding to 
ICAM-3. It will be interesting to know whether the recently described fourth member of the CD18 
integrins CD1 Id/CD 18 contains the Ile-Lys-Gly-Asn sequence in the I domain, since there is evi­
dence that this heterodimer binds to ICAM-3 with high affinity (36). 
Collectively, these findings demonstrate for the first time that the I domain of CD1 la contains 
distinct functional subdomains for ligand specific binding; a conserved Asp-137 important for 
binding of ICAM-1 and -3, an Ile-Lys-Gly-Asn domain important for binding of ICAM-3, and dis­
tinct, yet to be defined residues important for binding of ICAM-1 (37) Our finding that low con­
centrations of I domain peptides significantly inhibit ICAM-3 dependent immune function, without 
affecting ICAM-1 dependent function, may direct the development of a new class of anti- inflam­
matory / immunosuppressive agents for the treatment of diseases such as arthritis or graft rejection 
after organ transplantation. 
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Summary 
Several studies indicate that the I domain located in the α chain (CD1 la) of leuko­
cyte function-associated antigen 1 (LFA-1, CD11 a/CD 18), plays an essential role in 
ligand recognition We recently identified three distinct epitopes (IdeA, IdeB and 
IdeC) within the CD1 la I domain, recognized by antibodies that block binding of 
LFA-1 to intercellular adhesion molucule (ICAM) 1, 2 and 3 In the present study, 
we used a series of human/murine CD1 la I domain chimeras, to localize a fourth I 
domain epitope (IdeD), recognized by three independently derived anti-CDl la anti­
bodies that selectively block the binding of LFA 1 to ICAM-3, but not to ICAM-1 
The IdeD epitope depended on human CD1 la residues Asp182 and Ser184 and was not 
present in CD1 lb or CD1 lc Although mutation of Asp'82 and Ser18'' failed to abolish 
ICAM-3 adhesion of LFA-1 transfectants, alignment of these residues with the 
crystal structure of the CD1 la I domain, suggested that the IdeD epitope is located 
in close proximity to residues (He126 and Asn129) recently implicated in the ICAM-3 
binding site (1) Interestingly, the IdeB and IdeC epitopes appeared to be in close 
proximity of a divalent cation binding pocket within the CD1 la I domain that regu­
lates both ICAM-1 and ICAM-3 adhesion Taken together, these data indicate that 
distinct regions of the CD1 la I domain contain epitopes for antibodies that either 
selectively inhibit binding of LFA-1 to ICAM 3, or interfere with both ICAM-1 and 
ICAM-3 binding of LFA 1 
T he leukocyte integnn LFA 1 (CD1 la/CD18) is a cell surface receptor that mediates adhesive interactions and signal transduction in the immune system (2 5) LFA-1 is expressed by leu­
kocytes and belongs to the β2 family of integnns, in which a common β subunit (CD 18), is associ­
ated with any of three distinct, but structurally homologous, α subunits, a L (CD 11 a, LFA-1), ctM 
(CD1 lb, Mac-1) and o^ (CD1 lc, ρ 150,95) (2) The extracellular domain of the LFA-1 α subunit 
contains two domains thought to be of functional significance These include a putative divalent 
cation binding region, consisting of three tandem repeats of an EF hand motif, also found in other 
integnns (6,7) and a 200-amino acids inserted or 'I ' domain (8), which is also present in α
Μ
 a
x
 a,, 
a 2 and av subunits (2,9) The I domain contains sequences homologous to the type A domains of 
von Willebrand factor, cartilage matrix binding protein and complement factor В (8) 
LFA-1 is known to recognize three ligands ICAM 1 (10), ICAM-2 (11) and ICAM-3 (12-14), all 
of which are members of the Ig super family, and have five, two and five Ig-hke domains respec-
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tively ICAM-1 is expressed on many cells, including lymphocytes and endothelial cells, and its 
expression is cytokine inducible (15) ICAM-2 is expressed on lymphocytes, endothelial cells and 
platelets (16,17), whereas ICAM 3 is only expressed on leukocytes (18) In contrast to ICAM-1, 
expression of ICAM-2 and -3 is not induced by cytokines (18,19) 
LFA-1 mediated adhesion requires activation of the LFA-1 molecule (20-22) Activation can be 
induced by intracellular signals generated upon cross-inking of cell surface receptors (T cell re-
ceptor/CD3) (21,22), upon binding of activating anti-LFA-1 antibodies (23-27), or divalent cations, 
such as Mn2+ (28) Activation of LFA-1 and subsequent ligand binding is thought to result from 
conformational changes in the α/β heterodimer and requires binding of divalent cations, such as 
Mg2+ and Ca2+, an intact cytoskeleton and a physiological temperature (29) While Ca2+ binding 
supports clustering of LFA-1 on the cell-surface, presumably resulting in enhanced ligand binding 
avidity, Mg2+ binding to LFA-1 has been suggested to alter the affinity of LFA-1 for its ligands 
(28,30) 
Recent findings indicate that the I domains of CD1 la, CD1 lb, CD1 lc as well as I domain se­
quences of the a, and a2 chains of β, class of integnns, are involved in ligand binding Evidence 
comes from the finding that purified aL (CD1 la), aM (CD1 lb) and a, I domains directly bind their 
respective ligands, ICAM-1, fibrinogen and iC3b, or collagen (31 33) Secondly, mutation of 
aspartic acid or threonine residues within the I domains of aM, aL a, and o^  affects cation binding 
and impairs adhesion (33-37) Furthermore, we identified residues lie126 and Asn129 within the 
CD1 la I domain to be critical for adhesion to ICAM-3, but not tor ICAM-1 binding, indicating that 
the CD1 la I domain contains distinct binding sites for different ligands (1,27) Finally, most anti-
CD 1 la, CD1 lb, CD1 lc antibodies that block ligand interactions recognize the I domain (38-40) 
Previous investigations have revealed that anti-human CD1 la antibodies do not cross-react with 
murine LFA-1, implying that sequences in the I domain important for mAb binding can be located 
by replacing human CDlla sequences with the murine homologues (40) Using human/mouse I 
domain mutants in which sequences from the human CD1 la I domain were substituted into murine 
I domain residues, we recently demonstrated that anti-CDl la I domain antibodies that inhibit the 
interaction of LFA-1 to ICAM-1, 2 and -3 (e g TS 1/22, 25 3 and MHM 24) (M E Binnerts, Y 
van Kooyk and С G Figdor, unpublished observation, 39,40), recognized three distinct epitopes 
within the CDlla I domain (IdeA res 126-129, IdeB res 143-148 and IdeC res 197 203)(40) 
In the present studies, we identified a lourth epitope within the CD1 la I domain (IdeD), that is 
recognized by three anti-CDl la antibodies that selectively inhibit the binding ot LFA I to ICAM-
3 Alignment of the IdeD epitope with the recently solved crystal structure of the CD1 la I domain 
(41), suggested that it is located in close proximity to I domain residues lie126 and Asn129 critical 
for ICAM-3, but not ICAM-1 binding of LFA-1 (1) 
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Materials and methods 
Antibodies. 
A panel of mouse monoclonal antibodies (mAbs) was used, MEM-83 (24), YTH81 5 (39,42), 
122 2A5 (39), NKI-L15 (43) and NK1-L16 (23) directed against CD1 la, MHM 23 (44), KIM185 
(26) and MEM-48 (27) directed against CD 18, REK-1 directed against ICAM-1 (27), AZN IC3 1 
directed against ICAM-3 (M E Binnerts, Y van Kooy,k and С G Figdor, manuscript in prepara­
tion), and T3b directed against CD3 (45) 
Generation of CDl la I domain mutants. 
The construction of chimeric human/mouse C D l l a I domain variants (H/M48-H/M54) and the 
generation of the D137A mutant has been described previously (1,37,40) The H/M48-H/M54, 
D137A and D239A mutants were generated by oligonucleotide directed mutagenesis using a plas-
mid containing the entire human CD11 a chain (pRKLFAam), as a template After each polymerase 
chain reaction step, clones were checked by sequencing for correct incorporation of oligonu­
cleotides 
Expression of CDl la mutants in 293 cells and immunofluorescence analysis of transfectants 
Chimeric C D l l a and wild type CD18 cDNAs were cloned into the RK 5 and RK. 7 expression 
plasmids and transfected into the 293 human kidney adenocarcinoma cell line, using a standard 
calcium phosphate coprecipitation method (46) Transfection efficiencies ranged from 30-70% 
Three days after transfection, transfectants were harvested by EDTA (5 niM) treatment and expres­
sion of CDlla/CD18 on the transfectants was determined by immunofluorescence Cells (2xl0' i) 
were incubated for 1 h at 4°C with appi opriate dilutions of the different mAbs (2 μg/ml) in Hepes 
buffer (0 02 M Hepes, 0 14 M NaCl, 0 2% glucose, 1 mM MgCl2 and 1 mM CaCl2), followed by 
incubation with FITC-labeled goat (Fab'), anti mouse (Cappel, Ine , West Chester, PA) or anti-rat 
IgG (Caltag, Los Angeles, CA) antibodies, for 1 h at 4°C The percentage of positive cells was de­
termined by FACScan analysis (Becton Dickinson, Mountain View, CA) 
Immunoprecipitation of CDl la variants expressed in 293 Cells 
The method used for immunoprecipitation of CD1 la variants has been described in detail else­
where (37,40) Briefly, two or three days after transfection of CD1 la chimeras into 293 cells, trans­
fectants were metabohcally labeled in methionine-free Dulbecco s Modified Eagles Medium 
(DMEM) with 100 μθ/ml of ["S]methionine for 4-5 h The medium was removed and the cells 
were lysed in 1 ml of lysis buffer ( 1 % Nomde Ρ 40, 10 mM Tris-HCl (pH 7 5), 2 mM CaCI2 and 2 
mM MgCl2)/10 cm dish Cell debris and nuclei were pelleted and the supernatant was used for sub-
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sequent immunoprecipitations Antibodies (1-2 pg/immunoprecipitation) were incubated with 100 
μΐ of labeled lysate and 2 μg of ïabbit anti-mouse IgG (Cappel) for 2 h at room tempeiature The 
antibody/antigen complexes were precipitated using 2 mg Protein A/Sepharose CL-4B beads 
(Pharmacia, Ine , Uppsala, Sweden), the beads were washed two times in wash buffer (0 5% 
Nonidet P-40, 0 01% sodium dodecyl sulphate (SDS), 400 mM NaCl, 10 mM Tns-HCl (pH 7 5), 2 
mM CaCl2, 2 mM MgCl2) and resuspended in 30 μΐ of 2x concentrated SDS-polyacrylamide gel 
electrophoresis sample buffer, boiled for three minutes, and centnfuged briefly The clanfied sam­
ple was then resolved on 6% SDS-polyacrylamide gels 
Adhesion assay. 
ICAM-1 and ICAM-3 fusion proteins consisting of the five domains ot ICAM-1 or ICAM-3 
fused to a human IgGl Fc fragment (ICAM-lFc and ICAM-3Fc, respectively) were isolated fiom 
supernatants of L cell cultures stably transfected with pICAM-lFc and pICAM-3Fc, íespectively 
(13,47) Culture supernatant was purified by protein A column affinity chromatography and eluted 
by 0 01 M Hepes buffer at pH 7 0, containing 0 15 M NaCl, 3 5 M MgCl, and 10% (w/v) glycerol 
96-well flat bottomed plates (Maxisorb, Nunc, Roskilde, Denmark) pre coated with 4 μg/¡rιl goat 
anti-human Fc (Jackson Immunoresearch Laboratories, Ine , Westgrove, PA) lor 2 h at 37CC, and 
blocked with 1% bovine serum albumin (Boehnnger Mannheim) (I h at RT), were coated over­
night at 4°C with ICAM-1 Fc or ICAM 3Fc proteins (300 ng/ml, 50 μΐ/well) A stable human LFA-
1 transfected 293 cell line (293-LFA), or transiently transfected 293 cells (100,000/well oi 200 000 
per well, respectively), were added in adhesion buffer (0 14 M NaCl, 0 2 % glucose, 0 02 M Нереь, 
1 mM CaCl2i 1 mM MgCl2) in the presence of the indicated mAbs ( 10 50 μg/ml) and incubated tor 
1 5 h at 37°C Non-adherent cells were removed by three washes with adhesion buffer, and cell at­
tachment was measured using the PNAG method of Landegren (48) Results arc expressed at mean 
OD405 values of triplicate wells For adhesion of the human Τ cell line HSB (obtained from 
ATCC), cells (40,000/well) were labeled with 51Cr for 45 min at 37°C and incubated on ICAM lFc 
or ICAM-3FC coated plates for 30 mm at 37°C Non-adherent cells were removed by three washes 
with adhesion buffer, adhering cells were lysed with 1% Triton-XlOO, and radioactivity was quan­
tified Results are expressed as the mean percentage of adhesion of triplicate wells 
Proliferation assay 
96-flat bottomed wells (Maxisorb) were coated with suboptimal concentrations ot anti-CD3 anti­
bodies (T3b, 30 ng/ml, 100 μΐ/well, 1 h 37°C), followed by Goat anti human Fc (Jackson Im­
munoresearch Laboratories, Ine , 4 ц^ті , 100 μΐ/well, I h 37°C), 1% BSA (100μl/well, 30 min at 
37°C) and ICAM-lFc or ICAM-3Fc proteins (300 ng/ml, 50 μΐ/well, 1 h at 37°C) Resting 
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Figure 1. The CDlla I domain specific mAbs MEM-83, YTH81.5 and J22.2A5 selectively inhibit 
the LFA-l/ICAM-3 interaction. After activation of LFA-1 with the CD18 activating antibody 
MEM-48 (5-20 l¡g/ml), the capacity of HSB Τ cells or 293 cells transected with CD I la/CD 18 
constructs, to bind purified ICAM-lFc or lCAM-3Fc proteins (300 ng/ml; 50 μΐ/well) was deter­
mined, in the absence of presence of mAbs MEM-83, YTH81.5, 122.2A5, or NKI-L15 (CDlla) at 
10-50 μξΜ. Results are expressed as the mean percentage of adherent cells from triplicate wells. 
One representative experiment out of three is shown. 
peripheral blood lymphocytes (PBL) obtained by Ficoll-Hypaque density centrifugation and subse­
quent depletion of monocytes by adherence to plastic, were added (100.000 cells/well) and cultured 
for three days. On day 3 cells were pulsed for 16 h with ['HJthymidine (1.52 TBq/mmol, 0.5 
цСіЛ еІІ; Amersham, Buckinghamshire, United Kingdom), to measure ICAM-l or ICAM-3 de­
pendent proliferation. To determine whether induced proliferation was LFA-1- and ICAM-l- or 
ICAM-3-specific, cells were cultured in the presence of function blocking antibodies at a concen­
tration of 10 μg/ml. 
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Results 
MEM-83, YTH81.S and 122.2A5 selectively block the binding of LFA-1 to ICAM-3, but not 
to ICAM-1 
To characterize antibodies that recognize functionally important epitopes within the C D l l a I 
domain, we determined the ability of several anti-CDl la mAbs to selectively inhibit the binding of 
LFA-1 to ICAM-3 (Fig. 1). The capacity of the LFA-1 positive Τ cell line HSB and transfected 293 
cells (293-LFA-l) to bind purified ICAM-1 (ICAM-lFc) or ICAM-3 (ICAM-3Fc) coated onto tis­
sue culture plates in the presence of the anti-CDl la mAbs MEM-83, YTH81.5, 122.2A5, or NK1-
L15 was determined. Activation of LFA-1 by an activating anti-CD 18 mAb (MEM-48), induced 
adhesion of both HSB and 293-LFA-l cells to ICAM-lFc and ICAM-3Fc proteins. The anti-
CDl la mAb NKI-L15 blocked binding to ICAM-1 as well as ICAM-3 (Figure 1). In contrast, the 
anti-CDl la mAbs MEM-83, 122.2A5 and YTH81.5 blocked only adhesion to ICAM-3 and not to 
ICAM-1. Inhibition of LFA-1/ICAM-3 adhesion by these antibodies was also observed when LFA-
1 on the HSB cells was activated with phorbol 12-myristate 13-acetate PMA or Mn2+ (data not 
shown). 
control - | | 
CD3-1 
ICAM-1 - 1 
CD3+ICAM-1 - J B 
+NKI-L15 -i 
+REK-1 - | H | 
+AZN-IC3.1-b| 
+MEM-83 - H I 
+ 122.2A5-J 
+YTH81.5-|| 
Η—ι 
| 1 
ι 1 
ICAM-1 
• • • i 
1 
control 
CD3 - | I 
1САМ-3-І 
CD3+ICAM-3 
ICAM-3 
CPM CPM 
Figure 2. MEM-83, YTH81.5 and 122.2A5 inhibit ICAM-3 dependent costimulation of Τ cells. 
Resting Τ cells were plated on ICAM-lFc or ICAM-3Fc, together with sub-optimal concentrations 
of coated anti-CD3 antibodies (30 ng/ml; 50 μΐ/well), in the presence or absence of mAbs MEM-
83, YTH8L5, 122.2A5, NKI-L15 (CDlla), REK-1 (ICAM-1) or AZN-IC3.1 (ICAM-3). at 10 ng/ml. 
After three days of culture, [3 HJincorporation was determined. Results are expressed as the mean 
counts/min of triplicate wells. Data are representative of three experiments. 
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MEM-83, YTH81.5 and 122.2A5 inhibit ICAM-3 dependent costimulation of Τ cells 
We next determined whether MEM-83, YTH81 5 and 122 2A5 interfered with ICAM-3 or 
ICAM-1 dependent costimulation of Τ cells Resting peripheral blood lymphoytes obtained from 
healthy donors were plated on ICAM-1 Fc or ICAM-3Fc proteins together with sub-optimal con­
centrations of coated anti-CD3 antibodies, in the presence of either MEM-83, YTH81 5, 122 2A5, 
or in the presence of blocking antibodies directed against LFA-1, ICAM-1 or ICAM-3 Figure 2 
demonstrates that although MEM-83, YTH8I 5 and 122 2A5 selectively inhibited LFA-l/ICAM-3 
adhesion, they interfered with both ICAM-1- and ICAM-3-dependcnt Τ cell proliferation ICAM-1 
and ICAM-3 dependent proliferation was prevented by blocking antibodies against LFA-1 and by 
antibodies directed against ICAM-1 or ICAM 3, respectively, indicating that proliferation was 
LFA-1 and ICAM specific Interestingly, proliferation on ICAM-lFc was also prevented by 
blocking antibodies directed against ICAM 3, suggesting that piohfeiation on ICAM-1 involves 
LFA-l/ICAM-3 inteiactions between proliferating cells These data may indicate that MEM-83, 
YTH81 5 and 122 2A5 inhibit prolireiation on ICAM-1 Fc, by pieventing these LFA-l/ICAM-3 
interactions 
Mapping of the epitope recognized by MEM-83, YTH81.5 and 122.2A5 within the CD 11a I 
domain 
MEM-83, YTH81 5 and 122 2A5 have previously been shown to bind to the CD1 la I domain 
(24,39) To localize residues within in the CD1 la I domain important foi the binding of these 
mAbs, a panel of human/mouse CD1 la chimeras (H/M48 54) was used in which small clusters of 
amino acids from murine CD1 la replaced the corresponding residues of the human CD1 la 1 do­
main (37,40) A diagram of the chimeric gene products is provided in Figuie 3 
To identify residues within the CD1 la I domain critical for binding of TCAM-3 blocking CD1 la 
antibodies, we determined the ability of MEM 83, 122 2A5 and YTH81 5 to immunoprecipitate 
chimeric C D l l a proteins Irom transiently transfected 293 cells The MEM-83, 122 2A5 and 
YTH81 5 antibodies all readily immunoprecipitated H/M53, H/M52 and H/M54 proteins (Fig 4), 
showing that these antibodies did not bind to the previously identified IdeA, IdeB, or the IdeC epi­
topes within the CD1 la I domain (40) In contrast, the ICAM 3 blocking antibodies were unable to 
immunoprecipitate the H/M48 protein, suggesting that antibody binding depended on Asp"12 and 
Ser184 residues, replaced by Thr and Leu respectively, in the H/M48 chimeia The H/M 48 mutation 
did not simply inhibit antibody binding by disiupting the overall conformation of C D l l a , since 
monoclonal antibodies recognizing the IdeA, IdeB or IdeC epitopes, were still able to bind the 
H/M48 protein (40) Thus, H/M 48 appeared to define a new epitope recognized by several inde­
pendently isolated monoclonal antibodies 
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human/mouse chimeric CD11a I domain mutants 
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Figure 3. Amino acid sequences of murine and human CDlla I domains and human/murine 
substitution mutants. A) schematic representation of CDlla with respective locations of the ¡do-
main and the putative metal binding (EF-hand) domains B) in the human/murine chimeras 
(H/M48-54), one to five human residues were substituted for murine residues. In D137A and 
D239A mutants, aspartic acid residues were substituted for alanine. 
Since we observed some reduced immunoprecipitation of the H/M50 chimera by 122 2A5, wc 
investigated the ability of human CD 18 to form a heterodimenc complex with chimeric CD1 la, to 
verify the conformational integrity of the H/M chimeras. In these experiments full-length chimeric 
C D l l a variants were co-transfected with wild type human CD18 into 293 cells and transfectants 
were assayed for antibody binding by FACS analysis. Co-expression of CD18 with all CD1 la vari-
ants was detected on the cell surface (Table I), suggesting that the CD1 la I domain mutations pre-
served the structural elements required for heterodimer formation and export to the cell surface. 
Another indication for the conformational integrity of the H/M variants was provided by binding of 
a murine antibody to human CD 18 (MHM.23), that recognizes an epitope critically dependent on 
α/β association of CD 11 a and CD 18 (44,49). The observation that MHM 23 bound all of the I do­
main variants examined (Table I) provided further data that the I domain variants used for epitope 
mapping studies did not interfere with structural features required for heterodimer 
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Figure 4. Immunoprecipitation of human Culla variants with ICAM-3 blocking CDlla mono­
clonal antibodies MEM-83, YTH81.5 and 122A.5. The human kidney adenocarcinoma cell line 
293 was transfected with plasmids directing the expression of full length human CDlla (CDlla), 
or human CDlla I domain variants in which human CDlla I domain residues were replaced by 
corresponding murine residues (H/M48-H/M54). A diagram listing the mutations introduced in 
each variant is provided in Figure 3. ICAM-3 blocking anti-CDlla mAbs (MEM-83, YTH81.5, 
122.2A5) were added to detergent lysates of transfected cells metabolically labeled with [ S] me­
thionine and subjected to immunoprecipitation. MEM-83 is shown in panel A, YTH81.5 in panel В 
and 122.2A5 in panel С 
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formation. Similarly, the binding of the NKI-L16 mAb (CD 11a) to the conformation sensitive L16 
epitope (23) located outside the CD I la I domain (37,50), provided additional evidence that muta­
tions in the CD1 la I domain do not change the overall conformation of CD 1 la. 
Figure 5. Adhesion of CD 11a I 
domain mutants to ICAM-1 and 
ICAM-3. The capacity of 293 
ceils transfected with chimeric 
CDlla and wild type CD18 to 
bind ICAM-lFc or ICAMSFc 
was determined, in the presence 
of the activating CD18 mAb 
KIM 185 (5-10 ßg/ml). A. 293-
cells were transfected with 
CD18 alone (293-mock), with 
CD 18 and CDlla (CDlla). or with human/mouse chimeric CDlla constructs and CD 18 (H/M48 
and H/M53). B. the capacity of 293 cells cotransfected with CD 18 and CDlla point mutants 
D137A or D239A, to bind to ICAM-lFc or ICAM-3Fc was determined in the same experiment. Re-
sults are expressed as the mean OD405 from triplicate wells. One representative experiment out of 
three is shown. 
In contrast to the immunoprecipitation studies, mAb 122.2A5 readily bound the H/M50 chimera 
when complexed with CD 18 (Table I), suggesting that residues mutated in H/M50 do not directly 
contribute to the 122.2A5 epitope, but rather affect antibody binding by inducing subtle conforma-
tional changes in CD1 la, that are not apparent in the CDlla/CD18 heterodimer. Together, these 
studies demonstrate that antibodies that selectively inhibit the LFA-1/ICAM-3 interaction, recog-
nize a novel epitope within the CD1 la I domain, termed IdeD, dependent on residues Aspl82-Ser184. 
Table 1. LFA-1 epitope expression 
on human/mouse I domain mu-
tants. Summary of reactivity of anti-
CD I la mAbs on 293 transfectants, 
as determined by immunofluores-
cence flow cytometry. 293-cells were 
transfected with CD18 alone (293-
mock), with CD18 and CDlla 
(CDlla), or with human/mouse 
chimeric CDlla constructs and 
CDI8 (H/M48-H/M54). + repre-
sents positive staining of 30-60% of 
the transfected cells, - represents no significant staining (0-9% of transfected cells, not higher than 
the negative control). 
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Cells 
C D l l a 
293-mock 
H/M48 
H/M49 
H/M50 
H/M5I 
H/M52 
H/M53 
H/M54 
MHM.23 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
NKI-L16 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
mAb 
MEM-83 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
YTH81.5 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
122.2A5 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
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Spatial relationship between CDl la I domain residues involved in LFA-1 antibody and li-
gand binding 
Recently, the crystal structure of the I domain of the LFA-1 α chain (CD1 la) has been eluci­
dated (41). The C D l l a I domain comprises four parallel β strands (ßl-ß4) and one short anti-
parallel β strand (β2') ( surrounded by seven α helices (ocl-a7). 
Figure 6. Ribbon representation of CDlla I domain based on coordinates provided by Leahy et 
al. (41). Epitopes recognized by antibodies to CD1 la (IdeA, IdeB, IdeC, and IdeD) have been 
aligned with the CDlla sequence and are shown as black ribbon or tube. Mn2* ion (black sphere), 
and N- and C- termini have also been labeled. Ribbon diagram was drawn using the MIDAS pro­
gram (University of California, San Francisco). Positions corresponding to the IdeB epitope 
(residues 143-148). the IdeC epitope (residues 197-203). and the IdeD epitope (Asp'"2 and Ser'84) 
are indicated. Of the IdeA epitope (He126 and Asn'29) only the fourth residue (Asnl29) is indicated, 
since the first three residues were not included in the CDlla I domain crystal. 
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A single cation binding pocket or metal ion dependent adhesion site (MIDAS) (36), consisting 
of five cation coordinating residues, is located at the top of the β sheet on the surface of the I do­
main (41). Residues important for LFA-1-ligand and antibody binding were aligned with the 
CD1 la I domain crystal structure, to analyze their spatial organization (Fig. 6). Inteiestingly, two 
of the epitopes (IdeB and IdeC) recognized by mAbs that block LFA-1 binding to ICAM-1, -2 and 
-3 (M.E. Binnerts, Y. van Kooyk and С G. Figdor, unpublished observation, 39,40) aie located in 
helical domains adjacent to the cation binding site. This cation binding site controls both ICAM-1 
and ICAM-3 adhesion, since mutation of the cation coordinating residues Asp117 and Asp2 3 9 into 
alanine (D137A, D239A), abolished LFA-1 binding to both ICAM-1 and ICAM-3 (Rcf 1, Figure 
5). The third epitope (IdeA), recognized by mAbs that block ICAM-1, -2 and -3 binding (M E. 
Binnerts, Y. van Kooyk and C G . Figdor, unpublished observation; 39,40) is spatially distinct from 
the IdeB and IdeC epitopes and is located at the N-terminus of the first β strand ot the CD1 la I 
domain (ßl). In figure 6, only the fourth residue of the IdcA epitope is depicted, since the first three 
residues were not included in the C D l l a I domain crystal. Recently, we showed that replacement 
of He126 and Asn'29 by Met and Lys, respectively, selectively destroyed antibody binding to the 
IdeA epitope and the ability of the H/M53 chimera to bind to ICAM-3, while preserving its ability 
to bind ICAM-1 (Ref. 1, Fig. 5). Thus, residues critical for ICAM-3 binding appear to coincide 
with the IdeA epitope located at the very beginning of the first β strand of the CD1 la I domain 
(ßl). Finally, residues Asp182 and Ser18J in the ct2 helix define the IdeD epitope, recognized by anti-
bodies that selectively inhibit LFA-1 binding to ICAM-3. Disruption of the IdeD epitope (H/M48) 
did not result in reduced binding to ICAM-3 (Ref. 1, Figure 5), indicating that the IdeD epitope 
does not contain residues directly involved in ICAM-3 binding. However, although Asp182 and 
Ser18'1 are located a considerable distance away from the IdeA epitope in pnmary structure, when 
placed on the C D l l a I domain crystal, the IdeD epitope appears to be in close proximity of the 
IdeA epitope and residues critical lor ICAM-3 binding, at the N-terminus oí the first β stiand of the 
C D l l a I domain (ßl). Thus, regions important for ICAM-3 binding and binding of mAbs that 
block ICAM-3 binding to CD1 la appear to be located in similar parts of the molecule 
Discussion 
We have demonstrated that the C D l l a I domain specific antibodies MEM-83, YTH81.5 and 
122.2A5 that selectively inhibit the interaction of LFA-1 with ICAM-3 (27,39), bind to a novel 
epitope (IdeD) in the I domain of CD1 la. This is distinct from the previously identified IdeA, IdeB 
and IdeC epitopes, recognized by antibodies that block LFA-1 binding to ICAM-1, -2 and -3 (M.E. 
Binnerts, Y. van Kooyk and CG. Figdor, unpublished observation; 39,40) Site directed mutagene-
sis demonstrated that the IdeD epitope comprises amino acids Asp1"2 and Ser184, although mutation 
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of these residues failed to inhibit the binding of LFA-1 to ICAM-3 Thus antibody binding to the 
IdeD epitope appears to interfere with ICAM-3 binding by stenc hindrance rather than by competi­
tive binding to the ligand binding site Placement of the IdeD epitope on the crystal structure of the 
CD1 la I domain (41) suggested that the IdeD epitope was located in close proximity to residues 
recently identified as being critical for ICAM 3 binding to LFA 1 (1) 
Interestingly, residues critical for ICAM-3 binding (He126 and Asn129) and the IdeD epitope are 
both unique to human CD1 la and are not found in CD1 lb or CD1 lc, suggesting that these repre­
sent a structural feature (г e all or part of a ligand binding domain) unique to LFA 1 These data 
are consistent with earlier observations that MEM 83, YTH81 5 and 122 2A5 failed to cross-react 
with CD1 lb or CD1 lc (39) Although MEM 83, YTH81 5 and 122 2A5 all bind the IdeD epitope, 
they show some functional differences, since MEM-83 can activate LFA-1 mediated adhesion to 
ICAM-1 (24,27), whereas 122 2A5 and YTH81 5 cannot (39) This suggests that MEM-83 can in­
duce or stabilize an active ICAM-1 binding conformation of LFA-1 (24) Surprisingly, we ob­
served that MEM-83, YTH81 5 and 122 2A5, as well as blocking antibodies directed against 
ICAM-3, inhibited ICAM 1 induced Τ cell proliferation These data suggest that although Τ cell 
costimulation in this system is dependent on engagement of LFA 1 by coated ICAM-1, optimal 
proliferation may require LFA 1/ICAM 3 inteiaclions between proliferating cells, that are pre­
vented by IdeD specific anti-CDlla antibodies We previously reported that MEM-83 (27), but 
also YTH81 5 and 122 2A5 (data not shown), are potent inhibitors of the LFA l/ICAM-2 interac­
tion, suggesting that residues critical for ICAM-2 and ICAM 3 binding may be located in close 
proximity It will therefore be important to determine whether the sequence that has been shown to 
be essential for ICAM-3 binding, is also involved in LFA-1 binding to ICAM-2 
In addition to ligand specific sequences, the LFA-1 I domain contains conserved sequences re­
quired for adhesion of LFA-1 to all hgands Interestingly, when aligned with the CD1 la I domain 
structure (41), two of the recently identified CD1 la I domain epitopes (IdeB and IdeC) recognized 
by antibodies that block ICAM-1, ICAM 2, and ICAM-3 binding (M E Binnerts, Y van Kooyk 
and С G Figdor, unpublished observation, 39,40), were located in close proximity to the divalent 
cation binding pocket, or MIDAS motif (36) Residues within this motif (Asp1", Asp™, Thr206) 
have been implicated in cation binding (34) and/or ligand binding of the I domain containing inte 
grins Mac-I, Ojß,, α,β, and LFA-1 (Refs 1, 33-37 and 51, Figure 5) In the CD1 la I domain crystal 
structure, a Mn2* ion is coordinated by five cation coordinating residues A critical acidic glutamate 
residue (E) within the integnn binding motif I/L E T-P/S-L in the first Ig-hke domains of ICAM-1, 
-2 or -3 (47,52), may provide the sixth cation coordinating residue in vivo, implying a role for 
metal ions in the stabilization of LFA-1/ligand interactions (36,53) In addition, residues in prox­
imity of the divalent cation binding pocket (Met1*10, Glu146, Thr,4\ Ser24,1) were shown to be critical 
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for binding of LFA-1 to ICAM-1 (50), underlining the importance of this I domain region in LFA-
1/ligand interactions It is tempting to speculate that antibodies recognizing the IdeB and IdeC epi 
topes interfere with LFA-1 function by inhibiting actual ligand binding residues in this area, or by 
altering the conformation of such residues Alternatively, these antibodies may affect adhesion by 
altering the conformation of residues involved in cation coordination, resulting in destabilization of 
the cation binding site 
Our data identify two distinct regions within the CD1 la I domain that contain residues critical 
for ICAM-3 binding' the region involved in cation binding and the region defined by the IdeA 
epitope at the other side of the I domain These regions may both contain actual contact sites for 
ICAM-3, implying that ICAM-3 contacts a relatively large binding face on LFA-1 However, it is 
also possible that mutations introduced in either one of these regions induce subtle confoimational 
changes in the CD1 la I domain, that reduce binding to ICAM-3 As yet we cannot distinguish be­
tween these possibilities 
In conclusion, our data indicate that distinct regions of the CDlla I domain contain epitopes 
recognized by antibodies that either selectively inhibit binding of LFA-1 to ICAM-3, or inhibit 
both ICAM-1 and ICAM-3 adhesion of LFA-1 These antibodies may inhibit LFA-1 function by 
either interfering with ligand specific sequences, or conserved domains within the CD1 la domain, 
that are required for binding of LFA-1 to both ICAM-1 and ICAM-3 The challenge of tuture re­
search will be to understand how during integnn activation subtle conformational changes within 
the α and β subunits lead to exposure of these functionally important domains and subsequent li­
gand binding The ability of antibodies to selectively inhibit LFA-1-ligand binding, might find 
utility in the development of immune response and inflammatory response modulators Moreover, 
these results suggest that the capacity of anti-CDl la antbodies to interfere with leukocyte function 
(e g antigen presentation, cytotoxic killing, and В cell activation), histoucally attributed to disrup­
tion of LFA-l/ICAM-1 interactions, should be re-examined to evaluate the possible role of ICAM-
2 and ICAM-3 
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Regulation of LFA-1 function by low affinity LFA-l/ICAM-3 interactions 
Summary 
ICAM-3 has been implicated in both adhesion and signal transduction, but its func­
tion in the immune system remains unclear Here we investigated the role of ICAM-
3 in LFA-1-mediated adhesion and signal transduction We found that although 
ICAM-3 binds poorly to LFA-1 on testing Τ cells and K562-LFA-1 transfectants, 
engagement of LFA-1 on these cells by recombinant ICAM-3Fc, specifically in­
creased LFA-1-mediated adhesion to 1С AM-1 In addition, we found that transtec-
tion of K562-LFA-1 cells with ICAM-3 lacking the cytoplasmic tail, enhanced LFA-
1/1CAM-1 dependent adhesion These results show that low affinity binding ot 
LFA-1 to ICAM-3 augments adhesion of LFA 1, independent or 1CAM 3-mediated 
signal transduction, defining a novel function foi ICAM-3 We subsequently inves­
tigated whether low affinity interaction of LFA-1 with ICAM-3 was required tor 
LFA-1/lCAM-l-mediated signal transduction in resting Τ cells Surprisingly, we 
found that blocking anti-ICAM-3 antibodies completely inhibited LFA-l/ICAM-1 
dependent Τ cell proliferation Together, these data show that ICAM-3 is critical tor 
regulation oí LFA-1/1СAM 1-mediated adhesion and signal transduction, during the 
initiation of an immune response 
T he integnn LFA-1 (CD1 la/CD 18) is a leukocyte adhesion receptor which coordinates different adhesive interactions in the immune system, including T/B cell interactions, CTL/target inter­
actions and adhesion and subsequent migration ol leukocytes through endothelial cell layers into 
inflamed tissue (1-7) LFA-1 belongs to the ß,-CD18 family ot integrins, which shaie a common β 
subunit (CD 18), but have distinct but structurally homologous α subunits a L (CDПа, LFA-1), aM 
(CDllb, Мае-I), a< (CDllc, pl50,95) and ocD (CDlld) (1,8,9) LFA-1 mediates cell cell adhesion 
upon binding to one of its hgands ICAM-1 (10-12), ICAM-2 (13) or ICAM-3 (14 16), which are all 
members of the Ig-superlamily, and have 5, 2 and 5 Ig-hke domains, respectively ICAM-1 is ex­
pressed on many cell types, including lymphocytes and endothelial cells, and its expression is cy­
tokine inducible (17) ICAM-2 is expressed on lymphocytes, endothelial cells and platelets (18,19), 
whereas ICAM-3 is only expressed on leukocytes, with the exception of endothelial cells in certain 
tumors (20-24) In contrast to ICAM-1, expression of ICAM 2 and 3 is not enhanced by cytokines 
(20,25,26) 
LFA-1 mediated cell adhesion requires activation of the LFA-1 molecule (27-30) and is de­
pendent on the presence of divalent cations, such as Mg2+ and Ca2+ (31), an intact cytoskeleton and 
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a physiological temperature (32) Activation can be induced by intracellular signals generated upon 
cross-linking of surface receptors like the TCR/CD3 complex (28,29), or upon addition of phor-
bolesters that directly activate protein kinase С (33) LFA-I can also be activated directly by addi­
tion of activating antibodies directed against the extracellular domains of the a, or ß2 subunit (34-
37) Activation of LFA-1 and subsequent ligand binding is thought to result from conformational 
changes in the α/β heterodimer, that increase the affinity of LFA-1 for its ligands (27) 
It has been clearly demonstrated that engagement of LFA-1 on Τ cells by purified 1CAM-1, -2 
or -3 molecules can costimulate Τ cell proliferation (38-43) Several reports suggest that 1CAM-3 
may also function as signal transduction molecule Cross-linking of ICAM-3 induces protein tyro­
sine phosphorylation and elevation of intracellular calcium levels, induces costimulation and mor­
phological changes in Τ cells, and can lead to activation ot β, and ß2 integrins (44-53) Since 
ICAM-3 is the dominantly expressed ICAM molecule on resting lymphocytes, it was originally 
proposed to be the most important LFA-1 ligand during the initiation of an immune response (41), 
although later reports showed that ICAM-3 binds poorly to LFA-1 (54,55) Despite this fact, 
blocking antibodies directed against ICAM-3 have been shown to inhibit Τ cell proliferation in 
mixed lymphocyte reactions with DCs or Langerhans cells, suggesting that LFA-1/ICAM-3 inter­
action is required for binding of Τ cells to antigen presenting cells (43,56-59) In this study we in­
vestigated whether ICAM-3 contributes directly to LFA-1-mediated adhesion, oi is involved in the 
regulation of LFA-1 function We obtained evidence that although ICAM-3 binds poorly to LFA-1, 
low affinity interactions of LFA-1 with ICAM-3 are critical for LFA-l/ICAM-1 dependent adhe­
sion and signal transduction in the immune system 
Materials and Methods 
Antibodies 
The following antibodies were used NKI-L7, NKI-L15 (60) and YTH81 5 (61) directed against 
CDlla, T3b directed against CD3 (62), REK-1 (55) and RR 1/1 (63) directed against ICAM-1, 
CBR-IC2/2 (18) directed against ICAM-2, 186-269 and AZN-IC3 1 (6,h International Leukocyte 
Workshop 1996) directed against ICAM-3, NKI-NBL-1 directed against N-CAM (5lh International 
Leukocyte Workshop 1993) and TS2/9 (64) directed against LFA-3 For activation of LFA-1, the 
LFA-1 activating mAbs KIM 185 (34) and MEM-48 (55), directed against CD 18 were used 
Cells 
Peer Τ cells were cultured in Iscove s medium (Gibco, Life Technologies ltd , Paisley, Scotland) 
supplemented with 5% FCS and 1% antibiotics/antimycotics (Gibco) Resting Τ cells weie ob-
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tamed by centrifugal elutridtion of PBMC irom bone marrow of healthy donors, as described (65) 
The Τ cell fractions used contained over 90% CD3 positive cells and were cultured in RPMI 1640 
(Gibco), supplemented with 10% FCS and 1% antibiotics/antimycotics (Gibco) 
Immunofluorescence analysis 
Cells (0 1 Χ 106) were incubated with appropriate dilutions of mAb (10 μg/mI, 25 μΐ/well) in 
PBS containing 0 5% bovine serum albumin and 0 0 1 % NaZ3 (РВА), for 30 minutes at 4°C After 
one wash with cold РВА, cells were incubulcd wilh FITC-labeled Goat anti mouse secondary anti­
bodies (Zymed, San Francisco, CA, 1 50 dilution in РВА), foi 30 minutes at 4°C After another 
РВА wash fluorescence was measured using a FACScan® (Becton and Dickinson & Co , Oxnard, 
CA) 
Generation of K562 translatants 
5 χ IO6 K562 LFA-1 cells generated as described previously (66), were transfected with 10 μg 
of N-CAM or PCRIIICAM-3 Rl plasmids. together with 2 μg of PGK-hyg vector (67) encoding 
hygromycin-B resistance, by electioporalion at 250V, 960 μΡ, using a Biorad genepulser 
(Richmond, CA) After 24 h cells were selected toi hygromycin-B resistance in RPMI/lscove's 
(75 25) (Gibco) containing 7 5% FCS and 1 mg/ml Hygromycin-B (Calbiochem, San Diego, CA) 
To maintain LFA-1 expression, Geneticin was added (Gibco, 2 mg/ml) After staining Hygromy-
cin-B resistant cells with the anti-ICAM 3 (AZN-IC3 1) oi anti N-CAM (NBL-1) mAb and GaM-
FITC, ICAM-3 oi N-CAM positive cells were sorted using the Coulter Epics Elite (Coulter, 
Hialeah, FL) 
Adhesion assay 
96-flat bottomed wells (Maxisoib, Nunc, Roskilde, Denmark) were coated with Goat anti-
human Fc antibodies (4 μg/ml, 50 μΐ/well, Jackson immunoresearch laboratories, Ine , Westgrove, 
PA) in TSM (150 mM NaCl, 10 mM Tns/Hcl, 2 mM MgCl2, I mM CaCl2, pH 8 0), for 60 min at 
37°C After blocking the wells with 1% BS A in TSM (100 μΐ/well, 30 mm at 37 °C), wells were 
coated O/N at 4°C with ICAM-lFc or ICAM-3Fc containing supernatants at the indicated concen­
trations, from stable CHO-K1 transfectants geneiated by cotransfection of the ICAM-1 IgGl Fc, or 
ICAM-3 IgGl Fc (15) plasmids (20 μg), with the pEE14 plasmid (5 μg), as described (Binnerts et 
al , in preparation) Cells (20 40,000/well) were labeled in PBS with Calcein-A (25 
μg/107cells/ml, Molecular probes, Eugene, OR) for 30 min at 37°C and incubated on ICAM coated 
plates for 45 min at 37°C, in the presence oi absence of the indicated mAb Non adherent cells 
were removed by three washes with warm wash buffer (TSM + 0 5 % BSA) , adhering cells were 
lysed with lysis buffer (50 mM Tris, 0 1% SDS), and fluorescence was quantified using the Cyto-
99 
Chapter 5 
fluometer (Biorad, Richmond CA) Results are expressed as the mean percentage of adhesion of 
triplicate wells 
Fluorescent beads adhesion assay 
Carboxylate-modified TransFluorSpheres (488/645 nm, 1 0 μΜ, Molecular Probes, Eugene, 
OR), were coated with ICAM-3Fc or ICAM-lFc proems, as desenbed (Geitenbeek et al, submit 
ted) Briefly, 8x107 carboxylate-modified TransFluorSpheres covalently coupled to streptavidin, 
were incubated with biotinilated anti-human Fe antibodies (Jackson Immunoresearch Laboratories, 
Ine , 3 μg in 0 5 ml РВА (PBS + 0 5 % BSA + 0 002 M NaZ1 ), 2h at 37°C), washed with РВА, in 
cubated with ICAM-lFc or ICAM-3Fc containing supernatants from stable CHO-transfectants 
(250 ng/ml, overnight at 4CC) and washed again with РВА 
50,000 cells were pre-incubated for 10 in at RT in TSA (0 5 % BSA, 150 mM NaCl, 10 mM 
Tns/Hcl, 2 mM MgCl2, 1 mM CaCl2, pH 8 0), with or without blocking mAb directed against LFA-
1 (NKI-L15, 20 μg/ml) Pre-incubated cells were incubated in a 96 wells V-botlomed plate with 
ICAM-lFc or ICAM-3FC coated beads (20 beads/cell) in TSA for 30 mm at 37°C, in the presence 
or absence of the CD18 activating mAb KIM185 (10μg/ml), or PMA (100 nM) After 1 wash with 
warm TSA, cells were resuspended in 100 μΙ TSA, and the percentage of cells that had bound fluo 
rescenl beads was quantified by flow cytometry, using a FACScan (Becton Dickinson & Co , 
Oxnard, CA) 
Costimulation assay 
96-flat bottomeded wells (Maxisorb, Nunc, Roskilde, Denmark) were coated with suboptimal 
concentrations of anti-CD3 antibodies (T3b, 30 ng/ml, 50 μΐ/well, 1 hr 37°C) followed by Goat 
anti-human Fc antibodies (Jackson Immunoresearch Laboratories, Ine , Westgrove, PA, 4 μg/ml, 
50 μΐ/well, 1 h 37°C), 1% BSA (100 μΐ/well, 30', 37°C) and ICAM lFc protein (200 ng/well, 50 
μΐ/well, 1 h at 37°C) Resting Τ cells were added (100 000 cells/well in RPMI 1640 (Gibco) + 10% 
FCS) and cultured for three days On day 3 cells were pulsed lor 16 h with ['HJthymidine (1 52 
TBq/mmol, 0 5 μθ/well, Amersham, Buckinghamshire UK), to measure 1CAM-1 dependent pro­
liferation Cells were cultured in the presence of the indicated function blocking antibodies at a 
concentration of 10 μg/ml 
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Results 
LFA-l on resting Τ cells binds poorly to ICAM-3 
To determine the role of ICAM-3 in the adhesion of Τ lymphocytes, we compared the capacity 
of LFA-l expressing resting and activated Τ cells to bind to ICAM-lFc or ICAM-3Fc proteins 
coated onto plastic (Fig. 1). 
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Figure 1. Adhesion of resting and activated Τ lymphocytes to ICAM-IFc and ICAM-3Fc. Acti­
vated HSB-2 Τ cells or resting Τ lymphocytes were incubated on wells coated with a range of 
ICAM-IFc or ICAM-3Fc proteins, in the absence or presence of the phorbolester PMA (50 nM), or 
the LFA-l activating mAb KIM185 (10 pg/ml). Results are expressed as the mean % of LFA-
1/ICAM-l specific adhesion, of triplicate wells. Specific adhesion: percentage of bound cells - per­
centage of cells bound in the presence of a LFA-l blocking antibody (NKJ-L15). Data are repre­
sentative of three experiments. Ai Adhesion of HSB-2 Τ cells to ICAM-IFc. B) Adhesion of HSB-2 
Τ cells to ICAM-3Fc. C) Adhesion of resting Τ cells to ICAM-IFc. D) Adhesion of resting Τ cells to 
ICAM-3FC 
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Maximal adhesion of activated HSB-2 Τ cells to ICAM-lFc could be observed at all ICAM-lFc 
concentrations (25-500 ng/ml), without prior activation of LFA-1 (A). Upon activation of LFA-1 
with the activating antibody KIM 185, HSB-2 Τ cells bound to ICAM-3Fc as well (B), although to 
a lesser extent than to ICAM-lFc proteins, since a 12 fold higher concentration of lCAM-3Fc was 
required for maximal adhesion. When adhesion of resting Τ cells was examined, they were found 
to adhere less well to ICAM-lFc than activated Τ cells, as adhesion required activation of LFA-1 
and higher ICAM-lFc concentrations for maximal adhesion. In contrast, even upon activation of 
LFA-1, resting Τ cells could not adhere to ICAM-3Fc, at all concentrations tested. 
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Figure 2. Adhesion of resting Τ cells to ICAM-lFc or ICAMSFc coated beads. Resting Τ cells 
were incubated with fluorescent beads coated with ICAM-lFc or ICAM-3Fc proteins, in the ab­
sence or presence of the phorholester PMA (100 nM), or the LFA-1 activating niAb KIM185 or 
MEM-48 (10 pg/ml). Adhesion was quantified by flow cytometry. Results are expressed as the 
mean % of LFA-1 specific adhesion of 10.000 cells. Specific adhesion: percentage of cells with 
bound beads - percentage of cells with bound heads after pre-incubation of cells with an blocking 
antibody directed against LFA-1 (NK1-L15, 20pg/ml). 
To further investigate the capacity of resting Τ cells to bind to ICAM-3, we employed a novel 
adhesion assay using ligand-coated fluorescent beads, in which weak adhesive interactions can be 
detected by flow cytometry (Geitenbeek et al., in preparation). Using this assay, adhesion of resting 
Τ cells to ICAM-3Fc coated beads could be detected, although ICAM-3Fc coated beads bound to a 
lesser extent than beads coated with ICAM-lFc, to LFA-1 (Figure 2). Together, these results sug-
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gest that ICAM-3 is not very effective as adhesion ligand for LFA-1 on resting Τ cells and binds 
LFA-1 on these cells with low affinity. 
100 
. 1CAM 
250 500 
3 F t ( n ^ m l ) 
D ICAM-1 
• ICANM 
[CAM-1 + ICAM-3 
— О — Medium 
- 0 — PMA 
• О - MEM48 
- Δ — KIV1185 
ICAM-1 
ICAM-3 
ICAM-1 + ICAM-3 
Medium 
M KM-48 
KIMI85 
Figure 3. Solid phase ICAMSFc enhances adhesion of K562-LFA-1 transfectants or Peer Τ 
cells to ICAM-lFc. Flat bottomed wells precoated with ICAM-lFc (25 ng/ml). were coated with 
ICAM-iFc at 50 ng/ml (A, B, D), or at a range of concentrations (C). As control, wells were coated 
with ICAM-lFc (25 ng/ml) or ICAMSFc (50 ng/ml), alone. Resting Peer Τ cells (A) or K562-LFA-
I transfectants (B, C, D), were incubated on the coated plates in the absence or presence of the 
phorbolester PMA (50 nM) or the LFA-1 activating antibodies KIM185 or MEM-48 (10 pg/ml). In 
Figure 3D, K562-LFA-1 cells were incubated in the presence or absence of blocking antibodies 
directed against ICAM-3 (186-2G9) or LFA-1 (NKI-L15). In А, В, C, results are expressed as the 
mean % of LFA-1/1СAM-1 specific adhesion, of triplicate wells, calculated as in Fig. 1. In D, re­
sults are expressed as the mean percentage of adhesion of triplicate wells. Data are representative 
of three experiments. 
Low affinity interaction of LFA-1 with recombinant ICAM-3 enhances LFA-1-mediated adhe­
sion to ICAM-1 
We next investigated whether low affinity interaction of LFA-1 with ICAM-3 could regulate 
LFA-1-mediated adhesion, by analyzing adhesion of resting Τ cells and K562-LFA-1 transfectants 
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to wells coated with a combination of ICAM-lFc and ICAM-3Fc proteins, or wells coated with 
only ICAM-lFc or ICAM-3Fc. Figure ЗА shows that although coated ICAM-3Fc was unable to 
support adhesion of resting Peer Τ cells, interaction of LFA-1 with immobilized ICAM-3Fc en­
hanced LFA-1-mediated adhesion of Peer Τ cells to ICAM-lFc, upon activation of LFA-1 with the 
activating antibodies MEM-48 or KIM 185. The observed increase in adhesion was ICAM-3 spe­
cific, since co-coating of ICAM-lFc with CD14Fc did not increase adhesion (not shown). To in­
vestigate whether LFA-1 on LFA-1 transfectants is also affected by ICAM-3Fc engagement, we 
performed a similar experiment using K562-LFA-1 transfectants. Figuie 3B shows that interaction 
of LFA-1 with immobilized ICAM-3Fc, also specifically enhanced adhesion of KIM 185 or MEM-
48 stimulated K562-LFA-1 cells to ICAM-lFc Only little amounts of coated ICAM-3Fc were re­
quired for enhancement of adhesion, since a maximal increase of adhesion was already observed at 
a ICAM-3FC concentration of 50 ng/ml (Fig. 3C). No increase of adhesion was observed in the 
presence of blocking antibodies directed against ICAM-3, confirming that the observed increase 
was ICAM-3 dependent (Fig. 3D). Together, these data show that low affinity inteiactions of LFA-
1 with ICAM-3 regulate LFA-1 function m both resting Τ cells and K562-LFA-1 transfectants. 
Expression of ICAM-3 specifically enhances LFA-1-mediated adhesion of K562-LFA-1 trans­
fectants, independent of the ICAM-3 cytoplasmic tail 
To investigate whether ICAM-3 expressed on cells could similarly regulate LFA-1 function, we 
transfected ICAM-3 into ICAM-3 negative K562 cells previously transfected with LFA-1. These 
K562-LFA-1 cells, like resting Τ cells, fail to bind to coated ICAM-3Fc (Fig 3), but show some 
adhesion to ICAM-3Fc coated beads (not shown) 
control CDlla CD18 ICAM-1 ICAM-2 ICAM-3 N-CAM 
K562-LFA-1 4 212 92 82 20 7 7 
K562-LFA-1 ICAM-3 Rl 5 139 78 90 20 71 6 
K562-LFA-1 N-CAM 3 149 94 64 17 5 244 
Table 1. Expression of LFA-1 and CAM's on K562 transfectants K562-LFA-J, K562-LFA-1 
ICAM-3 Rl and K562-LFA-1 N-CAM transfectant<¡ were stained with antibodies directed LFA-1 
(NKI-L15), ICAM-1 (REK-1), ICAM-2 (CBR-IC2/2), ICAM-3 (AZN-IC3 I) and N-CAM (NBL-1), 
and GaM-FITC antibodies. Fluorescence was quantified using a FACscan (Becton Dickinson) and 
is depicted as mean fluorescence intensity. 
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Since ICAM-3 has been shown previously to function as a signal transduction molecule, we used a 
truncated ICAM-3 construct lacking the cytoplasmic tail (K562-LFA-1 ICAM-3 Rl), to exclude 
signaling through ICAM-3. As control, we also generated transfectants expressing LFA-1 and N-
CAM (K562-LFA-1 N-CAM). After three rounds of sorting of CAM expressing cells, transfectants 
were obtained that expressed high levels of ICAM-3 or N-CAM, and comparable levels of LFA-1 on 
the cell surface. In addition, all transfectants expressed similar levels of endogenous 1С AM-1 and 
ICAM-2 (Table 1). 
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Figure 4. Expression of ICAM-3 enhances adhesion of KS62-LFA-1 transfectants to ICAM-lFc. 
Calcein labeled K562-LFA-1 cells or K562-LFA-1 cells expressing ICAM-3 lacking the cytoplas­
mic tail (K562-LFA-1 ICAM-3 Rl) or N-CAM (K562-LFA-1 N-CAM), were incubated on ICAM-
IFc coated plates for 45 min at 37°C, in the presence or absence of blocking antibodies directed 
against LFA-1 (NKI-L15; 10 pg/ml). Cells were incubated in the presence or absence of the LFA-1 
activating antibodies KIM185 or MEM-48 (10 ßg/ml), or the phorbolester PMA (50 nM), to acti-
vate LFA-1. Results are expressed as the mean % of LFA-1 specific adhesion, of triplicate wells. 
Specific adhesion: percentage of bound cells - percentage of cells bound in the presence of the 
blocking antibody NKI-L15. Data are representative of three experiments. 
We subsequently investigated the capacity of the different K562-LFA-1 transfectants to adhere 
to coated ICAM-lFc (Fig. 4). All transfectants showed comparable ICAM-1 adhesion upon activa-
tion of LFA-1 with the CD18 activating mAb KIM185. Surprisingly, upon activation of LFA-1 
with the phorbolester PMA or the CD18 activating mAb MEM-48, K562-LFA-1 cells expressing 
tail-less ICAM-3 (K562-LFA-1 ICAM-3 Rl), bound better to ICAM-lFc than control K562-LFA-
1 cells. The observed increase in adhesion was specific, since expression of N-CAM did not result 
105 
Chapter 5 
in enhancement of adhesion. These results suggest that low affinity interaction of LFA-1 with 
ICAM-3 on an opposing cell, enhances LFA-1 function in these cells, independent of ICAM-3-
mediated signal transduction. 
LFA-ІЛСАМ-З interactions are critical for LFA-1 and ICAM-1 dependent Τ cell proliferation 
Since these results indicate that low affinity interaction of LFA-1 with ICAM-3 regulates LFA-
1/ICAM-l dependent adhesion, we subsequently investigated the role of ICAM-3 in LFA-1/ICAM-
1 dependent signal transduction. To this end we analyzed costimulation of resting Τ cells by coated 
ICAM-1 Fc proteins and suboptimal amounts of anti-CD3 antibodies (Fig. 5). 
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Figure 5. Costimulation of resting Τ cells by recombinant ICAM-lFc is inhibited by anti-ICAM-
3 mAb. After culturing resting Τ cell on plates coated with ICAM-lFc proteins and suboptimal 
amounts of anti-CD3 antibodies for three days at 37°C, proliferation was determined using 
[3H]thymidine incorporation. To determine the specificity of proliferation, cells were incubated in 
the presence or absence of blocking antibodies directed against LFA-1 (NKI-L15), ICAM-1 (REK-
l), ICAM-3 (186-269) or the anti-CDlla I domain antibody YTH81.5 that selectively inhibits LFA-
1 interaction with ICAM-3. Proliferation from triplicate wells is depicted. Data are representative 
of three experiments. 
Incubation of resting Τ cells on ICAM-lFc and anti-CD3 coated plates resulted in strong prolif­
eration, that was LFA-1 and ICAM-1 dependent, since it was prevented by addition of blocking 
antibodies directed against CD1 la or ICAM-1. Surprisingly, LFA-l/ICAM-1 dependent prolifera­
tion was completely inhibited by addition of blocking antibodies directed against ICAM-3, or ad­
dition of anti-CD 1 la I domain antibodies that selectively interfere with LFA-1 binding to ICAM-3 
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(YTH81 5) Together, these results clearly show that weak intercellular interactions mediated by 
LFA-1 and ICAM-3, are necessary for LFA-l/ICAM-1 dependent costimulation of resting Τ lym­
phocytes 
Discussion 
In the past few years both adhesive and signaling functions have been reported lor ICAM-3, al­
though the function of ICAM 3 within the immune system remains poorly defined In this study, 
we therefore investigated the role of ICAM-3 in LFA 1 dependent adhesion and signal transduc­
tion We found that ICAM-3 is unable to support adhesion of resting Τ lymphocytes, indicating that 
ICAM-3 does not directly contribute to adhesion of these cells Secondly, we found that low affin­
ity interaction ot LFA 1 with recombinant ICAM-3 or cell-bound ICAM-3, enhances LFA 1 de­
pendent adhesion to ICAM-1, independent of ICAM 3 mediated signaling Finally, we demonstrate 
that low affinity LFA-l/ICAM-3 dependent intercellular interactions are critical for costimulation 
of resting Τ cells by ïecombinant ICAM-1, indicating that interaction of LFA-1 on resting Τ cells 
with ICAM-3 is critical for the initiation of an immune response 
Our results suggest that enhancement of LFA-1 dependent Τ cell prohleration by LFA-1/ICAM-
3 intercellular interactions is independent of signals transmitted by ICAM-3 This notion is sup­
ported by several studies in which activation of Τ cells by different types ot antigen presenting 
cells was investigated Resting or activated Langerhans cells express ICAM-3, and it was found 
that blocking of ICAM-3 on LC inhibited Τ cell proliferation in a MLR (57,58) Similarly, Τ cell 
proliferation induced by DCs generated from lineage marker negative PBMC upon cultunng with 
IFN γ, was prevented by pre incubation of DC s with anti ICAM 3 antibodies (43) Combination of 
these observations with our results, suggests that LFA 1 dependent Τ cell proliferation in vivo re­
quires low affinity interaction of LFA 1 on the Τ cell with ICAM-3 on the antigen presenting cell 
In MLR s in which LFA-Γ DCs generated from CD34+ cells by cultunng with TNF-ot, or al­
logeneic PBMC were used as stimulator cells, proliferation was inhibited by pre incubation of ei­
ther Τ cells or stimulator cells with anti-ICAM-3 antibodies (56,59) This could imply that in 
MLR's using these types oí antigen presenting cells, signals generated upon engagement of ICAM-
3 on the Τ cell contribute to Τ cell activation Alternatively, since LFA-1 on activated cells can 
bind to ICAM-3 (Fig 1 and (55)), these results may indicate that in these experiments ICAM-3 on 
the Τ cell directly contributes to Τ cell/APC adhesion, by binding to active LFA 1 molecules on 
these antigen presenting cells Together, these studies show that different types of antigen piesent-
íng cells may use different combinations of adhesion molecules to bind to resting Τ cells 
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Our results indicate that low affinity LFA-1/ICAM 3 interaction enhances LFA-1 Junction, but 
is not sufficient to induce adhesion of LFA-1 to ICAM 1, since enhancement of adhesion is only 
observed upon activation of LFA-1 with PMA or activating antibodies It is possible that binding of 
ICAM-3 to LFA-1 induces an hgand dependent conformational change in LFA-1, that facilitates its 
subsequent interaction with ICAM-1 Although it has been shown that fixation of LFA-1 molecules 
in an ICAM-1 bound state facilitates subsequent interaction with othei ICAM-1 or ICAM-3 mole 
cules (68,69), it is hard to envisage that LFA-1 molecules can maintain a conformation induced by 
weak interaction with ICAM-3, once this hgand dissociates from LFA 1 Another possibility is that 
upon weak engagement of LFA-1 by ICAM-3, LFA-1 may transmit signals into the cell that en­
hance LFA-1 function Upon hgand binding, β, and β, integrins organize into structures called fo­
cal adhesions, that strengthen integrin adhesion by linking them to the cytoskeleton, and contain a 
variety of cytoskeletal proteins and signaling molecules (70-73) Whether ß, integrins form similar 
focal adhesions is not well established, but it has been shown that the cytoplasmic tail of β2 can link 
to the cytoskeletal proteins α actinin, and filamin (74,75) and that threonine residues in the β2 
subunit are essential for cell spreading and stable hgand binding of β, integrins (76) It is tempting 
to speculate that upon engagement of LFA-1 by ICAM 3, proteins involved in ß2-mediated signal 
transduction and spreading associate with the cytoplasmic domains of LFA-1, facilitating stable 
interaction of LFA-1 with ICAM-1 Finally, it has been shown that during activation of resting Τ 
cells in culture, LFA-1 organizes into clusters on the cell surface that facilitate LFA-l/ICAM-1 in­
teractions and can be detected by the NKI-L16 antibody (36,77) It will be interesting to determine 
whether engagement of LFA-1 by ICAM 3 enhances the avidity of LFA-1/ICAM 1 interactions, 
through reorganization of LFA-1 on the cell surface 
It has been previously reported that antibody cross linking ol ICAM-3 induces costimulation, 
elevation of intracellular calcium levels, activation ol Srt, lamily kinases, tyiosine phosphorylation 
of intracellular proteins and moiphological changes in Τ cells (44 53) Howevei, it lemains unclear 
whether physiological engagement of ICAM-3 by binding to LFA 1 can induce these Τ cell re­
sponses in vivo Our finding that only LFA 1 on activated cells can bind to ICAM 3, may indicate 
that induction of ICAM 3 mediated signals in Τ cells may depend on interaction of resting Τ cells 
with antigen presenting cells that express highly active LFA-1, or othei ß, integrins that can bind to 
ICAM-3 with high affinity It is tempting to speculate that the recently cloned aDß2 integrin ex 
pressed on cells of the myeloid lineage, that appears to bind to ICAM-3 with high affinity (9), may 
be able to trigger ICAM-3 dependent signal transduction m vivo Alternatively, it is also possible 
that low affinity interactions between LFA-1 ICAM 3 arc sulficient to elicit ICAM 3 dependent 
signal transduction in lymphocytes Whether ICAM 3 dependent signal transduction depends on 
high or low affinity interaction ol ß, integrins with ICAM-3, remains to be established 
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In summary, our results for the first time show that physiological, low affinity interactions be­
tween LFA-1 and ICAM-3 contribute to LFA-1 dependent adhesion and signal transduction. Since 
ICAM-3 is restricted to cells of hematopoetic origin, it is tempting to speculate that the main func­
tion of ICAM-3 in the immune system is to ensure that adhesive interactions of resting Τ cells will 
be restricted to interaction with antigen presenting cells, that express ICAM-3 and are very efficient 
in presenting antigenic peptide to Τ cells 
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Characterization ofLFA l/ICAM-1 interactions by surface plasmon resonance 
Summary 
LFA-l (aLß2, CD 11 a/CD 18) mediates cell-cell adhesion in the immune system by 
binding to its ligand ICAM-1 (CD54) To date, affinity and kinetics ol LFA-
1/ICAM-l interactions remain poorly defined In this study we used surface plasmon 
resonance to characterize binding of LFA 1 to monomeric or dimeric forms of 
1С AM-1 To this end, purified LFA-l was immobilized indirectly onto a sensorchip 
surface, by binding to a covalently coupled non-blocking anti-CDlla antibody 
(TS2/4) TS2/4 captured LFA 1 was recognized by activating antibodies directed 
against CD 18 and blocking antibodies directed against CD 18 and CD 11a, suggest­
ing that the TS2/4 antibody captured functional LFA-l heterodimers Interestingly, 
dimeric Fc-ICAM-1 bound specifically to TS2/4 captured LFA-l, at a concentration 
of 0 5 μΜ Binding reached equilibrium within seconds of the start of the injection, 
whereas bound Fc ICAM-1 dissociated slowly after termination of the injection, in 
dicative of multivalent binding In contrast, binding ol monomeric sICAM-1 to 
LFA-l was undetectable, even at a concentration of 120 μΜ Since sICAM-1 and 
Fc-ICAM-1 proteins were recognized to similar extents by function blocking anti­
bodies and readily bound to LFA-l positive cells when immobilized on plastic, these 
results indicate that LFA-l binds to sICAM-1 with very low affinity and show that 
dimenzation of ICAM-1 dramatically increases its capacity to bind to LFA-l 
T he leukocyte integrin LFA 1 mediates cell-cell adhesion within the immune system by bind­ing to its ligand ICAM-1, that belongs to the Ig-superfamily and has 5 Ig-like domains (1-3) 
ICAM-1 is expressed on many cell types, including lymphocytes and endothelial cells and its ex­
pression can be strongly enhanced by inflammatory cytokines (4) LFA-l ICAM-1 interactions 
have been shown to be involved in a variety of immunological processes, including CTL/target in­
teractions, T/B cell interactions and the adhesion and subsequent migration of Τ cells through en­
dothelial cell monolayers into inflamed tissue (5 8) LFA-l mediated Τ cell adhesion to ICAM-1 
can be strongly enhanced by intracellular signals that are generated upon cross-linking of surface 
receptors like the TCR/CD3 complex, often referred to as inside-out signaling (9,10) Inside-out 
signaling is thought to induce conformational changes in integrins that enhance the affinity of inte 
grins for their hgands (11) 
That cell-cell adhesion is also dependent on the avidity ol integrin-ligand interactions, is demon­
strated by the finding that Ca2+ dependent reorganization of LFA-l into clusters on the cell surface, 
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strongly enhances LFA-1 mediated Τ cell adhesion to ICAM 1 (12,13) Recent reports suggest that 
adhesion is also affected by the surface distribution of ICAM-1, since ICAM-1 appears to be ex­
pressed as a dimer on the cell surface and dimenc ICAM-1 is more effective than monomenc 
ICAM-1 (sICAM-1) in supporting LFA-1 mediated adhesion (14,15) In addition to its cell surface 
expression, soluble ICAM-1 molecules can be detected in serum and levels appear to be correlated 
with disease progression, although the physiological role of sICAM-l in vivo is unknown (16,17) 
Several reports have shown that sICAM-1 molecules can inhibit LFA-1 mediated adhesion in vitro, 
but the concentrations of sICAM-1 reported to inhibit LFA-1 mediated adhesion range from 10 nM 
(serum levels) to 50 μΜ (18-20) To get insight in the binding of LFA-1 to ICAM 1 at the molecu­
lar level, several investigators have tried to determine the affinity of LFA-1 tor ICAM-1, by ana­
lyzing binding of sICAM-1 to cell-bound LFA-1, or purified LFA-1 immobilized on plastic How 
ever, data from these studies remain inconclusive, since the affinities reported for LFA-1 binding to 
sICAM-1 range from 100 μΜ to 130 nM (21,22) What is apparent from these studies however, is 
that dimenc ICAM-1 molecules are more potent inhibitors of LFA-1/1СAM-1 dependent adhesion 
and appear to bind with higher affinity to LFA 1 than monomenc ICAM-1 molecules 
(14,15,18,21,23) In this study, we used surface plasmon resonance experiments to characterize 
LFA-1 binding to ICAM-1 We obtained evidence that LFA-1 binds with very low affinity to si 
CAM-1, and that dimenc ICAM 1 is far more effective than monomenc ICAM-1 in binding to 
LFA-1 
Materials and methods 
Antibodies and reagents 
The following monoclonal antibodies were used TS2/4 (24), NKI L15, NKI-L7 (25) directed 
against CDlla, AZN-L27 (6,h International Leukocyte Workshop 1996), KIM185 (26) and MEM-
48 (27) directed against CD18, CA7 (16), REK-1 (27) GP89BA14 (28) and FIO 2 (29) directed 
against ICAM-1 (CD54), and R10Z8E9 directed against the Fc portion oí human IgG (30) Purified 
CTLA-4FC (31) was kindly provided by Dr van der Mcrwe 
Production of recombinant sICAM-1 and Fc-ICAM-1 
The cDNA encoding human ICAM-1 was isolated as a Xba-I fragment from the pCDM-8 
ICAM-1 vector (3) and cloned into the Xba-I site of the pAlter vector (Promega, Madison, WI) 
sICAM-1 encompassing domains 1 to 5, was generated as described previously (32), by mutating 
Y452 to F and replacing E453 with a translational stopcodon, using the pAlter mutagenesis system 
according to manufacturers procedures (Promega, Madison, WI) After checking the mutated 
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ICAM-1 for correct incorporation of oligonucleotides, the sICAM-1 cDNA was cloned as a Xba-1 
fragment into the Xba-I site of the pEE14 plasmid, that contains a glutamine synthetase gene that 
can be used to select transfectants for glutamine independent growth (33) Chinese Hamster Ovary-
Kl cells (CHO) were transfected with the sICAM-l/pEE14 plasmid (20 μg) by calcium phosphate 
coprecipitation, using the calcium phosphate transfection system (Gibco, Life technologies, Pais­
ley, Scotland), according to manufacturers procedures Transfectants containing multiple copies of 
the pEE14 plasmid due to gene duplication, were selected in glutamine free medium containing 10 
% dialyzed FCS (Gibco) and 50 μΜ of the glutamine synthetase inhibitor MSX (Sigma), as de­
scribed previously (34) Clones expressing high amounts ot sICAM 1 were selected in a sandwich 
ELISA U-bottom wells in a Microtest III plate (Falcon, Becton Dickinson, Oxnard, CA) were 
coated ON at 4°C with the CA7 mAb directed against the 51'1 domain of ICAM-1, at a concentration 
of 5 μ£/πι1 in TSM (150 raM NaCl, 1 mM CaCl2, 2 mM MgCl2, 10 raM Tns/HCl, pH 8 0, 50 
μΐ/well) Wells were blocked with 1% BSA in TSM (Boehnnger Mannheim, 100 μΐ/well) for 30' at 
37°C, followed by incubation of dilutions of supernatants in TSM/BSA of MSX resistant clones 
(50 μΐ/well), for 1 hour at RT After 5 washes with TSM containing 0 05% Tween, wells were in­
cubated with biotinilated anti-ICAM-1 mAb FIO 2 (2 μg/ml in TSM/Tween, 50 μΐ/well) for 30' at 
RT, washed again and incubated with HRP conjugated streptavidin (Zymed, San Francisco, CA) in 
TSM/Tween (0 03%, 50 μΐ/well) After washing away unbound antibodies, wells were developed 
with 100 μg/ml TMB in 0 1 M NaAc pH 4 0 containing 0 01% H202, and the reaction was termi­
nated by addition of 0 8 M H2SOj (50 μΐ/well) The best clone (secreting -5 mg/1) was grown up to 
confluence in roller bottles before switching to medium containing 5% FCS and 2 mM Na butyrate 
(Sigma) The cultures were then left for a further 2-3 weeks prior to harvesting sICAM-1 was puri­
fied from the spent tissue culture supernatant (-30 mg/1) by affinity chromatography using 
sepharose CL-4B beads (Pharmacia, Uppsala, Sweden) coupled to GP89BA14 (-6 6 mg mAb/ml 
resin) After washing the column with 10 volumes of wash buffer (50 mM NaH2PO.,, 0 15 M NaCl 
pH 7), sICAM-1 was eluted with 50 mM Na2HP04, 0 15 M NaCl pH 12, collected in 1 ml fractions 
and neutralized directly with 250 μΐ 0 5 M NaH2P04 sICAM-1 was further purified by size exclu­
sion chromatography on a SUPERDEX S200 HR 10/30 column (Pharmacia), using HBS as running 
buffer (150 mM NaCl, 1 mM MgCl,, 1 mM CaCl2 and 10 mM Hepes 10, pH 7 4) (Fig 1) The ex­
tinction coefficient (at 280 nm) of purified sICAM-1 was determined by amino acid analysis to be 
0 9 ml mg ' 
CHO-cells expressing Fc-ICAM-1 were generated by cotiansfecting the ICAM-1 IgGlFc plas­
mid (35) (20 μg) with the pEE14 plasmid (5 μg) and selecting MSX ìesistant clones as described 
above A Fc ICAM-1 producing clone (secreting -1 mg/L) was selected in a IgGl ELISA Fc-
ICAM-1 was produced in bulk culture as described above and isolated by affinity chromatography, 
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using a separate GP89BA14 affinity column The extinction coefficient of Fc-ICAM-I was as 
sumed to be 1 0 ml mg 'at 280 nm Samples of the sICAM-1 and Fc ICAM-1 containing fractions 
were resolved on reducing and non reducing SDS-polyacrylamide gels and analysed by silver 
staining SDS-Page was carried out on vertical slab gels (5-15% gradient) according to a modifica­
tion of the Laemmli procedure (36) For BIAcore experiments, Fc ICAM-1 was concentrated four 
fold, resuspended to the original volume in HBS, and concentrated again, five fold 
Purification of LFA-1 
LFA-1 was purified using a protocol adapted from (37) Briefly, 10 χ IO9 LFA-1 expressing 
lymphocytes left over from bone marrow of healthy donors, were pelleted by centrifugation and 
lysed with 45 ml ice-cold lysis buffer (25 mM Tns/HCl, 0 02% NaN„ 1% Triton X-100, 1 mM 
PMSF, 0 02 mg/ml Trypsin inhibitor, 1 mM CaCl, and 2 mM MgCl , pH 8 0) After removal of 
insoluble particles by ultracentnfugation and clearing the lysate over a NMS-sepharose column 
(CL-4B sepharose, Pharmacia), the lysate was passed over a TS2/4 conjugated CL-4B sepharose 
column After washing the column with 10 volumes of wash buffer (25 mM Tns/HCl, 150 mM 
NaCl, 2 mM MgCl2, 0 02 % NaN·,, pH 8 0) containing 1% Triton, and 5 volumes ot wash buffer 
containing 1% ß-D-octylglucoside (Sigma), LFA-1 was eluted from the column with 10 volumes of 
elution buffer at pH 4 0, containing 1% β D octylglucoside, 50 mM citric acid, 150 mM NaCl, and 
2 mM MgCl2 Fractions of 1 ml were collected and neutralized with 100 μΐ neutralization buffer (1 
M Tris and 5 mM MgCl2, pH 9 6) After taking samples of each fraction for analysis, fi actions 
were snap frozen in liquid nitrogen Samples were resolved on reducing SDS page gels and ana 
lyzed by silverstaining SDS-page was carried out on vertical slab gels (5-15% gradient) according 
to a modification of the Laemmli procedure (36) The extinction coefficient of purihed LFA-1 was 
assumed to be 1 ml mg ' at 280 nm 
Adhesion assay 
96-flat bottom wells (Maxisorb, Nunc, Roskilde, Denmark) pre-coated with Goat anti-human Fc 
(Jackson Immunoresearch Laboratories, Ine , Baltimore) or CA7 antibodies (4 μg/ml, 50 μΐ/well) 
for I hr at 37°C, and blocked with 1% BS A (Boehnnger Mannheim) (30 min at RT), were coated 
O/N at 4°C with purified Fc-ICAM-1 or sICAM-1 proteins, respectively, at the indicated concen­
trations Alternatively, wells were directly coated with purified sICAM-1 or Fc-ICAM-1 proteins 
(ON at 4°C), at the indicated concentrations, and were subsequently blocked with 1% BSA To 
determine adhesion to purified LFA-l, wells were coated with dilutions ol LFA-1 in TSM (ON at 4 
°C) and blocked with 1% BSA in TSM Cells (40,000/weIl) were labeled in PBS with Calcein-A 
(25 μg/107 cells/ml, Molecular probes, Eugene, OR) for 30 min at 37°C and incubated on 1CAM 1 
or LFA-1 coated plates for 45 min at 37°C in the presence or absence ot the indicated m Ab Non 
120 
Chm acto nation of LFA 1/ICAM I interactions by surface plasmon resonance 
adherent cells were removed by three washes with warm wash buffer (TSM + 0 5% BSA) , adher­
ing cells were lyscd with lysis buffer (50 raM Tris, 0 1% SDS , 100 μΐ/well) and fluorescence was 
quantified using a Cytofluometer (Biorad, Richmond, CA) Results aie expressed as the mean per­
centage of adhesion of triplicate wells 
BIAcore experiments 
Al binding experiments were performed at 25°C on a BIAcore 2000IM (BIAcore AB, Steven-
hagc, Herts, UK) with Hepes buffered saline (HBS) as running buffer, unless indicated otherwise 
HBS comprised 150 mM NaCl, 1 mM MgCl,, 1 mM CaCl2 and 10 mM Hepcs 10 (pH 7 4) Pro­
teins were covalently coupled to the carboxymethylatcd dextian matrix on research grade CM5 
sensor chips (BIAcore) via primary amine groups, using the Amine Coupling Kit (BIAcore) as de­
scribed (38), except that a flow rate of 10 μΐ/min was used throughout the immobilization The pu 
rified mAb R10Z8E9 was coupled and legenerated as described previously (30) The mAbs TS2/4 
at 28 μg/ml in 10 mM NaAcetate (pH 4 5), or CA7 at 25 μg/ml in 10 mM NaAcetate (pH 5 0), 
were coupled by injecting them over the activated sensoichip surface for 7 min Immobilized TS2/4 
was regenerated at a flow rate of 10 μΐ/ml by injecting 10 mM NaOH over the surface foi 3 min, 
and immobilized CA7 was regenerated by injecting 50 mM NaOH over the sui face for 1 min (data 
not shown) Using the BIAcore 2000 in multichannel mode, the same samples were injected over 
different flow cells in series, allowing the use of one of four flow cells to measure background re­
sponse 
Results 
Analysis of purified sICAM-1, Fc-ICAM-1 and LFA-1 proteins 
A soluble fragment of sICAM 1 containing the entire extracellular domain, generated by trun­
cating ICAM-1 at amino acid 453, was expressed in Chinese Hamster Ovary-Kl (CHO) cells and 
purified on a anti-ICAM-1 affinity chromatography column as described under materials and 
methods The isolated protein migrated at - 65 kDa under reducing conditions, consistent with the 
calculated protein molecular weight of 50 kDa and glycosylation of several of the 8 potential re­
linked glycosilation sites (Fig 1A) sICAM-1 migrated at similar size under non-reducing condi­
tions, demonstrating that it does not form protein aggregates in solution (not shown) 
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Figure 1. Analysis of purified 
sICAM-1, Fc-ICAM-1 and 
LFA-1. A) purified sICAM-1 
and Fc-ICAM-1 proteins (500 
ng) were analyzed by reducing 
SDS-PAGE on 5-15% gradient 
Polyacrylamide gels, and sil-
verstaining. A: MW markers; 
B: Fc-ICAM-1, C: sICAM-1. 
B) purified LFA-1 was ana-
lyzed by reducing SDS-PAGE 
on 5-15% gradient Polyacry-
lamide gels, and silverstaining. 
A: MW markers; B: LFA-1. C) 
purification of sIC AM-1 by 
size-exclusion chromatogra-
phy. sIC AM-1 (5 mg in 0.5 ml) 
was run on a SUPERDEX 
S200 HR10/30 column (Phar-
macia) at 0.5 ml/min in HBS. 
The calibration markers shown 
(Sigma) are alcohol dehydro-
genase (Mr 150.000) and BSA 
(Mr 66.000). The indicated 
fractions (*) were combined, 
concentrated 16 fold, and used 
within 48 h after storage at 
4°C. 
Characterization ofLFA 1/ICAM-l interactions by surface plasmon resonance 
Fc-ICAM-1 expressed in CHO cells was also purified by anti-ICAM affinity chromatography 
and migrated at - 100 kDa, under reducing conditions (Fig 1A) LFA-1 purified from a lysate of 
lymphocytes on a anti-CDl la affinity column, migrated as two bands of -180 kDa and -95 kDa, 
consistent with the expected size of the a, and β, subunit of LFA-1, respectively (Fig IB) 
To ensure that the purified sICAM-1 is monomenc in solution even at high concentrations, size 
exclusion chromatography was peiformed (Fig 1С) At a concentration of 10 mg/ml, ICAM-1 
eluted as a single peak of -104 kDa, whereas no larger aggregates could be detected Although sl-
CAM-1 elutes earlier than expected from the Mr measured by SDS-page (~ 65 kDa, Fig 1A), this 
does not indicate that the sICAM 1 is dimenc, since it has been shown that asymmetric glycosy­
lated proteins like the elongated rod shaped sICAM-1, typically elute much earlier in size exclusion 
chromatography than predicted by their Mi (39) That sICAM 1 is monomenc m solution, is further 
supported by a previous report, in which elution of monomenc sICAM-1 in size exclusion chro­
matography was comparable to oui results (14) BIAcore experiments were performed using the 
monomenc peak within 48 h of size exclusion chromatography 
Purified sICAM-1, Fc-ICAM-1 and LFA-1 proteins support cell adhesion 
We next deteimined the ability of the punhed proteins to support cell adhesion Figure 2A 
shows that ICAM-1 positive K562 cells specifically bound to purified LFA-1 immobilized onto 
plastic, at concentrations ranging trom 25 - 1 μg/ι'nl, without previous activation of LFA-1 The 
finding that punhed LFA 1 immobilized on plastic is spontaneously active, suggests that the LFA-
I fraction contains molecules in a high affinity state To determine the ability of monomenc sI­
CAM-1 and dimenc Fc ICAM 1 to support LFA-1 mediated Τ cell adhesion, different concentra­
tions of sICAM-1 or Fc ICAM 1 were coated directly onto plastic, or captured by coated anti-
ICAM 1 or anti-human Fc antibodies, iespectively Since Fc ICAM-1 is a dimer of 200 kDa and 
sICAM-1 a monomer of 65 kDa, upon coating of equal concentrations (m/v) of these proteins, 
more LFA-1 binding sites are available on sICAM-1 coated wells, than on wells coated with Fc-
ICAM 1 Figuie 2B shows that activated HSB Τ cells bound to dnectly coated sICAM-1 oi Fc-
ICAM 1 proteins at concentrations ι anging Irom 10 - 4 μg/ml, upon activation ol LFA 1 with the 
activating antibody KIM 185 (CD 18) However, at lower concentrations, Fc-ICAM 1 was more ef­
fective in supporting adhesion than sICAM-1, since Fc-ICAM 1 also supported Τ cell adhesion at a 
concentration of 2 μg/ml, whereas at this concentration no adhesion to the slCAM-1 was detected 
Also when sICAM-1 and Fc-ICAM-1 pioteins were captured on antibodies, sICAM 1 was less ef­
fective than Fc-ICAM-1 in supporting LFA-1 dependent Τ cell adhesion, at low concentrations 
(Fig 2C) At concentrations ranging fiom 1000 - 50 ng/ml, both sICAM-1 and Fc-ICAM-1 sup­
ported adhesion ot KIM 185 stimulated HSB Τ cells Howevei while Fc-ICAM-1 could still sup-
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port adhesion at a concentration of 20 ng/ml, sICAM-1 failed to support adhesion at this concen­
tration. 
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A Figure 2. Purified sICAM-1, Fc-
ICAM-1 and LFA-1 proteins 
support cell adhesion. A) adhe­
sion of ICAM-1 expressing K562 
cells to wells coated directly with 
purified LFA-1 at concentration 
ranging from ~ 25 pg/ml to 1 
μg/ml (50 μΐ/well). B) adhesion of 
LFA-1 expressing HSB-2 Τ cells 
activated with the LFA-1 activat­
ing antibody K1M185 (CD18; 10 
μg/ml), to wells directly coated 
Ώ with purified sICAM-1 or Fc-
ICAM-l proteins at concentra­
tions ranging from 10 - 0.2 ßg/ml 
(50 μΐ/well). С) Adhesion of 
KIM185-activated HSB-2 Τ cells 
to sICAM-1 and Fc-ICAM-1 im­
mobilized on plastic-coated CA7 
or anti-human Fc mAbs, respec­
tively (5 μg/ml; 50 μΐ/well), at 
concentrations ranging from 1000 
- 5 ng/ml (50 μΐ/well). Results are 
expressed as the mean % of LFΑ­
Ι/1С AM-1 specific binding, of 
triplicate wells. Specific adhesion: 
percentage of bound cells - per­
centage of cells bound in the pres­
ence of a LFA-1-blocking anti­
body (NK1-L15). Data are repre­
sentative of three experiments. 
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Together, these data indicate that both sICAM-l and Fc-ICAM-1 are functionally active, since 
they both bind to LFA-1 on Τ cells However, despite the fact that more LFA-1 binding sites are 
present on wells coated with sICAM-l than on Fc ICAM-1 coated wells, purified Fc-ICAM 1 is 
more effective in supporting LFA-1 mediated Τ cell adhesion than sICAM-l, at low concentra­
tions Since immuno precipitation studies indicate that sICAM-l and Fc ICAM 1 proteins are both 
properly folded (data not shown), these results suggest that even when immobilized onto plastic, 
dimenc Fc-ICAM-1 molecules are more effective than monomenc sICAM-l molecules in binding 
to LFA-1 
Antibody captured LFA-1 is recognized by function-blocking antibodies directed against 
CDl la and CD18 
We next determined whether functional LFA 1 heteiodimers could be immobilized onto a sen-
sorchip surface, in BIAcore experiments In these experiments, protein binding to receptors immo 
bihzed onto the dextran matrix of a sensorchip, is detected as a change in reft active index near the 
sensorchip surface, using an optical technique based on surface plamon resonance, and reported as 
response units (RU) 100 RU is equivalent to a protein load of -100 pg/ mm' sensor surface, or a 
protein concentration of -1 mg/ml within the dextran matrix (40) Preliminary experiments indi 
cated that direct covalent coupling of LFA-1 to the sensorchip surface resulted in inactivation of 
the molecule (not shown) We therefore determined whether functional LFA-1 heterodimeis could 
be immobilized indirectly via a non-function blocking anti-CDl la antibody (TS2/4), since TS2/4 
captured LFA-1 was previously shown to bind to ICAM-1 in an ELISA formal (van Kooyk et al , 
in preparation) Purified LFA-1 readily bound to TS2/4 antibodies that were covalently coupled to 
the dextran matrix of a sensorchip (Fig ЗА) 
Figure 3. Binding ofmAb to TS2/4-captured LFA-1 A) LFA-1 (-1000 RU) nas immobhzed to the 
sensor surface by injecting it at 50 pg/mlfoi 20 min, over a sensor surface to which -10000 RU of 
TS2/4 had been covalently coupled The large increase m signal immediately upon the stait of the 
injection (1) 14 due to the buffer in which the LFA 1 is dissolved During the sloping peut of the 
curve (2) LFA-1 is binding to TS2/4 and net binding of LFA 1 (-1000 RU) is calculated b\ sub 
trading the signal befoie the start of the injection f ι от the signal after termination of the injection 
(3) B) Binding ofmAbs to LFA-1 was determined by injecting them over ~ 1400 RU ofTS2/4 cap­
tured LFA-1, during 240 s at a flow rate of 5 pi/min and a concentration oj 50 pg/ml As a control 
the mAbs were also injected over a flow cell containing only immobilized TS2/4 but no binding 
was observed (not shown) Since the SPR signal is proportional to immobilized mass the percent 
age of LFA 1 that bound to antibodies, was calculated by dividing the measured response (RU), by 
the calculated maximal signal (350 RU) expected fi от binding oj antibodies (150 kDa) to the \m 
mobilized LFA-1 (275 kDa) assuming bivalent mAb binding 
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Figure 4. Binding of Fc-ICAM-1 and CTLA-4Fc to immobilized LFA-1. An equal amount of the 
TS2/4 antibody was covalently coupled to the sensorchip surface of two flow cells (FCl and 2; 
-7000 RU). Subsequently LFA-1 (933 RU) was immobilized to TS2/4 in one of the flow cells (FCl), 
by injecting it over the sensorchip surface at a concentration of 50 pg/ml in two injections (flow 
rate 5 μΐ/min, 120s; flow rate 1 μΐ/ml, 600s). Using the BIAcore 2000 in multichannel mode, the 
same CTLA-4Fc or Fc-ICAM-1 samples were subsequently injected over the flow cell containing 
covalently coupled TS2/4 and immobilized LFA-1 (FCl) and the flow cell containing only TS2/4 
(FC2), in order to measure the background response, at a flow rate of 1 ml/min during 300s. The 
responses inflow cells I and 2 are overlaid and the difference between the LFA-1 flow cell (FCl) 
and the control flow cell (FC2) represents specific binding . (A) Injection of'CTLA-4Fc (100 pg/ml; 
1 pM) (B) Injection of Fc-ICAM-1 (100 pg/ml; 0.5 pM), in the presence of 5 mM EDTA. (C) Injec­
tion of Fc-ICAM-1 (100 pg/ml; 0.5 μΜ) without EDTA. In this experiment HBS without Ca2* or 
Mg2* was used as running buffer, but Fc-ICAM-1 or CTLA-4Fc proteins were injected in HBS with 
Ca2* and Mg2+. The percentage ofTS2/4 captured LFA-1 that bound to Fc-ICAM-1, was calculated 
by dividing the measured response (RU). by the calculated maximal signal expected from binding 
of Fc-ICAM-1 (200 kDa) to the immobilized LFA-1 (275 kDa). 
TS2/4 captured LFA-1 retained the epitopes recognized by anti-CD 18 antibodies, indicating that 
that the anti-CDl la antibody TS2/4 captured intact α/β heterodimers of LFA-1 (Fig. 3B). Assum­
ing bivalent mAb binding, all of the captured LFA-1 was recognized by the activating antibody 
KIM 185, and 84% by the blocking antibody AZN-L27. Only 22% and 14% of the immobilized 
LFA-1 bound to the CD1 la mAbs NKI-L7 and NKI-L15, respectively. Since LFA-1 was captured 
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by the non function-blocking mAb TS2/4 directed against α,, it is possible that immobilization ot 
TS2/4 in the dextran matrix reduces the accessibility of the α subunit for binding of other anti-
CD 1 la antibodies, although the epitopes recognized by NKI-L7 and NKI L15 do not overlap with 
the TS2/4 epitope Together, these results indicate that the TS2/4 antibody captures intact LFA 1 
heterodimers and that the majority of captured LFA-1 molecules aie pioperly folded, since they 
retain the epitopes recognized by both blocking and LFA-1 activating antibodies 
TS2/4 captured LFA-1 specifically binds to dimeric Fc-ICAM-1 
Since the adhesion and mAb binding expenments indicated that punhed LFA-1 was functional, 
we investigated whether TS2/4 captured LFA-1 could bind to dimeric Fc-1CAM 1 To this end wc 
injected the same samples of Fc-ICAM-1 or CTLA 4Fc as a control, over a flow cell with cova-
lently coupled TS2/4 (FC2) and a How cell that contained both TS2/4 and immobilized LFA-1 
(FC1) Because the BIAcore detects changes in refractive index, injection ol high protein concen­
trations gives a large backgiound signal Subtraction of the background response in the flow cell 
containing only immobilized TS2/4 (FC2), from the flow cell containing both TS2/4 and LFA 1 
(933 8 RU, FC1), yields the actual piotein binding to LFA 1 In figuie 4, an overlay of the response 
in flow cells 1 and 2 is depicted Upon injection of CTLA-4Fc dunng 300s (A), no binding of 
CTLA-4Fc (1 μΜ) to immobilized LFA-1 was detectable As expected, also Fc-ICAM-1 (0 5 μΜ) 
failed to bind to LFA-1 upon chelation of divalent cations by coinjection of 5 mM EDTA (B) 
However, in the presence of divalent cations Fc-ICAM-1 readily bound to LFA 1, and reached 
equilibrium within seconds of the start of the injection (C) Bound Fc ICAM I dissociated slowly 
after the end of the injection, consistent with multivalent binding At equilibrium, - 30% of the 
immobilized LFA-1 bound Fc-ICAM-1 (280 RU) Together, these data show that TS2/4 captuied 
LFA-1 is capable of binding to dimeric Fc-ICAM-1, in surface plasmon îesonance expenments 
Specificity of binding is demonstiated by the dependency on divalent cations and by the finding 
that a control Fc-chimera fails to bind to LFA-1 
Monomeric sICAM-1 is less effective in binding to purified LFA-1 than dimeric Fc-ICAM-1 
We subsequently tested whethci immobilized LFA 1 could also bind to monomenc sICAM 1 
As depicted m figure 5, upon injection ol sICAM-1 at a concentration ol 8 mg/ml (~ 120 μΜ), no 
binding of sICAM-1 to immobilized LFA-1 could be detected (A) As expected, Fc-ICAM-1 bound 
to LFA-1 at a concentration of 500 μg/ml (~2 5 μΜ) (В) Approximately 7% ol antibody captured 
LFA-1 bound to Fc-ICAM-1, compared to 30% in the previous experiment Although this may in­
dicate that in this experiment less immobilized LFA-1 was in an active slate, these data neverthe­
less suggest that monomenc sICAM-1 is less effective in binding to LFA-1 than dimeric Fc-
ICAM-1, since sICAM-1 was injected at a 50 fold higher molar concentration than Fc ICAM-1 
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Figure 5. Binding of Fc-ICAM-1 and sICAM-1 to TS2/4 captured LFA-1. An equal amount of 
the TS2/4 antibody was covalently coupled to the sensorchip surface of two flow cells (FCl and 2; 
~ 12000 RU). Subsequently LFA-1 (1341 RU) was immobilized on TS2/4 in one of the flow cells 
(FCl), by injecting it over the sensorchip surface at a concentration of 50 pg/ml and a flow rate of 
1 μΐ/min, during 20 min. Using the BIAcore 2000 in multichannel mode, subsequently the same sl-
CAM-1 or Fc-ICAM-1 samples were injected over the flow cell containing covalently coupled 
TS2/4 and immobilized LFA-1 (FCl) and the flow cell containing only TS2/4 (FC2), in order to 
measure the background response. The responses inflow cells 1 and 2 are overlaid and the differ­
ence between the LFA-1 flow cell (FCl) and the control flow cell (FC2) represents specific bind­
ing. (A) Injection of sICAM-1 at a concentration of 8 mg/ml (120 μΜ), at a flow rate of 3 pi/min 
during 200s. (B) Injection of Fc-ICAM-1 (500 μg/ml; 2.5 μΜ) at a flow rate of 3 μΐ/min during 
200s. The percentage ofTS2/4 captured LFA-1 that bound to slCAM-1 or Fc-ICAM-1, was calcu­
lated by dividing the measured response (RU), by the calculated maximal signal expected from 
binding ofsICAM-1 (65 kDa) or Fc-ICAM-1 (200 kDa) to the immobilized LFA-1 (275 kDa). 
Antibody captured sICAM-1 and Fc-ICAM-1 proteins are recognized by function blocking 
antibodies 
To further analyze the activity of purified sICAM-1 and Fc-ICAM-1, these proteins were cap­
tured on covalently coupled anti-ICAM-1 (CA7) or anti-human Fc (R10Z8E9) m Abs, respectively 
(Fig 6). The immobilized antibodies captured approximately 1100, 1700 and 2300 RU of sICAM-
1, Fc-ICAM-1 and CTLA-4Fc proteins, respectively. Subsequently, both the sICAM-1 and Fc-
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ICAM-1 reacted with function blocking antibodies directed against ICAM-1, whereas CTLA-4Fc 
was not recognized (Fig. 6). 
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Figure 6. mAb binding to sICAM-1 and Fc-ICAM-1. A) Fc-ICAM-1 (0.5 mg/ml) and CTLA-4Fc 
(50 pg/ml) as a control, were immobilized to the sensor surface, by injecting them over a sensor-
chip surface to which ~ 11000 RU of the anti-human Fc mAb R10Z8E9 was covalently coupled, for 
15 and 5 min, respectively. Similarly, sJCAM-1 was immobilized by injecting it over a sensorchip 
to which -13000 RU of the mAb CA7 was covalently coupled, at a concentration of 0.5 mg/ml and 
a flow rate of 1 pi/min, during 15 min. В) Binding of the function blocking mkbs F 10.2 (J) and 
REK-1 (2) was determined by injecting them over the sICAM-1, Fc-ICAM-1 and CTLA-4Fc coated 
sensorchip surfaces, at a concentration of 50 pg/ml and a flow rate of 2 ml/min, during 300 s. As­
suming bivalent mAb binding, the percentage of immobilized Fc-ICAM-1, CTLA-4Fc and sICAM-1 
proteins that bound to antibodies, was calculated by dividing the measured response (RU), by the 
calculated maximal signal expected from binding of antibodies (150 IcDa) to the immobilized Fc-
ICAM-1 (200 kDa), CTLA-4FC (100 kDa) and sICAM-1 proteins (65 kDa). 
Assuming bivalent mAb binding, approximately all the immobilized sICAM-1 and Fc-ICAM-1 
was recognized by the anti-ICAM-1 antibody FIO.2, whereas -75% of these proteins was recog­
nized by the ICAM-1 blocking antibody REK-1. Since both purified sICAM-1 and Fc-ICAM-1 
proteins express epitopes recognized by function blocking antibodies, these results confirm that the 
majority of the sICAM-1 and Fc-ICAM-1 proteins is properly folded. 
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Discussion 
In this study we for the first time used surface plasmon resonance to analyze binding of purified 
LFA-1 to monomenc and dimeric forms of ICAM-1. We obtained evidence that (A) LFA-1 binds 
monomeric ICAM-1 with very low affinity and (B) that dimenzation of ICAM-1 dramatically en­
hances its capacity to bind to LFA-1 
It has been reported that ICAM-1 exist as a dimer on the cell surface and that dimeric ICAM-1 
binds better to immobilized LFA-1 than a monomenc, GPI-hnked foim of ICAM-1 (14,15). Sur­
prisingly, in this study we found that even when immobilized onto plastic, dimeric ICAM-1 mole­
cules are more effective in supporting LFA-1 mediated adhesion than monomeric ICAM-1 mole­
cules, at low densities. These data support and extend the observation that dimeric ICAM-1 is more 
potent than monomeric ICAM-1 in binding to LFA-1. The notion that monomeric ICAM-1 binds 
poorly to LFA-1 is supported by surface plasmon resonance experiments, since we could detect no 
binding of sICAM-1 to antibody captured LFA-1, even at a concentration of 120 μΜ, while spe­
cific binding of Fc-ICAM-1 was observed. Although we were not able to measure the affinity of 
LFA-1 for sICAM-1 directly, these data indicate that the affinity will likely be lower than 120 μΜ. 
Using Fc-ICAM-1, we obtained information about the kinetics of the interaction of LFA-1 with 
dimeric ICAM-1. We found that Fc-ICAM-1 binds to immobilized LFA-1 with a fast association 
rate, since binding reaches equilibrium in seconds Bound Fc-ICAM-1 dissociates slowly, consis­
tent with multivalent binding. These data suggest that dimeric ICAM-1 binds with higher apparent 
affinity to LFA-1 than monomeric ICAM-1 through a decrease in the off rate of the binding reac­
tion. 
Several investigators have used other approaches to determine the affinity of LFA-1 for ICAM-
1. By analyzing competition between sICAM-1 and a monomeric, function blocking antibody, for 
binding to LFA-1 on Τ cells, Lollo and coworkers (22) determined the affinity of LFA-1 on resting 
Τ cells to be low (100 μΜ). Activation of Τ cells resulted in a 200 fold increase in the affinity of a 
small proportion of LFA-1 molecules (-400 nM). A low affinity for LFA-1 is consistent with a 
study in which the capacity of sICAM-1 to inhibit LFA-l/ICAM-1 mediated cell adhesion was in­
vestigated (18). sICAM-1 inhibited LFA-1 mediated Τ cell aggregation or Τ cell adhesion to im­
mobilized sICAM-1, with an IC50 of 20-40 μΜ However, sICAM-1 inhibited adhesion of purified 
LFA-1 to immobilized sICAM-1 with an IC50 of -200 nM, suggesting that LFA-1 expressed on 
cells is in a lower affinity state than purified LFA-1. In line with this, Woska and coworkers calcu­
lated the affinity of LFA-1 for sICAM-1 to be around 130 nM (21), by measuring binding of sl-
CAM-1 to LFA-1 immobilized on plastic. Together, these studies suggest that the affinity of active 
LFA-1 for ICAM-1 is around 130-400 nM, whereas the affinity of resting LFA-1, as found on Τ 
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cells, is around 100 μΜ These studies may indicate that the LFA-1 used in the present study is in a 
low affinity state, since our results point to an affinity lower than 100 μΜ We punlied LFA-1 by 
elution of a TS2/4 affinity column at low pH, whereas LFA-1 used in the studies described above, 
was eluted at high pH Although our LFA-1 readily bound ICAM 1 in adhesion assays (Fig 2), it is 
possible that our LFA 1 preparation contains only a small proportion of LFA-1 molecules in a high 
affinity state It will be interesting to determine whether LFA 1 molecules eluted at high or low pH 
represent different activation states of the LFA-1 integnn 
For valid affinity and kinetic analysis, it is essential to exclude the presence of protein aggre 
gates in protein preparations, since these dramatically increase the strength and stability of an inter 
action, resulting in overestimation of affinities (40) The study by Woska and coworkers in which a 
very high affinity of LFA-1 for ICAM 1 (130 nM) was calculated from binding of sICAM-1 to 
coated LFA-1 (21), lacks detailed analysis of the presence ol protein aggregates in the sICAM-1 
preparations, like gelfiltration studies Therefore, it can not be excluded that the altinity reported 
for LFA-l/ICAM-1 binding in this study is too high 
Several studies have reported affinities for other integrin/ligand interactions Cai and coworkers 
(41) determined the affinity of the leukocyte integnn Mac-1 for its ligand C3bi to be -12 nM, using 
binding of an alkaline phosphatase conjugate of C3bi to immobilized purified Mac-1 Interestingly, 
an inactive form of Mac-1, obtained by eluting Mac 1 with EDTA irom an C3bi affinity column, 
could bind ligand upon treatment with the activating antibody KIM127 Since K.IM127 did not 
change the affinity of Mac-1 for C3bi, it was postulated that KIM 127 enhances binding of Mac-I 
by lowering the activation energy for acquiring an active state of the molecule In contrast, the ac 
tivating antibody TS2/16 directed against β, integnns, increased the affinity of VLA-5 for Fn 80 
from 4 to 1 nM (42), suggesting that activating antibodies can increase ligand binding of integnns 
through different mechanisms Using radiolabeled GST-osteopontin (OSN), also the affinity of 
immobilized β, integnns tor OSN was found to be in the nM range (5 50 nM) (43) In surface 
plasmon resonance experiments measurement of α
ν
β, to immobilized OSN yielded even higher 
affinities (0 43-11 nM) (44), although it is possible that these high affinities are due to measure 
ment of multivalent binding of α
ν
β, micelles to OSN Finally, using surface plasmon resonance, 
also high affinities of a,Ibß, for fibrinogen were reported (155-180 nM and 20-70 nM) Together, 
these studies point to affinities of integnns for their ligands in the nM range Howevei, as discussed 
above, it can not be ruled out that also these affinities were overestimated, due to the presence of 
protein aggregates in the purified ligand preparations 
Using measurement of monomenc interactions in surface plasmon experiments, the affinity and 
kinetics of interactions between a number of other adhesion molecules and their ligands have re-
cently been determined A striking observation from these studies is that adhesion molecules gen-
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erally interact with their ligands with low affinities and very fast kinetics For instance, CD2 and 
LFA-3, both members of the Ig-superfamily, bind with an affinity of 9-22 μΜ and a dissociation 
rate constant (k
off) of at least 4s '(39) Similarly, B7-1 binds to CD28 and CTLA-4Fc with affinities 
of 4 and 0 42 μΜ, respectively (31) Together, these studies suggest that adhesion interactions are 
generally of low affinity and that multivalent interactions are required for stable cell-cell binding It 
is therefore very important to determine, using defined monovalent interactions, whether integnns 
bind to their ligands with high affinity, or that integrin mediated adhesion is regulated by the avid­
ity of integrin/ligand interactions, as has been reported for other adhesion molecules The latter hy­
pothesis is supported by our finding that although slCAM-1 fails to bind to immobilized LFA-1 in 
solution, it effectively supports LFA-1 mediated cell adhesion when presented multivalently, by 
coating it onto plastic at high densities 
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General discussion: molecular and structural analysis of 
LFA-1/ligand binding 

Discussion 
T o get insight in integrin function, but also to design drugs or peptides that can interfere with integnn adhesion in vivo, numerous investigators have attempted to characterize binding of 
integrine to their ligands at a molecular level Functionally important domains in integrins and inte­
grin ligands have been identified by analysis of recombinant protein fragments and mutational 
studies, although the three-dimensional oiganization of these domains remained elusive However, 
recent crystallographic studies are starting to provide insight into the topology of residues that are 
critical for binding of integrins to their ligands In this chapter current evidence about the structural 
features of integnn ligand binding will be discussed 
Role of the I domain in ligand binding of integrins 
Function and structure of the I domain 
A subgroup of integnn α subunits (a,, a, a,, aM, a x , aL, aD and a,) contains a N-terminal 
stretch of 200 amino acids, termed Inseited (I) or A domain, that shaies homology with the family 
of von Willebrand Factor A domains (1-4) Integrin I domains appeal to have evolved in a subfam­
ily of integrins, as a domain specialized in ligand binding Recombinant I domain fragments of α,, 
aM, a, and a, subunits have been shown to contain ligand binding activity and specificity (5-19) 
The findings that recombinant I domain peptides directly bind divalent cations (20) and that muta­
tion of acidic residues involved in divalent cation coordination abrogates ligand binding, indicate 
that binding of divalent cations is essential for interaction ol integnn I domains with ligand (7,20-
28) The recent resolution of the ciystal structures of the CD1 lb and CD1 la I domains has revolu­
tionized our view on I domain function (21,29) (Fig 1) Both the CD l i b and CD1 la I domains 
adopt a classic dinucleotide binding or Rossmann fold, a topology that is lound in a variety of in­
tracellular enzymes, consisting ol 6 hydrophobic ß-sheets, surrounded by five amphipatic a-
helices In enzymes adopting the Rossmann or dinucleotide-binding fold, a ligand binding site is 
formed by a crevice on top of the β sheet, that often includes a divalent cation A similar cievice is 
also found on top of the CD1 lb and C D l l a I domain structures (Fig 1), suggesting that this part of 
integrin I domains is also involved in ligand binding Interestingly five acidic residues in this aiea 
constitute a divalent cation binding pocket, tei med MIDAS (metal ion dependent adhesion site) 
(Fig 1) (21,29) The identification of this I domain MIDAS explains the previously identified 
metal ion binding capacity of integnn I domains (20) and for the fust time reveals how previously 
identified critical residues within the I domain contribute to cation cooidination 
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Figure IA. Crystal structure of the 
CDUa I domain. The CDlla I 
domain comprises four parallel β 
strands (ßl-ß4) and one short anti-
parallel β strand (βΤ), surrounded 
by seven a helices (al-a7). A sin­
gle cation binding pocket consist­
ing of five cation coordination resi­
dues is located on top of the I do­
main. Residues critical for 1CAM-1 
binding (Met'40, Glu14", Thr243, 
Ser24') and ICAM-3 binding (lie126, 
Asn'14) are indicated. Epitopes rec­
ognized by antibodies that interfere 
with binding of LFA-1 to all li-
gands (IdeA, IdeB, IdeC), or selec­
tively inhibit binding of LFA-I to 
ICAM-3 (IdeD) are highlighted in 
black. lle'2t'-Glym', not present in 
the CDlla 1 domain crystal struc­
ture, are added to figure 1A. 
The role of MIDAS residues in ligand binding has now been clearly established, since it has 
been shown that mutation of residues contributing to the MIDAS motif (Asp137, Ser" 9, Ser141 and 
Thr2 0 6 in the CD1 la I domain), abrogates ligand binding of all I domain containing integrins (Fig. 
2). (7,20-28). Together, these data suggest that integrins have adopted a region from the Rossmann 
fold crucial for enzyme-substrate interactions, into a domain critical for ligand binding of integrins. 
Evidence for differential ligand binding to integrin I domains 
Many I domain containing integrins can bind to multiple ligands. Although MIDAS residues are 
critical for binding to all ligands, identification of other residues within integrin I domains that 
contribute to ligand binding, suggests that binding sites for different ligands are overlapping, but 
not identical. Huang and Springer identified a number of residues within the I domain of CD1 la 
that are critical for LFA-1 binding to ICAM-1 (Met140, Glu146, Thr243 and Ser245) (30). Interestingly, 
these residues are localized in close proximity of the MIDAS residues when aligned with the 
CD1 la I domain crystal structure (Fig. 1), suggesting that they constitute a ICAM-1 binding sur­
face on top of the CD1 la I domain. 
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Figure IB. Coordination 
of a Mn2* ion by cation 
coordinating residues in 
the CDlla I domain. I 
domain residues, water 
molecules, and a chloride 
ion that contribute to co-
ordination of the Mn2* ion 
are indicated. Hydrogen-
bridges are indicated by 
open lines. Figure 1 was 
generated with the pro-
gram SYBYL 6.3 (Tripos, 
Inc., St. Louis, MO), using 
the CDlla I domain co-
ordinates in the Brook-
haven Protein Data Bank, 
entry 1LFA, as provided 
by Dr. Leahy (29). 
However, it remains to be established whether these residues are selectively involved in binding 
of LFA-1 to ICAM-1, or also contribute to ICAM-2 and -3 binding of LFA-1. Data described in 
chapters 2, 3 and 4 of this thesis, indicate that binding of LFA-1 to ICAM-1 and ICAM-3 may in-
volve distinct residues within the CD1 la I domain. Mutation of lie126 and Asn129 selectively abro-
gates LFA-1 binding to ICAM-3 and does not affect adhesion to ICAM-1 (Chapter 3). Alignment 
of Ile126-Asn'29 with the CD1 la I domain crystal structure reveals a novel region within the I do-
main that is critical for LFA-1/ICAM-3 binding, diametrically opposite of the metal binding site 
(Chapter 4, Fig. 1). 
Different ligands of Mac-1 also bind to partly overlapping, but distinct sequences within the 
CD1 lb I domain (Fig. 2). Binding of Mac-1 to C3bi, Fg, ICAM-1 and the hookworm derived neu-
trophil inhibitory factor (NIF), all critically depend on the MIDAS motif (12,20,21,26,31,32). NIF 
binding to Mac-1 furthermore depends on residues surrounding the MIDAS motif (Gly14', Asp149, 
Glu'78-Glu179 and Arg208), and three stretches of ami no-acids spanning Pro147-Arg152, Pro201-Lys217 
and Asp248-Arg261 (32,33). 
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Binding of NIF, СЗЬі, Fg or denatured ovalbumin (dOva) to Mac-1, is abrogated by mutation or 
deletion of a stretch of 7 aminoacids in the a! helix that is not present in C D l l a I domain 
(D248PLGY) (22,27), thus identifying a region within the C D l l b I domain that contributes to the 
capacity of Mac-1 but not LFA-1, to bind to these ligands In contrast, substitution of a 
R2 8 IQELNTI motif for C D l l a sequence, selectively abrogates Mac-1 binding to Fg or dOva, 
whereas adhesion to NIF and C3bi is unaffected (22). Another ligand of Mac-1 is ICAM-1. The 
finding that some antibodies directed against the CD1 lb I domain interfere with Mac-1 binding to 
Fg, but not with binding of Mac-1 to ICAM-1, suggests that residues critical for ICAM-1 binding 
to Mac-1 are distinct from residues involved in binding to Fg (34). These results show that al­
though the ligand specificity of Mac-1 differs from the specificity of LFA-1, different ligands of 
LFA-1 and Mac-1 both bind to partly overlapping, but distinct sequences within their respective I 
domains. Although Mac-1 and LFA-1 I domains do not share a high degree of sequence homology, 
both LFA-1 and Mac-1 bind ICAM-1. It will be interesting to determine whether residues sur­
rounding the divalent cation pocket in the Mac-1 I domain, contribute to ICAM-1 binding similar 
to residues surrounding the LFA-1 MIDAS 
To date little is known about sequences within the I domains of CD1 lc and CD1 Id that are in­
volved in ligand binding. It has been shown that ρ 150,95 like Mac-1, binds to fibrinogen, C3bi and 
denatured proteins (35-37). The sequences identified within the C D l l b I domain implicated in 
binding to these ligands (D2 4 8PLGY and R2 8 ,QELNTI) are largely conserved within the CD1 lc I 
domain (Fig. 2), suggesting that these residues may also contribute to binding of Ρ 150.95 to these 
ligands. In contrast, it remains unclear whether P150.95, like Mac-1, binds ICAM-1. Since the li­
gand specific residues identified within the CD I lb 1 domain are largely conserved in the CD1 lc I 
domain, this implies that the CD1 lb I domain may contain unique as yet unidentified residues that 
contribute to the ability ot Mac-1, but not ρ 150,95, to bind to ICAM-1. The lourth member of the 
β2 family exuß,, was recently cloned and reported to bind to ICAM-3 (2) Surprisingly, the I domain 
of CD1 Id shares high homology with the I domain of CD1 lb, especially in the sequences that are 
critical for Mac-1 binding to C3bi, Fg and denatured proteins. It will therefore be important to de-
termine whether aDß2 selectively binds to ICAM-3, or binds to a variety of protein ligands as has 
been reported for ρ 150,95 and Mac-1 It is also important to determine which amino-acids contrib­
ute to selective binding of aDß, to ICAM- 3, since lesidues in the CD1 la I domain that are critical 
for LFA-1 binding to ICAM-3 (Chapter 3), are not conserved within the I domain of CDl ld (Fig. 
2). 
In addition to regions in integnn I domains (hat directly conti ibute to ligand binding, amino-
acids have been identified that appear to control I domain confonnation (Fig. 2). Mutation of two 
stretches of amino-acids in the CD1 lb I domain (Glu'62-Leu17" and Glnl)0-Ser147), results in consti-
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tutively active α
Μ
β2 mtegnns, suggesting that conformational changes in integnn I domains may be 
important during integnn activation (38) Finally, studies on integnn I domains have levealed the 
localization of epitopes recognized by antibodies that interfere with hgand binding of I domain 
containing mtegnns (Fig 2, 30,39) Chapter 4 of this thesis describes the identification of the IdeD 
epitope, recognized by anti-CDl la I domain antibodies that selectively interfere with LFA 1 bind­
ing to ICAM-2 and -3, but not with binding ot LFA-1 to ICAM-1 Interestingly, alignment of the 
IdeD epitope with the crystal structure of the CD1 la I domain, reveals that the IdeD epitope is in 
close proximity of He126 and Asn129 residues, that are cntical for LFA-1 binding to ICAM-3 Since 
antibodies recognizing the IdeD epitope also inhibit LFA 1 adhesion to ICAM 2, it is templing to 
speculate that He126 and Asn12) are also important for binding of LFA-1 to ICAM-2 Similarly, two 
previously identified epitopes recognized by antibodies that interfere with binding of LFA-1 to all 
ligands, are close to the metal ion binding site on top of the I domain (Fig 1, Chapter 4 and (30)) 
Since mutation of the epitopes recognized by these blocking antibodies does not abrogate adhesion, 
these antibodies likely interfere with integnn function by stenc hindrance of functionally impoitant 
domains within integnn I domains 
Role of divalent cations in Hgand binding by the I domain 
The resolution of integnn I domain crystal structures in the presence of dillercnt divalent ca­
tions, has been informative about the role of divalent cations in ligand binding to integnn I do 
mains In the first resolved crystal structure of the CD1 lb I domain, five I domain amino acids co­
ordinate a Mg2* ion (21), while the sixth cation coordinating residue is provided by an acidic glu 
tamate residue from a neighboring I domain molecule in the crystal lattice Based on this finding, it 
was hypothesized that divalent cations can stabilize integnn ligand interactions, by connecting ca 
tion coordinating residues in the I domain with acidic residues in integnn ligands (21,40) Suipris-
ìngly, resolution of the Mn2+ occupied crystal structure of the CD1 la I domain (Fig 1), revealed a 
different coordination of the divalent cation In the CD1 la I domain crystal structure, the sixth ca-
tion coordinating residue is not provided by a second I domain molecule, but by a chloride ion, 
suggesting that in the Mn2+ occupied CD1 la I domain the divalent cation does not directly contrib-
ute to ligand binding (29) Together, these findings suggest that binding of different divalent ca-
tions to the cation binding pocket in the I domain, affects the conformation of the I domain and 
thus the capacity of the divalent cation binding pocket to contribute to ligand binding This hy-
pothesis has been challenged in subsequent studies, by comparing crystal structures of the CD1 la I 
domain obtained in the presence of Mg2+, Mn2t, or in the presence ot EDTA (41) Surprisingly, di-
valent cation coordination and I domain conformation are similar in both Mg2+ and Mn2+ occupied 
CD1 la I domain crystal structures In the absence of cations, the crystal structure obtained closely 
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matches that of Mn1* or Mg2* occupied CD1 la I domains, apart trom a shift in the a7 helix Since 
this shift is not correlated with other conformational changes in the I domain, these results suggest 
that the cc7 helix is a labile structuie in integrin I domains, and that shifts in the a? helix are inde 
pendent of correlated movements in the metal-binding site (41) Importantly, from these results it 
can be concluded that divalent cation binding is not required for structural integrity of the CD1 la I 
domain, and that binding oí Mg2* or Mn1* to the CD1 la 1 domain does not alter metal cooidination 
or I domain conformation (41 ) 
By contrast, comparison of Mn* or Mg1* occupied CD I lb I domain ciystal structures, suggests 
that Mn2* and Mg1* differentially regulate I domain conformation, since substitution of Mg2* for 
Mn2* significantly alters divalent cation coordination resulting in a shift in the al helix and burial 
of Phe275 and Phe1"2 residues into the hydrophobic core of the molecule (42) This discrepancy be 
tween CD1 la and CD1 lb I domains, suggests that Mn2* oi Mg2* differentially regulate the confor 
mation of CD 11 a and CD l i b i domains However, as pointed out by Qu and Leahy (41), it is also 
possible that the altered metal coordination and resulting conformational changes observed in the 
CD1 lb I domain, do not reflect naturally occurring differences in I domain structure, but rathei re 
suit from different protein protein interactions in Mg1* or Mn1* containing crystal lattices If cor 
reel, this implies that cations directly contribute to hgand binding by I domains, thiough connection 
of acidic residues in I domains with acidic amino acids in integrin hgands 
Role of EF-hand like domains in integrins 
Integrin α subunits contain a second region implicated in both cation binding and hgand bind­
ing the EF-hand like domains (Fig 3) These resemble classical EF hand domains in calcium 
binding proteins like calmodulin and troponin-C, that coordinate divalent cations by a clustei of 
oxygenated residues In contrast to classical EF-hands, integrin EF hand like domains lack the sixth 
cation coordinating residue (43), suggesting that acidic íesidues in integrin hgands oi integrin β 
subunits contribute to cation coordination to integrin EF-hands, similar to what has been proposed 
for the I domain MIDAS It has been shown that EF hands in aMI) can bind divalent cation and a Fg 
derived γ-peptide (44,45) and that ICAM-1 binds to the EF-hand containing region of a; (46) sug­
gesting that integrin EF-hands are indeed involved in both cation and hgand binding Howevei, 
how EF-hands precisely contribute to adhesion remains poorly defined It has been shown that 
mutation of the third oxygenated residue in the first, second or third EF hand motif of the a4 
subunit, equally diminishes adhesion to the Fn derived CSI peptide or VC AM 1, while adhesion to 
the bacterial protein invasin is unaffected (47) 
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These findings may indicate that each individual EF-hand directly stabilizes interaction with li-
gand, or may indicate that EF-hands cooperatively regulate integrin conformation. 
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Figure 3. Integrin EF-hand like motifs. The EF-hand like domains within CDlla (domains V-VII) 
are aligned with the consensus motif of classical EF-hands found in Ca2+ binding proteins, such as 
calmodulin. While amino-acids at positions 1, 3, 5, 7, 9 in the integrin EF-hand like motif are also 
present in classical EF-hands, integrin EF-hand like motifs lack the coordinating residue at posi­
tion 12. Schematic cation coordination by integrin EF-hand like domains is indicated in the lower 
part of the figure. Black spheres: cation coordinating residues; gray sphere: divalent cation; dot­
ted lines: coordination. 
Ligand binding domains in integrin β subunits 
Within integrin β subunits a conserved region is found that contains a number of conserved oxy­
genated residues (AA 125-309; Fig. 4). The first evidence for the involvement of this region in li­
gand binding of integrins, comes from a study in which a peptide spanning residues Met" 8 -Ile '" 
from the β3 subunit was found to bind to a RGDF peptide derived from the a]]bß3 ligand Fg, and to 
inhibit binding of aMbß, integrin to Fg. Interestingly, the β, peptide binds to the cation T b u , but fails 
to bind cation upon substitution of Asp"'' for Ala. (48). Together, these data have for the first time 
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implicated integrin β subunits in both cation and ligand binding. Identification of a divalent cation 
binding pocket in the crystal structures of the CDlla and CD1 lb I domains (21,29), has further 
prompted researchers to investigate whether homologous oxygenated residues in the so-called β I 
domain are important for integrin-ligand binding, and whether these conserved residues can adopt a 
similar three-dimensional fold. 
ß2 LYLRPGQAAA FNVTFRRAKG 
ßi LRLRSGEPQT FTLKFKRAED 
ß.i LRLRPDDSKN FSIQVRQVED 
RIGFGSFVDK TVLPFVN.TH 
RIGFGSFVEK TVMPYIS.TT 
RIGFGAFVDK PVSPYMYISP 
"MIDAS" 
ι --. 
23(1 232 235 
QLISGNLDAP EGGLDAMMQV 
QRISGNLDSP EGGFDAIMQV 
QSVSRNRDAP EGGFDAIMQA 
DGRCHLE.DN LYKRSNEFDY 
DGQCHLE.NN MYTMSHYYDY 
DGQCHVGSDN HYSASTTMDY 
Figure 4. Amino-acids in β I domains involved in ligand binding. The I domain like regions in β,, 
β2 and β, suhunits are aligned. Amino-acids important for ligand binding identified by mutagenesis 
are indicated in bold. Conserved residues are highlighted by vertical shaded bars. The β, derived 
peptide that binds to Thu and Fg is underlined. "MIDAS": residues important for cation binding to 
the β I domain. 
It has now been clearly demonstrated that the conserved DxSxS sequence in the β I domain is 
critical for ligand binding of integrins (23,48-51). However, identification of other important resi­
dues within integrin β subunits, indicates that coordination of divalent cations to integrin β subunil 
may be similar, but not identical to cation coordination by I domains in integrin α subunits. In ad­
dition to residues in the DxSxS motif, divalent cations are coordinated by two other critical resi­
dues in the CD1 lb and CDlla I domain crystal structures: Thr0 6 and Asp239 (Fig. 2). While the 
Asp219 homologue in the β subunit is also critical for ligand binding (23,51-53), mutation of the 
Thr206 homologue in the β subunit does not affect integrin mediated adhesion (52). In addition, two 
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/ I \ loss surface expression 
134 I.« 1 3 8 ^ " ^ 
YPIDLYYLMD LSYSMLDDLR NVKKLGGDLL RALNEITESG 
YPIDLYYLMD LSYSMKDDLE NVKSLGTDLM NEMRRITSDF 
YPVDIYYLMD LSYSMKDDLW SIONLGTKLA TQMRKLTSNL 
P3 peptide 
212 
PDKLRNPCPN KEKECPPPFA FRHVLKLTNN SNQFQTEVGK 
PAKLRNPC.T SEQNCTTPFS YKNVLSLTNK GEVFNELVGK 
PEALENPCYD MKTTCLPMFG YKHVLTLTDQ VTRFNEEVKK 
no effect 
AACPEEIGWR NV.TRLLVFA TDDGFHFAGD GKLGAILTPN 
AVCGSLIGWR NV.TRLLVFS TDAGFHFAGD GKLGGIVLPN 
TVCDEKIGWR NDASHLLVFT TDAKTHIALD GRLAGIVQPN 
PSVGQLAHKL AENNIQPIFA VTSRMVKTYE KLTEIIPKS 
PSIAHLVQKL SENNIQTIFA VTEEFQPVYK ELKNLIPKS 
PSLGLMTEKL SQKNINLIFA VTENWNLYQ NYSELIPGT 
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other conserved amino-acids in integnn β subunits (Glu,,s and Asn™ in β2) that are important tor 
mtegnn-ligand binding, are not present in α subunit I domains (23,52,53) 
Attempts to model the conserved domain in integnn β subunits onto the crystal structure ot the 
CDlla I domain, suggest that the β subunit domain can adopt a three-dimensional fold that is 
similar, but not identical, to the I domain fold (23,51,52,54) In the model proposed by Tozer and 
coworkers (52), the position of the conserved DxSxS motif. Asp212 and Glu2", suggests that these 
amino-acids indeed contribute to cation coordination In previous studies, a β, peptide containing 
only the DxSxS motif bound divalent cations (48), suggesting that these residues within the 
MIDAS motif are essential for the formation of a divalent cation binding pocket within integnn β 
subunits, and that other oxygenated residues may be less critical for cation binding Together, these 
data support the notion that integnn β subunits can adopt a functional, MIDAS like divalent cation 
binding pocket Crystallization of the I domain like region in integnn β subunits, will reveal the 
accuracy of the proposed models for this region Interestingly, mutation of β2 residue Ser
118
 to Ala 
abrogates Mac-1 binding to C3bi, whereas binding to NIF is unaffected In addition, it was found 
that although mutation of Glu235 abrogates binding of Mac-1 to C3bi and Fg, binding to C3bi, but 
not Fg, could be restored by activating antibodies directed against ß2 (53) Together, these data 
suggest that binding of Mac-1 to different hgands not only involves distinct residues in the CD1 lb 
I domain, but also depends on distinct residues within the ß2 subunit Alternatively, these data may 
indicate that binding of Mac-1 to different hgands may involve different confoimations of the inte-
gnn In addition to MIDAS residues, integnn I domains contain other regions that are crucial for 
ligand binding, as described above It will be interesting to determine whethei similar domains in 
the I domain like region in integnn β subunits, also contribute to ligand binding and specificity 
Topology of ligand binding sites in ICAM-1, -2 and -3 
LFA-l mediates cell-cell interactions, by binding to one of its three hgands ICAM-1, -2 or -3 
Early studies on function of ICAM-1 molecules have shown that the lirst domains of ICAM-1, -2 
and -3 are necessary and sufficient for binding to LFA-l (55-58) Mutational analysis of ICAM-1 
and ICAM-3, has identified amino-acids within the first domains of ICAM molecules that are enti 
cal for adhesion Key residues within ICAM 1,-2 and -3 for binding to LFA-l, are Glu" and Gin" 
(in ICAM-2) (55-59) In addition, mutagenesis studies have identified other conserved amino-acids 
(Ser25, Thr18 Lys42 and Туг54 in ICAM-2) that contribute to ligand binding of ICAM s (57-59) (Fig 
5) However, since mutation of Ser25 and Lys42 has opposite effects on binding of ICAM-1 or 
ICAM-3 to LFA-l (58,59) (Fig 5), it remains to be established whether the conseived Thr1g and 
Туг
54
 are equally important for binding of ICAM-l, -2 and -3 to LFA-l (Fig 5) Interestingly, 
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alignment of non-conserved residues in ІСЛМ molecules important for binding to LFA-1 in figure 
5, reveals that integrin binding sites in ICAM molecules are likely overlapping, but not identical. 
For instance, the amino-acid Asn23 that is essential for ICAM-3 binding to LFA-1 (58), is con­
served in ICAM-2, but absent from ICAM-1. Furthermore, non conserved amino-acids at identical 
positions in ICAM-1 (Met64, Tyr66, Asn68) and ICAM-3 (Leu66 and Ser68) are critical for binding of 
ICAM-1 or ICAM-3 to LFA-1 (Fig. 5) (56,59). 
y no effect 
20 22X 34 35 39 52 
ICAM-1 QTSVSPSKVI LPRGGSVLVT CSTSCDQPKL LGIETPLPKK ELLLPGNNRK VYELSNVDED 
23 25 37 38 42 54 
ICAM-2EVHVREKKLA VEPKGSLEVN CSTTCNQPEV GGLETSINKI LLDEQAQ.WK HYLVSNISHD 
ICAM-3LLRVEPQNPV LSAGGSLFVN CSTDCPSSEK IALETSLSK. ELVASGMGWA AFNLSNVTGN 
-PA- —ßA'— ßB — ßC \|-ßD ßE -
no effect 
SQPMCYSN 
TVLSCHFT' 
SRI LCSVY 
Ρ DGQSTAKTFL TVYWTPER 
;S GK^ESMNSNV SVYQPPRQ 
N GSQITGSSNI TVYGLPER 
—ßF-\— ßG 
non-conserved domain 
Figure 5. Amino-acids in ICAM-1, -2 and -3 important for binding to LFA-1. The first domains 
of ICAM-1, -2 and -3 are aligned. Amino-acids important for ligand binding identified by mu-
tagenesis are indicated in bold. Conserved residues are highlighted by vertical shaded bars. Non-
conserved domain: non-conserved amino-acids important for binding of ICAM-1 and ICAM-3 to 
LFA-1. Localization of β strands (ßA-ßG) as defined for the ICAM-2 crystal structure (Fig. 6), is 
indicated. 
The recent resolution of the crystal structure of ICAM-2, has given insight into the three-
dimensional organization of amino-acids in ICAM molecules important for binding to LFA-1. The 
two Ig-like domain of ICAM-2 are each composed of seven β -sheets (60). Interestingly, a rela­
tively flat binding surface on top of the first domain of ICAM-2 is exposed to the extracellular 
space through a bend in a connecting loop between domains 1 and 2 of ICAM-2, suggesting that 
amino-acids on this binding face may directly interact with LFA-1 (60). In Figure 6, I have super­
imposed all residues important for binding of ICAM-1, -2 and -3 to LFA-1 (Fig. 5), onto the crystal 
structure of ICAM-2 (60). Localization of Glu37 and Gin" on the binding face, supports the notion 
that these amino-acids are important for direct binding of all ICAM's to LFA-1. Similarly, the po­
sition of Tyr54 indicates that this amino-acid may also directly contact LFA-1. In contrast, localiza­
tion of the conserved Ser25 and Lys42, suggests that these amino-acids do not directly contribute to 
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ligand binding, while Thr38 may contribute to ligand binding by positioning the critical Glu" resi-
due (60). Interestingly, the non conserved residues (Met64, Tyr66, Asn68 in ICAM-1; Leu66 and Ser68 
in ICAM-3 ) and Asn" (Thr in ICAM-1) highlighted in figure 5, appear to be located on the same 
ligand binding face as Glu37, suggesting that these amino-acids also directly contribute to adhesion. 
Based on these findings, it is tempting to speculate that differences in the binding face on top of the 
first domains of ICAM-1 and -3, may contribute to the different capacities of these ligands to sup-
port LFA-1 mediated adhesion. 
GLN75 
Figure 6. Topology of residues in ICAM-
1, -2 and -3 involved in binding to LFA-1. 
The Amino-acids important for binding of 
ICAM-1, -2 and -3 to LFA-1, as defined by 
mutagenesis, are highlighted on the crystal 
structure of the first domain of ICAM-2. 
Conserved amino-acids important for 
binding of ICAM-1, -2 and -3 to LFA-1 
(Glu37, Gin7'') are highlighted. Other con-
served (Ser\ Thr3", Lys42 and Tyr4) resi-
dues implicated in binding to LFA-1 are 
indicated as well. The position of non-
conserved residues implicated in binding to 
LFA-1 (Met64, Tyr66, Asn6" in ICAM-1; 
Leu66 and Ser6* in ICAM-3) is indicated by 
a black arrow. Asn2i: non conserved resi-
due (Thr in ICAM-1) implicated in ICAM-3 
binding to LFA-1. This figure has been 
generated using the program SYBYL 6.3 
program (Tripos), using the ICAM-2 coor-
dinates in the Brookhaven Protein Data 
Bank, entry 1ZXQ, as provided by Dr. J.H. 
Wang (60). 
It has been suggested that the relatively flat binding surface on ICAM-2 may be well suited to 
interact with the relatively flat binding surface on top of integrin I domains, consisting of residues 
contributing to and surrounding the divalent cation binding pocket (60). In chapter 3 and 4 of this 
thesis, amino-acids critical for binding of LFA-1 to ICAM-3 were found to be localized on the op-
posite end of the I domain, implying that multiple regions within the CD1 la I domain may contact 
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ICAM-3 Since the crystal structures of the CD1 la I domain and the first domain of ICAM-2 are 
comparable in height (not shown), it is tempting to speculate that the first domain of ICAM-3 may 
indeed interact with two different domains on opposite ends of the CD1 la I domain Full under­
standing of the interaction of these different I domain regions with ICAM 3, will have to await the 
resolution of co-crystals of the CD l i a i domain with the first domains of ICAM-3 
Integrated models for integrin-ligand binding 
The analysis of different domains in integrin α and β subunits implicated in ligand binding, 
demonstrates that ligand binding and cation binding to integrins are intimately connected Cations 
have been suggested to contribute directly to integrin/ligand binding by bridging acidic residues 
within integrin hgands to cation coordinating residues in integrin α or β subunits In addition, ca­
tions are thought to be involved in proper folding of the integrin and regulation of integrin confor­
mation However, it remains unclear whether the different regions in integrin α and β subunits im­
plicated in ligand and cation binding equally contribute to adhesion, or have distinct roles in the 
regulation of integrin adhesiveness The latter possibility is supported by several studies that sug­
gest that ligand binding involves binding of different divalent cations to distinct classes of divalent 
cation binding sites within integrin molecules It has been shown that Mg'*, Mn2* and Ca2+ differ­
entially affect adhesion of α,β, and o^ß, integrins, since adhesion of these integrins is enhanced by 
Mg2* and Mn2*, but inhibited in the presence of Cd1* (61-65) Detailed analysis of the role of Ca2* in 
regulating α,β, and Oyß, integrins, supports the presence of two distinct Ca2* binding sites A ligand 
competent binding site binds Mg2* or Mn2* in α,β, andavß, integrins respectively, whereas a dis 
tinct, allostenc binding site specifically binds Ca2* (61,62) (Fig 7) Binding of Ca2* to these differ-
ent sites differently affects adhesion at low Ca?* concentrations, Ca2+ binding to the high affinity 
allostenc site enhances Mg2* oi Mn2+ dependent adhesion, while at high concentrations Ca2* di-
rectly competes with binding of Mg2+ or Mn2+ to the ligand competent site, resulting in inhibition of 
adhesion (61,62) 
Interestingly, Ca2* also has a dual role in the regulation of LFA 1 On one hand, Ca2+ inhibits 
LFA-1 function, since chelation of Ca1* enhances Mg2* or Mn2+ dependent adhesion of LFA 1 to 
ICAM-1, and Ca2* directly displaces Mg2* ions from LFA-1 (66,67) On the other hand, Ca2* en-
hances LFA-1 mediated adhesion, by reorganizing LFA-1 into clusters on the cell-surface, that in-
crease the avidity of LFA-1/ligand interactions and can be detected by an antibody directed against 
aL (NKI-L16) (68 70) In addition, Ca2* has been shown to increase LFA-1 mediated adhesion at 
low Mg2* concentrations (71) Based on these findings, I propose that the different effects of cal-
cium on LFA-1 function also result from binding of Ca1* to distinct ligand competent and allostenc 
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Ca 2 + binding sites, as suggested for β, and β, integrins. A model for this dual role of Ca2+ in the 
function of LFA-1 is presented in figure 7. 
Fibronectin 
«sßi 
ICAM-1, -2, -3 
В 
<\β2 
II 
Clustering 
Figure 7. Model for the role of divalent cations in integrin function. A) two distinct Ca2* binding 
sites can be defined within the asß, integrin: a ligand competent binding site (I) that binds Ca'* or 
Mg2* and an allosteric cation binding site that selectively binds Ca2* with high affinity (II). At low 
Ca2* concentrations, Ca2* binding to the allosteric site (II) enhances Mg2* dependent ligand bind-
ing to the ligand competent site (I), at high Ca2* concentrations Ca2* competes for Mg2* for the li-
gand competent site (I) resulting in inhibition of ligand binding. B) similar Ca'* binding sites are 
proposed to exist in LFA-1. Ca2* binding to the high affinity Ca2* binding site (II) enhances LFA-1 
function by induction of LFA-1 clustering, whereas at high concentrations binding of Ca2* to the 
ligand competent binding site (I) inhibits Mg2*-dependent ligand binding of LFA-1. 
Binding of Ca2+ to the ligand competent binding site serves to keep LFA-1 on lymphocytes in an 
inactive state, preventing spontaneous aggregation of lymphocytes in the bloodstream. As pointed 
out in the introduction, LFA-1 mediated Τ cell adhesion can be enhanced through intracellular sig­
nals that increase the affinity of LFA-1 for its ligands. Since both Ca2+ and Mg 2 t are both present in 
vivo, the model proposed in figure 7 would imply that this affinity change involves active exclu-
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Sion of Ca2* from the hgand competent site and rebinding of Mg2* In addition this model implies 
that enhancement of LFA-1 mediated adhesion by Ca2* dependent ìedistribution of LFA-1 on the 
cell surface, involves binding of Ca2* to a second allosteric high affinity Ca'* binding site Inter-
estingly, expression of several epitopes on β, or ß, subunits of mAb that stimulate integrin adhe-
sion, is inhibited by Ca2+, but promoted by Mg'* (72,73) These data suggest that Ca2+ and Mg2* 
regulate hgand binding by affecting the balance between inactive and active conformers of the in-
tegrin molecule (74) Detailed analysis of the effects of low and high concentrations of Ca2* on 
Mg2* and Mn2+ dependent adhesion oí LFA 1, will reveal whether hgand competent and allostenc 
Ca'* binding sites as defined fora,ß, and α
ν
β, integrins, indeed exist within LFA-1 
An important question is where hgand competent and allostenc cation binding are located 
within the α and β subunits of integrins A strong candidate for a hgand competent binding site is 
the divalent cation binding pocket in I domains, that has been clearly implicated in cation binding 
and hgand binding (7,20-28) This divalent cation binding pocket binds Mg2+ (41), fulfilling one ot 
the requirements of the hgand competent binding site However, if the model proposed in figure is 
correct, the divalent cation binding pocket must be occupied by Ca* in the inactive integrin Al­
though binding of Ca2+ to molecules that adopt a Rossmann fold is unusual (75), it will be interest­
ing to determine whether a Ca2* occupied CD1 la I domain crystal structure can be obtained and 
whether binding of Ca2+ will result in an I domain conformation that is distinct from the conforma­
tions of the of Mg2+ or Mn2* occupied CD1 la I domain crystal structures 
A second candidate for a hgand competent cation binding site is the conserved region in integrin 
β subunits that also has hgand and cation binding capacity (23,48-50,52,53) Interestingly, model­
ing of this conserved area onto integrin I domains, suggests that the divalent cation binding pocket 
in β subunits is different from the cation binding pocket in I domains (23,52,54) and may be suit­
able for coordination ot the larger Ca2+ ion (52) It will be important to resolve whether the β region 
indeed adopts a fold that contains a divalent cation binding pocket and if so, whether this pocket 
can bind both Ca2* and Mg'* 
In the model proposed in figure 7, binding of Ca2* to an allosteric Ca2+ binding site, enhances 
LFA-1 mediated adhesion trough induction of LFA-1 clustering Data presented in chapters 3, 4 
and (25), suggest that this allosteric Ca'* binding site may be located on the aL subunil C-terminal 
of the CD1 la I domain, since mutation of MIDAS residues in the I domain abiogates hgand bind­
ing, but does not affect expression of the Ca'+ and clustering dependent NKI L16 epitope on the a, 
subunit It is attractive to hypothesize that the allosteric Ca2* binding site is constituted by the EF-
hand like domains in integrin α subunits, that have been implicated in both hgand binding and ca­
tion binding to integrins (43-47) This would imply that integrin EF-hands are not directly involved 
in interaction with hgand This notion is supported by the finding that mutations in the first, second 
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or third EF-hand like domain of a,, equally affected VLA-4 mediated adhesion, suggesting that the 
three EF-hands cooperatively regulate integnn adhesion (47) The regulatory role of EF-hands in 
integrin adhesion is further supported by a novel model for the structure of integnn α subunits pro­
posed by Springer (75) In this model, seven domains in integnn α subunits are modeled onto a β-
propeller fold, a topology that is found in several enzymes and consists of seven four stranded β 
sheets arranged around a pseudo symmetry axis, like the blades of a propeller Integrin I domains 
are tethered to the top of the propeller domain by a hinge that allows movement of the domains 
relative to one another In the β propeller model the I domain is well exposed towards the ex­
tracellular milieu, consistent with a direct interaction of I domains with ligand Similarly, amino-
acids that are important for ligand binding of non-I domain containing integrins, are located in 
loops on top of the propeller, suggesting that these amino acids also directly contact ligand (75,76) 
In contrast, EF-hand like domains are located towards the lower face of the ß-propeller, suggesting 
that they do not directly interact with ligand, but are probably involved in regulation of integnn 
conformation (75), consistent with the requirements for the allosteric Cd2* binding site proposed in 
figure 7 
Together, the data presented here suggest that cations aie critically involved integnn activation 
and ligand binding, both by directly contacting ligand, and by regulating integnn conformation 
This view is in contrast with a study of D'Souza and coworkers (48), in which it is shown that li-
gand displaces cations fiom the integnn and that less cations bind to ligand occupied integrins than 
to ligand free integnn molecules The authors propose a model for integnn ligand binding m which 
cations are required for the formation of intermediate tertiary complex containing ligand, cation 
and integnn, but stable ligand binding requires expulsion of cations from this complex However, 
their data show that after ligand binding still one cation is complexed to the integnn molecule, sup-
porting the notion that stable interaction ol integnn and ligand requires binding of at least a single 
cation to integnn molecules 
Conclusion: evidence for distinct binding sites for ICAM-1 and 
ICAM-3 on LFA-1 
Expression of ICAM-3 is restricted to cells of hematopoetic origin, while ICAM-1 can be ex-
pressed on a variety of cells, suggesting that interaction of LFA-1 with ICAM-1 or ICAM-3 may be 
involved in different immunological processes in the body, as pointed out in the introduction This 
notion is supported by data described in chapters 2, 3 and 4, that suggest that binding of LFA-1 to 
ICAM-1 or -3, is structurally distinct In addition, data described in (77) and chapter 2 and 5 of this 
thesis, show that while ICAM-1 is very eflective as an adhesion ligand tor LFA-1, ICAM 3 is not 
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very efficient in supporting LFA-1 mediated adhesion Finally, data described in chapters 3, 4 and 
5 show that upon engagement of LFA-1 by ICAM 1 or ICAM-3, different signals are transmitted 
into the cell Together, these data suggest that adhesion of LFA-1 to ICAM-1 or ICAM-3 is func-
tionally different and îesulls in propagation of different hgand dependent conformational changes 
to the plasma membrane, that lead to induction of distinct LFA-1 dependent intracellular responses 
A prediction from the observed functional differences in binding of LFA-1 to ICAM-1 or 
ICAM-3, is that LFA 1 will bind to these ligands with different affinities In chapter 6, surface 
plasmon resonance experiments were carried out to characterize binding of monomeric or dimenc 
forms of ICAM-1, to purified LFA-1 Although recombinant dimenc ICAM-1 bound to purified 
LFA-1 in these experiments, recombinant monomeric ICAM-1 tailed to bind to LFA-1, even at 
very high concentrations These data suggest that although ICAM-1 is the best adhesion hgand of 
LFA-1, LFA-1 binds to ICAM-1 with relatively low affinity, and indicates that dimenzation of 
ICAM-1 greatly enhances its capacity to bind to LFA-1 In future experiments this approach will 
reveal whether differences in the capacity of ICAM 1 and ICAM 3 to bind to LFA-1 are due to a 
even lower affinity of LFA-1 tor ICAM-3 Interestingly, ICAM-1 was found to be expressed as a 
dimer on the cell-surface, indicating that dimenzation of ICAM-1 also conti ibutes to its adhesive 
capacity in vivo (78,79) Since to date no evidence is available that ICAM 3, like ICAM-1 is also 
present as a dimer on the cell surface, lack of dimenzation of ICAM 3 could contribute to the poor 
capacity of ICAM-3 to support LFA-1 mediated adhesion However recombinant dimenc ICAM 
3Fc is less potent than recombinant ICAM lFc in suppoiting LFA-1 mediated Τ cell adhesion and 
activation (Chapteis 2 and 5), indicating that lack of ICAM-3 dimenzation is not sufficient to ex­
plain the different adhesive capacities of these ligands 
In the past few years, analysis of the affinities of other adhesive interactions, including the inter­
action of members of the Ig-superfamily, indicates that adhesive interactions in the body are gener­
ally of low affinity (-100 μΜ) (80 82) A consequence of these low affinities is that multivalent 
interactions between adhesion molecules are required to achieve stable adhesion It has been shown 
that the cytoplasmic tail of ICAM-1 can associate with the cytoskeleton through binding of Us cy­
toplasmic tail to the actin binding protein α actinin (83), suggesting that cytoskeletal reorganization 
could result in the formation of large ICAM 1 aggregates on the cell surface Since also LFA-1 has 
been shown to reorganize into clusters on the cell surface (68,69), oiganization of ICAM-1 into ag­
gregates could greatly contribute to the strength of the LFA-1/ICAM-1 interaction (69) ICAM-3 
was recently shown to reorganize into a "uropod" like structure, upon stimulation of activated Τ 
cells with chemokines This redistribution may indicate that the cytoplasmic tail of ICAM-3 also 
associates with the cytoskeleton (84,85) It will be of inteiest to investigate whether linkage ot the 
cytoplasmic tails of ICAM-1 or ICAM 3 to difierent cytoskeletal proteins lesults in the formation 
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of different complexes of ICAM 1 or ICAM-3 molecules on the cell surface, that could contribute 
to the different capacities of these molecules to support LFA-1 mediated adhesion in vivo It is 
likely that differences in organization of ICAM-1 and ICAM-3 will also affect LFA-1 mediated 
signaling, since it is conceivable that LFA-1 dependent signaling is only achieved after a threshold 
of adhesive interactions is reached, as has been shown for TCR mediated signal transduction In 
addition, as pointed out in the introduction, it has been shown that integrin dependent signaling le-
quires engagement of integrins by multivalent Iigands, suggesting that clustered ICAM molecules 
may be more efficient for induction of LFA-1 dependent signaling than monomenc ICAM mole­
cules 
In conclusion, data presented here clearly indicate that interaction of LFA with its Iigands 
ICAM-1 and ICAM-3 is structurally distinct and differentially affects adhesion and signal 
transduction in the immune system 
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T o protect itself from micro organisms, the body is equipped with a specialized immune sys tem, that includes the white blood cells or leukocytes An important subgroup of leukocytes 
is formed by the Τ lymphocytes that recognize protein fragments (peptides) presented on the sur­
face of other cells During a first encounter with a viral infection, viral peptides on the surface of 
specialized antigen presenting cells are presented to Τ lymphocytes in the lymphoid organs Upon 
recognition of a viral peptide, Τ lymphocytes will proliferate and differentiate into cytotoxic Τ 
lymphocytes (CTL) that leave the lymphoid organs, migrate to the tissues and kill virus infected 
cells For the generation of such an immune response, interactions between cells are essential The 
migration of Τ lymphocytes to lymphoid organs or tissues involves interaction of the Τ lymphocyte 
with endothelial cells lining the blood vessels at these sites Recognition of viral peptides requires 
interaction of the resting Τ lymphocyte with antigen presenting cells, while lysis of virus infected 
cells only occurs upon tight, but temporary interaction of the CTL with its target cell To mediate 
these adhesive functions lymphocytes express specialized proteins on then cell sui face, the so-
called adhesion molecules An important group of adhesion molecules is foimed by the integiins, 
that consist of a complex of two protein chains, an α and a β subunit An integrin that is exclusively 
expressed on leukocytes, is the integrin LFA 1 LFA-1 mediates cell cell adhesion, by binding to 
its ligands intercellular adhesion molecules 1, 2 or 3 (ICAM 1, 2, -3) that are also cell sui lace 
molecules The aim of this thesis is to investigate whether binding oí LFA 1 to ICAM 1 or -3 is 
structurally distinct and to determine whether adhesion of LFA 1 to ICAM 1 or 3 is involved in 
distinct immunological processes 
Chapter 1 describes the distinct tissue distribution of ICAM 1, 2 and 3 and gives an overview 
of the current knowledge of different roles of ICAM-1, -2 and-3 within the immune system In ad 
dition, this chapter gives a detailed description of the structure of LFA-1 and its ligands and shows 
that binding of LFA 1 to ICAM 1, 2 or ICAM 3 diffeientially affects Τ lymphocyte function 
In chapter 2, LFA-1 mediated adhesion of activated Τ lymphocytes to ICAM I and ICAM 3 is 
compared These experiments show that ICAM-1 is the primary adhesion hgand foi LFA 1 
whereas ICAM-3 is not very effective in supporting LFA-1 mediated adhesion of Τ lymphocytes 
In addition, antibodies are defined that selectively inteifere with binding of LFA 1 to ICAM 3, 
whereas they do not affect binding of LFA I to ICAM-1, suggesting that different binding sites for 
ICAM-1 and ICAM-3 exist within LFA 1 
This notion is supported by data described in chapter 3 By introducing mutations in the I do­
main in the ctL subunit, a region in LFA-1 that is important for hgand binding of LFA 1 it was 
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found that amino-acids at the very beginning of the I domain of LFA-1 are critical for binding to 
ICAM-3, but not ICAM-1 In chapter 4, the epitope recognized by antibodies described in chapter 
2 that selectively inteifere with binding of LFA-1 lo ICAM-3, is localized within the I domain In-
terestingly, alignment of this epitope and amino-auds critical for binding of LFA-1 to ICAM-3 
with the recently resolved ciystal structure of the CD1 la I domain, revéales that they are both lo-
cated at the bottom o( the I domain, defining an area in the CD1 la I domain that is important for 
selective binding of LFA-1 to ICAM-3 
In chapter 5, the role of ICAM-3 within the immune system is investigated Although ICAM-3 
binds poorly to LFA-1, it is lound that this weak interaction of LFA 1 with ICAM-3 enhances 
LFA-1 mediated adhesion to ICAM-1 and is essential for LFA-1 and 1С AM 1 dependent activation 
of resting Τ lymphocytes These results show that ICAM 1 and ICAM 3 have distinct roles in the 
regulation of an immune response 
To understand how adhesion molecules contribute to íntei actions between cells, it is important 
to know whether interactions between individual adhesion molecules are transient or remain stable 
for consideiable time To investigate the dynamics ot the inteiaction between LFA-1 and ICAM-1, 
the interaction between purified ICAM-1 and LFA-1 molecules is measured in time in chapter 6, 
using a specialized optical detection system (surface plasmon íesonance) These experiments show 
that while monomenc ICAM-1 molecules bind poorly to LFA 1, dimenzation of ICAM-1 dramati 
cally increases its capacity to bind LFA-1 These results show that although ICAM-1 is the primary 
adhesion ligand foi LFA-1, individual interactions between LFA-1 and ICAM-1 are unstable, im-
plying that multivalent interactions between LFA 1 and ICAM-1 are lequired foi stable cell-cell 
adhesion 
Finally, in chapter 7, the cui rent knowledge about the interaction between integrins and their h-
gands is discussed, at the molecular level It has become apparent that multiple domains in integnn 
α and β subunits contribute to adhesion and that binding of divalent cations to these domains is es­
sential for the regulation of integnn function In addition, it has become clear that binding sites for 
different ligands in LFA-1 and other integiins are often oveilapping, but not always identical 
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O m zich te beschermen tegen schadelijke micro organismen, beschikt het lichaam over een geavanceerd afweer- of immuunsysteem, ddt onder meer bestaat uit de witte cellen in het 
bloed, de leukocyten Een belangrijke subgroep van leukocyten wordt gevormd door de Τ lymfo 
cyten, die fragmentjes van eiwitten (peptiden) kunnen herkennen die op het oppervlak van cellen 
gepresenteerd worden Wanneer het lichaam voor het eerst in aanraking komt met een virusinfectie 
worden in de lymfeklieren virale peptiden gepresenteerd op het oppervlak van gespecialiseerde an-
tigeen-presenterende cellen (APC) Als een in de lymfeklier aanwezige Τ lymphocyt een viraal 
peptide herkent, kan hij uitnjpen tot een cytotoxische Τ lymfocyt die de lymfeklier verlaat om in de 
geïnfecteerde weefsels virus-geïnfecteerde cellen te doden Tijdens het opwekken van deze im-
muunrespons zijn interacties tussen cellen heel belangrijk Τ lymfocyten migreren lymfeklieren ot 
weefsels in, na binding aan endotheelcellen die de bloedvaten in weefsels of lymfeklieren bek­
leden Om virale peptides te kunnen herkennen, is het nodig dat Τ lymphocyten aan antigeen pre 
senterende cellen binden Tenslotte moeten Τ lymphocyten aan virus geïnfecteerde cellen hechten, 
om deze te kunnen doden Voor deze verschillende bindings-functies hebben leukocyten gespe 
cialiseerde eiwitten op hun oppervlak, die adhesiemoleculen genoemd worden Een belangrijke 
groep van adhesiemoleculen wordt gevormd door de integrines, die bestaan uit een complex van 
een α en een β keten Een integrine dat alleen op leukocyten voorkomt is het integrine LFA-1 
(aLß2) LFA-1 kan adhesie van cellen bewerkstelligen door te binden aan drie verschillende eiwit-
ten (liganden) die ook op het oppervlak van cellen voorkomen de intercellulaire adhesiemoleculen 
1, 2 en 3 (ICAM-1, -2, -3) In dit proefschrift is onderzocht of LFA 1 op dezelfde maniei bindt aan 
ICAM-1 en ICAM 3, en hoe de binding van LFA 1 aan ICAM-1 en 1CAM-3 betrokken is bij ver 
schillende processen binnen het immuunsysteem 
In hoofdstuk 1 wordt beschreven op welke cellen ICAM 1, -2 and -3 voorkomen m het lichaam 
en wordt een overzicht gegeven van wat er reeds bekend is over verschillende functies van ICAM 
1, -2 en 3 in immunologische processen Tevens wordt de structuur van LFA 1 en ICAM-1, -2 en 
3 in detail behandeld en wordt besproken hoe binding van LFA-1 aan ICAM-1 2 of -3, op vci 
schillende wijze de functie van Τ lymfocyten kan bcivloeden 
In hoofdstuk 2 is de adhesie van LFA 1 op geactiveerde Τ lymfocyten aan ICAM 1 en ICAM 3 
vergeleken Uit deze experimenten blijkt dat ICAM 1 een veel beter adhesiehgand is voor LFA 1 
dan ICAM-3 Tevens is gevonden dat bepaalde antistoffen gericht tegen een domein in the α keten 
van LFA-1, het I domein, selectief de binding van LFA-1 aan ICAM-3 remmen, terwijl ze geen ef-
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feet hebben op de binding van LFA-1 aan ICAM-I Deze resultaten suggereren dat binnen het 
LFA-1 molecuul verschillende bindingsplaatsen bestaan voor ICAM-1 en ICAM-3 
Deze hypothese is bevestigd door experimenten beschreven in hoofdstuk 3 Door op verschil-
lende plaatsen in het I domein veranderingen aan te brengen, is gevonden dat aminozuren aan het 
begin van het I domein belangrijk zijn voor binding van LFA-1 aan ICAM-3, maar niet voor bind-
ing van LFA-1 aan ICAM-1 Tevens is in hoofdstuk 4 op dezelfde wijze de bindingsplaats 
(epitoop) van antistoffen die selectief adhesie van LFA-1 aan ICAM-3 kunnen remmen, gelocal-
ïseerd binnen het I domein Na analyse van de recent opgehelderde dne-dimensionale structuur van 
het I domein, blijken dit epitoop en de nabijgelegen aminozuien belangrijk voor binding van LFA-
1 aan ICAM-3, zich beide aan de onderkant van het I domein te bevinden Dit gebied in het I 
domein van LFA-1 is daarom betrokken bij selectieve binding van LFA-1 aan ICAM-3 
Hoofdstuk 5 behandelt de ιοί van 1С AM 3 in de regulatie van een immuunrespons Hoewel 
ICAM-3 een slecht adhesiehgand is voor LFA 1 op rustende Τ lymfocyten, blijkt zwakke adhesie 
van LFA-1 aan ICAM-3, binding van LFA-1 aan ICAM-1 te versterken en belangrijk te zijn voor 
LFA-1 en ICAM-1 afhankelijke activatie van rustende Τ lymfocyten Deze resultaten onderstrepen 
de verschillende functies van ICAM-1 en ICAM-3 binnen het immuunsysteem 
Om te begrijpen hoe adhesie moleculen bijdragen aan interacties tussen cellen, is het belangrijk 
te weten of de interactie tussen individuele adhesiemoleculen kortduiend is, of dat deze lange tijd 
stabiel blijft Om inzicht te krijgen in de dynamiek van de interactie tussen LFA-1 en ICAM-1, is in 
hoofdstuk 6 de binding van gezuiverd ICAM-1 aan gezuiverd LFA 1 in de tijd gemeten, door ge­
bruik te maken van een speciaal optisch detectiemechanisme (surface plasmon resonantie) Uit 
deze experimenten is gebleken dal een enkelvoudig, monomcer ICAM-1 molecuul slecht kan bin 
den aan LFA-1, maar dat tweevoudige, dimere ICAM-1 moleculen goed aan LFA-1 kunnen bin­
den Deze resultaten geven aan dal alhoewel ICAM-1 het beste adhesiehgand is voor LFA 1, de 
interactie tussen ICAM 1 en LFA-1 niet erg stabiel is Dit impliceert dat voor sterke cel-cel inter­
acties in het lichaam meerdeie interacties tussen adhesiemoleculen essentieel zijn 
Tenslotte worden in hoofdstuk 7 de huidige inzichten beschreven over de intei actie van inte 
grines met hun liganden, op moleculair niveau Het is duidlijk dat verschillende domeinen in de α 
en β keten van integrines belangrijk zijn voor de interactie met hgand en dat binding van cationen 
aan deze domeinen een essentiële rol speelt in de regulatie van integrine afhankelijke adhesie Te 
vens is duidelijk geworden dat bindingsplaatsen in LFA-1 en andere integrines voor hun verschil-
lende liganden overlappen, maar niet identiek zijn 
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behorende bij het proefschrilt 'ICAM 1 лпсі ICAM-3, two distinct ligands of LFA-1 ' 
1 ICAM-1 en ICAM-3 hebben verschillende functies binnen het immuunsysteem ICAM-1 is de 
belangrijkste adhesiereceptor vooi LFA 1, terwijl ICAM-3 vooral een rol speelt in de regulatie 
van LFA-1 afhankelijke adhesie (ditproefschrift) 
2 De bindingsplaatsen vooi ICAM-1 en ICAM 3 binnen het 'I domein' van LFA-1 zijn oveilap­
pend, maai niet identiek (dit pi oef schuft) 
3 Analyse van de knstalstructuui van het 'I domein' van LFA 1 heeft inzicht gegeven in de due 
dimensionale organisatie van aminozuren die belangrijk zijn voor het binden van hganden door 
LFA-1 (dit pi oefschrift) 
4 Hoewel adhesiemoleculen sterke inteiacties tussen cellen mogelijk maken, zijn individuele ad-
hesiereceptor-ligand interacties vaak van lage affiniteit (ditproefsclvift) 
5 Aangezien de aminozuur-volgorde in het 'I domein' van Mac-1 and pl50,95 belangiijk vooi 
binding aan C3bi, (ïbnnogecn en gedenatuieerde eiwitten geconserveerd is in het I domein van 
α
η
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